var title_f40_37_41552="Valgus stress test";
var content_f40_37_41552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F77592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F77592&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Valgus stress test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 290px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The valgus stress test is used to determine the integrity of the medial collateral ligament. One hand is placed above the knee along the lateral thigh and one hand is placed along the medial gastrocnemius muscle. The upper hand is used to stabilize the thigh while the lower hand places outward pressure on the calf. Pain, movement of the medial joint space, and elasticity of the ligament are noted.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41552=[""].join("\n");
var outline_f40_37_41552=null;
var title_f40_37_41553="Cutaneous squamous cell carcinoma";
var content_f40_37_41553=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F60026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F60026&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous squamous cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous, hyperkeratotic papule is present on the skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41553=[""].join("\n");
var outline_f40_37_41553=null;
var title_f40_37_41554="Retroflexion of endoscope within the stomach";
var content_f40_37_41554=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68753&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Retroflexion of endoscope within the stomach",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 508px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retroflexion of the endoscope permits visualization of portions of the stomach that are not well seen during forward-viewing with the endoscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41554=[""].join("\n");
var outline_f40_37_41554=null;
var title_f40_37_41555="Liposomal morphine: Patient drug information";
var content_f40_37_41555=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liposomal morphine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/16/18694?source=see_link\">",
"     see \"Liposomal morphine: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/11/30901?source=see_link\">",
"     see \"Liposomal morphine: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8776643\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DepoDur&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10025412\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10025411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to morphine sulfate or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Asthma, raised pressure in the brain, bowel block, or lung disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10025415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10025416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698182",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation or swelling where the shot was given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10025418\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10025414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into the spine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10025419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10025420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12260 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-6720EAAD2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41555=[""].join("\n");
var outline_f40_37_41555=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8776643\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025412\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025411\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025415\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025416\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025418\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025414\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025419\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10025420\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/16/18694?source=related_link\">",
"      Liposomal morphine: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?30/11/30901?source=related_link\">",
"      Liposomal morphine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_37_41556="Clotrimazole (topical): Patient drug information";
var content_f40_37_41556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Clotrimazole (topical): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29652?source=see_link\">",
"     see \"Clotrimazole (topical): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/28/13763?source=see_link\">",
"     see \"Clotrimazole (topical): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8011625\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Anti-Fungal&trade; [OTC];",
"     </li>",
"     <li>",
"      Cruex&reg; [OTC];",
"     </li>",
"     <li>",
"      Gyne-Lotrimin&reg; 3 [OTC];",
"     </li>",
"     <li>",
"      Gyne-Lotrimin&reg; 7 [OTC];",
"     </li>",
"     <li>",
"      Lotrimin&reg; AF Athlete's Foot [OTC];",
"     </li>",
"     <li>",
"      Lotrimin&reg; AF for Her [OTC];",
"     </li>",
"     <li>",
"      Lotrimin&reg; AF Jock Itch [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8011626\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Canesten&reg; Topical;",
"     </li>",
"     <li>",
"      Canesten&reg; Vaginal;",
"     </li>",
"     <li>",
"      Clotrimaderm;",
"     </li>",
"     <li>",
"      Trivagizole-3&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to clotrimazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030406\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696941",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use this drug if you have belly pain, fever, or bad-smelling discharge. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Vaginal irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If the yeast infection keeps coming back.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699053",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad vaginal irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Skin:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705579",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Vaginal:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696203",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use tablet or cream vaginally.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694695",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not mix-up vaginal tablet with the oral lozenge.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696167",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use at bedtime for best results.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695256",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use tampons.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11611 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41556=[""].join("\n");
var outline_f40_37_41556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011625\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8011626\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030402\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030401\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030406\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030407\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030409\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030404\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030405\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030410\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030411\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?34/60/35780?source=related_link\">",
"      Clotrimazole (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?5/44/5828?source=related_link\">",
"      Clotrimazole (oral): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?15/6/15460?source=related_link\">",
"      Clotrimazole (oral): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?28/61/29652?source=related_link\">",
"      Clotrimazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?13/28/13763?source=related_link\">",
"      Clotrimazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_37_41557="Ectopia lentis (dislocated lens) in children";
var content_f40_37_41557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ectopia lentis (dislocated lens) in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/37/41557/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/37/41557/contributors\">",
"     Kathryn M McCreery, FRCOphth, FRCSI, MRCPI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/37/41557/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/37/41557/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/37/41557/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/37/41557/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/37/41557/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lens dislocation (ectopia lentis) in children may occur after trauma or in association with ocular or systemic disease. Dislocated lens in children will be discussed here. Cataracts and",
"    <span class=\"nowrap\">",
"     optical/visual",
"    </span>",
"    rehabilitation of aphakic children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subluxation is the term used when the lens is partially dislocated but remains attached to the ciliary body (",
"    <a class=\"graphic graphic_figure graphicRef59910 \" href=\"mobipreview.htm?2/6/2150\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ]. Luxation is the term used when the lens is completely detached from the ciliary body. Luxated lenses may be loose in the posterior chamber or can present in the anterior chamber.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of dislocated lenses is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lens dislocation (ectopia lentis) in children may occur after trauma or in association with ocular or systemic disease. It is important to determine the etiology because the associated disorders have different requirements for monitoring",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dislocation of the lens (",
"    <a class=\"graphic graphic_picture graphicRef77130 \" href=\"mobipreview.htm?10/53/11103\">",
"     picture 1",
"    </a>",
"    ) may occur after blunt trauma to the head, orbit, or eye [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ]. It occurs most commonly when the",
"    <span class=\"nowrap\">",
"     eye/orbit",
"    </span>",
"    is hit directly with a high-energy projectile (eg, BB, golf ball, baseball).",
"   </p>",
"   <p>",
"    Lens dislocation may be associated with other ocular injury (eg, iris trauma, sphincter tear, anterior chamber angle recession, hyphema, cataract, vitreous hemorrhage, choroidal rupture, ruptured globe, and orbital fracture). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=see_link\">",
"     \"Traumatic hyphema: Clinical features and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9783?source=see_link\">",
"     \"Orbital fractures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=see_link\">",
"     \"Open globe injuries: Emergent evaluation and initial management\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lens dislocation that occurs after minor trauma should prompt consideration of an underlying ocular or systemic condition, discussed below [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Ocular causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular causes of ectopia lentis include simple ectopia lentis, ectopia lentis et pupillae, and aniridia.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Simple ectopia lentis &mdash; Simple ectopia lentis (MIM #129600) is inherited in an autosomal dominant fashion. It may be present at birth or appear later in life. It is usually bilateral and progressive with superotemporal lens dislocation.",
"     </li>",
"     <li>",
"      Ectopia lentis with ectopia of pupil &mdash; Ectopia lentis with ectopia of pupil (ectopia lentis et pupillae is a rare autosomal recessive condition (MIM %225200) characterized by displacement of the pupil to a non-central location (usually temporal) and displacement of the lens in the opposite direction. The pupil may be paracentral or near the limbus).",
"     </li>",
"     <li>",
"      Aniridia &mdash; Aniridia is a bilateral ocular condition manifested by a rudimentary iris, acquired cataract, lens dislocation, hypoplasia of the optic nerve and fovea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/2\">",
"       2",
"      </a>",
"      ]. It may be sporadic or inherited in an autosomal dominant fashion (MIM #106210) with complete penetrance but variable expressivity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The sporadic form can be associated with Wilms' tumor. Sporadic forms also are associated with genitourinary problems, intellectual disability (mental retardation), and have deletion of the short arm of chromosome 11 (Wilms tumor aniridia genitourinary anomalies mental retardation syndrome [WAGR]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2249?source=see_link\">",
"     \"Presentation, diagnosis, and staging of Wilms tumor\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Systemic causes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic causes of ectopia lentis include Marfan syndrome, homocystinuria, sulfite oxidase deficiency, Weill-Marchesani syndrome, and Ehlers-Danlos syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Marfan syndrome &mdash; Marfan syndrome (MIM #154700), an autosomal dominant condition, is the most common systemic condition associated with ectopia lentis (",
"      <a class=\"graphic graphic_picture graphicRef67015 \" href=\"mobipreview.htm?22/3/22578\">",
"       picture 2",
"      </a>",
"      ) . Ectopia lentis is present in 50 to 80 percent of cases. In approximately two-thirds of cases, subluxation is superior, but it may occur in any direction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. Other features include tall stature with increased arm span, arachnodactyly, mitral valve prolapse, aortic dilation and dissection, scoliosis, and hyperextensible joints. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=see_link\">",
"       \"Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Homocystinuria &mdash; Homocystinuria (MIM #236200) is an autosomal recessive metabolic disorder associated with intellectual disability, chest deformities, osteoporosis, and increased risk of thrombotic episodes. Ectopia lentis occurs in 90 percent of patients, usually between 3 and 10 years of age. In approximately 60 percent of cases, subluxation is inferior or nasal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/3,6\">",
"       3,6",
"      </a>",
"      ] Patients with homocystinuria who require anesthesia should be admitted preoperatively for hydration and medical evaluation due to the high risk of thrombotic events [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Sulfite oxidase deficiency &mdash; Sulfite oxidase deficiency (sulfocysteinuria, MIM #272300) is a rare, autosomal recessive cause of lens dislocation and intellectual disability. Sulfite oxidase converts sulfite to sulfate; deficiency of sulfite oxidase results in increased urinary sulfite. Additional clinical manifestations include delayed dental eruption and neurologic abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/8\">",
"       8",
"      </a>",
"      ]. The diagnosis is confirmed by the absence of sulfite oxidase activity in skin fibroblasts.",
"     </li>",
"     <li>",
"      Weill-Marchesani syndrome &mdash; Weill-Marchesani syndrome is a connective tissue disorder that has both autosomal dominant (MIM #608328) and autosomal recessive (MIM #277600) forms [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/9\">",
"       9",
"      </a>",
"      ]. It is characterized by short stature, short limbs, joint stiffness, and lens abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/10\">",
"       10",
"      </a>",
"      ]. In addition to lens dislocation, which occurs in 90 percent of cases, the lens may microspherophakic (small and spherical with an increased anteroposterior thickness). Pupil block glaucoma is common and prophylactic laser iridotomy may be indicated.",
"     </li>",
"     <li>",
"      Ehlers-Danlos syndrome &mdash; Ehlers-Danlos syndrome is a group of connective tissue disorders characterized by hyperextensible skin, hypermobile joints, fragile skin, poor wound healing, atrophic scarring, and easy bruisability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/11\">",
"       11",
"      </a>",
"      ]. Lens dislocation is a feature of type I Ehlers-Danlos syndrome (MIM #130000).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with ectopia lentis usually present with complaints of poor or variable vision [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ]. Tremulousness of the iris (iridodonesis) occurs in most cases and is a helpful clinical sign [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/12\">",
"     12",
"    </a>",
"    ]. Lenses that are mobile beneath the iris can rub against the pigment epithelium and cause shedding of pigments, which can lead to pigmentary glaucoma. The pupil is small and may be difficult to dilate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional clinical features depend upon the type and degree of dislocation.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the zonules (collagen fibers that hold the lens in place behind the iris) (",
"      <a class=\"graphic graphic_figure graphicRef59910 \" href=\"mobipreview.htm?2/6/2150\">",
"       figure 1",
"      </a>",
"      ) are uniformly loosened, the lens assumes a spherical shape (spherophakia). The focal point of the image occurs anterior to the retina (lenticular myopia). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28628?source=see_link&amp;anchor=H4#H4\">",
"       \"Refractive errors in children\", section on 'Myopia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the zonular abnormality is localized to one area, the optical system is not perfectly spherical, and astigmatism results. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28628?source=see_link&amp;anchor=H6#H6\">",
"       \"Refractive errors in children\", section on 'Astigmatism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      If the lens shifts off center, both myopia and astigmatism may result. Myopic astigmatism is best demonstrated with streak retinoscopy.",
"     </li>",
"     <li>",
"      If the dislocation is extensive, significant refractive shifts occur, particularly if the lens edge crosses the pupil aperture. In some cases, the lens may shift out of the pupillary aperture entirely (resulting in aphakia).",
"     </li>",
"     <li>",
"      Complete dislocation of the lens into the anterior chamber may cause acute angle closure glaucoma, a surgical emergency. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of glaucoma in infants and children\", section on 'Angle anomalies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dislocation into the vitreous can cause retinal detachment. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36504?source=see_link\">",
"       \"Retinal detachment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In older children who are able to cooperate, the diagnosis of a dislocated lens can be made with a slit lamp examination (",
"    <a class=\"graphic graphic_picture graphicRef77130 \" href=\"mobipreview.htm?10/53/11103\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44486?source=see_link\">",
"     \"Slit lamp examination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In younger children, examination with a penlight may demonstrate tremulousness of the iris (iridodonesis).",
"   </p>",
"   <p>",
"    After dilation of the pupils, the edge of the lens may be seen directly or on retroillumination. However, the pupil is often small and difficult to dilate, even with a combination of dilating agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a child has a history of intermittent eye pain and a condition associated with lens subluxation, the eye pain may represent intermittent angle closure glaucoma secondary to lens subluxation into the anterior chamber. In this situation, dilation of the pupil and assessment for glaucoma should be performed by an ophthalmologist.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with any type of subluxable or dislocated lens should be managed by an ophthalmologist. Depending upon the extent of dislocation, management may involve correction of myopic astigmatism, aphakia correction, or",
"    <span class=\"nowrap\">",
"     lensectomy/vitrectomy,",
"    </span>",
"    or, in some cases, intraocular lens implantation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Medical",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of management is realization of full visual potential [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/12\">",
"     12",
"    </a>",
"    ]. However, optical correction of the refractive error caused by lens dislocation is challenging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Initially, spectacle correction is sufficient, but progressive lens dislocation results in significant refractive errors, which, if left untreated, will cause amblyopia. The eccentrically displaced lens results in myopic astigmatism that is difficult to completely correct [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When the lens is so displaced that the edge of the lens is in the pupillary aperture, optical correction becomes impossible, as one-half of the pupil is aphakic, and the other one-half has a large degree of myopia and astigmatism.",
"   </p>",
"   <p>",
"    If the best corrected visual acuity does not permit the child to function at the level necessary for normal activity and education, surgical removal of the lens may be warranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1\">",
"     1",
"    </a>",
"    ]. Progressive lens dislocation has traditionally been managed conservatively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/13\">",
"     13",
"    </a>",
"    ]. However, several case series suggest that satisfactory visual outcome may be obtained with surgical intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/14-16\">",
"     14-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for ectopia lentis usually involves",
"    <span class=\"nowrap\">",
"     lensectomy/vitrectomy",
"    </span>",
"    with optical rehabilitation with a contact lens. The inherent deficit in the lens capsule usually precludes implantation of an intraocular lens. The Artisan iris clip lens, which sits on the iris, is an alternative to contact lenses. It has been used in aphakic patients with encouraging results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/17-19\">",
"     17-19",
"    </a>",
"    ], but has not been used much in children. Alternatively, a scleral-sutured posterior intraocular lens may be used, but there is a definite risk of suture breakage over time. Another option is the use of a capsular tension ring combined with lens aspiration and in the bag placement of an intraocular lens. The capsular tension ring may provide additional support to the capsular bag and requires suturing to the sclera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/20,21\">",
"     20,21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients who undergo surgery for dislocated lens have a satisfactory visual outcome, with over 90 percent achieving visual acuity of",
"    <span class=\"nowrap\">",
"     20/40",
"    </span>",
"    or better [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/1,14-16,22\">",
"     1,14-16,22",
"    </a>",
"    ]. However, the risk of long-term complications (eg, retinal detachment and glaucoma) have not been well determined [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41557/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lens dislocation in children may occur after trauma or in association with ocular or systemic disease. It is important to determine the etiology because the associated disorders have different requirements for monitoring",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      therapy. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Etiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dislocation of the lens (",
"      <a class=\"graphic graphic_picture graphicRef77130 \" href=\"mobipreview.htm?10/53/11103\">",
"       picture 1",
"      </a>",
"      ) may occur after blunt trauma to the head, orbit, or eye, which may be associated with other ocular injury. Lens dislocation that occurs after minor trauma should prompt consideration of an underlying ocular or systemic condition. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ocular causes of ectopia lentis include simple ectopia lentis, ectopia lentis et pupillae, and aniridia. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Ocular causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Systemic causes of ectopia lentis include Marfan syndrome (",
"      <a class=\"graphic graphic_picture graphicRef67015 \" href=\"mobipreview.htm?22/3/22578\">",
"       picture 2",
"      </a>",
"      ), homocystinuria, sulfite oxidase deficiency, Weill-Marchesani syndrome, and Ehler-Danlos syndrome. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Systemic causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with ectopia lentis usually present with complaints of poor vision. Tremulousness of the iris (iridodonesis) occurs in most cases and is a helpful clinical sign. Complete dislocation of the lens into the anterior chamber may cause acute angle closure glaucoma, which is a surgical emergency. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Clinical features'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of glaucoma in infants and children\", section on 'Angle anomalies'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The diagnosis of dislocated lens can be made by slit lamp examination (",
"      <a class=\"graphic graphic_picture graphicRef77130 \" href=\"mobipreview.htm?10/53/11103\">",
"       picture 1",
"      </a>",
"      ), penlight examination demonstrating iridodonesis (tremulousness of the iris), or by visualization of the edge of the lens after dilation of the pupil. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Children with dislocated lens should be managed by an ophthalmologist. The goal of management is realization of full visual potential. Depending upon the extent of dislocation, management may involve correction of the refractive error,",
"      <span class=\"nowrap\">",
"       lensectomy/vitrectomy,",
"      </span>",
"      and on occasion, intraocular lens placement. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Tesser RA, Hess DB, Buckley EG. Pediatric cataracts and lens anomalies. In: Harley's Pediatric Ophthalmology, 5th ed, Nelson LB, Olitsky SE (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.255.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/2\">",
"      Nelson LB, Spaeth GL, Nowinski TS, et al. Aniridia. A review. Surv Ophthalmol 1984; 28:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/3\">",
"      Neely DE, Plager DA. Management of ectopia lentis in children. Ophthalmol Clin North Am 2001; 14:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/4\">",
"      Cross HE, Jensen AD. Ocular manifestations in the Marfan syndrome and homocystinuria. Am J Ophthalmol 1973; 75:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/5\">",
"      Maumenee IH. The eye in the Marfan syndrome. Trans Am Ophthalmol Soc 1981; 79:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/6\">",
"      Jensen AD, Cross HE. Surgical treatment of dislocated lenses in the Marfan syndrome and homocystinuria. Trans Am Acad Ophthalmol Otolaryngol 1972; 76:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/7\">",
"      Lowe S, Johnson DA, Tobias JD. Anesthetic implications of the child with homocystinuria. J Clin Anesth 1994; 6:142.",
"     </a>",
"    </li>",
"    <li>",
"     Sulfocysteinuria. In OMIM Online Mendelian Inheritance in Man. Available at: www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=272300. Accessed on August 26, 2008.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/9\">",
"      Faivre L, Dollfus H, Lyonnet S, et al. Clinical homogeneity and genetic heterogeneity in Weill-Marchesani syndrome. Am J Med Genet A 2003; 123A:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/10\">",
"      Faivre L, M&eacute;garban&eacute; A, Alswaid A, et al. Homozygosity mapping of a Weill-Marchesani syndrome locus to chromosome 19p13.3-p13.2. Hum Genet 2002; 110:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/11\">",
"      Callewaert B, Malfait F, Loeys B, De Paepe A. Ehlers-Danlos syndromes and Marfan syndrome. Best Pract Res Clin Rheumatol 2008; 22:165.",
"     </a>",
"    </li>",
"    <li>",
"     Singh, D, Singh, K, Singh, R, Singh, R. Dislocated crystalline lenses. In: Pediatric Cataract Surgery. Wilson, ME, Trivedi, RH, Pandey, SK. Lippincott Williams &amp; Wilkins, Philadelphia 2005. p.205.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/13\">",
"      Nelson LB, Maumenee IH. Ectopia lentis. Surv Ophthalmol 1982; 27:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/14\">",
"      Johnston RL, Charteris DG, Horgan SE, Cooling RJ. Combined pars plana vitrectomy and sutured posterior chamber implant. Arch Ophthalmol 2000; 118:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/15\">",
"      Anteby I, Isaac M, BenEzra D. Hereditary subluxated lenses: visual performances and long-term follow-up after surgery. Ophthalmology 2003; 110:1344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/16\">",
"      Salehpour O, Lavy T, Leonard J, Taylor D. The surgical management of nontraumatic ectopic lenses. J Pediatr Ophthalmol Strabismus 1996; 33:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/17\">",
"      Sminia ML, Odenthal MT, Gortzak-Moorstein N, et al. Implantation of the Artisan iris reconstruction intraocular lens in 5 children with aphakia and partial aniridia caused by perforating ocular trauma. J AAPOS 2008; 12:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/18\">",
"      Oetting TA, Newsom TH. Bilateral Artisan lens for aphakia and megalocornea: Long-term follow-up. J Cataract Refract Surg 2006; 32:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/19\">",
"      Aspiotis M, Asproudis I, Stefaniotou M, et al. Artisan aphakic intraocular lens implantation in cases of subluxated crystalline lenses due to Marfan syndrome. J Refract Surg 2006; 22:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/20\">",
"      Vasavada V, Vasavada VA, Hoffman RO, et al. Intraoperative performance and postoperative outcomes of endocapsular ring implantation in pediatric eyes. J Cataract Refract Surg 2008; 34:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/21\">",
"      Bahar I, Kaiserman I, Rootman D. Cionni endocapsular ring implantation in Marfan's Syndrome. Br J Ophthalmol 2007; 91:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/22\">",
"      Plager DA, Parks MM, Helveston EM, Ellis FD. Surgical treatment of subluxated lenses in children. Ophthalmology 1992; 99:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41557/abstract/23\">",
"      Ruttum MS. Managing situations involving children with ectopia lentis. J Pediatr Ophthalmol Strabismus 1995; 32:74.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6264 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41557=[""].join("\n");
var outline_f40_37_41557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Ocular causes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Systemic causes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Medical",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6264\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6264|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/6/2150\" title=\"figure 1\">",
"      Cross section of the eye",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6264|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?10/53/11103\" title=\"picture 1\">",
"      Lens trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/3/22578\" title=\"picture 2\">",
"      Marfan syndrome dislocated lens",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/3/20538?source=related_link\">",
"      Genetics, clinical features, and diagnosis of Marfan syndrome and related disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8745?source=related_link\">",
"      Open globe injuries: Emergent evaluation and initial management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/35/9783?source=related_link\">",
"      Orbital fractures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2249?source=related_link\">",
"      Presentation, diagnosis, and staging of Wilms tumor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/41/36504?source=related_link\">",
"      Retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/28/44486?source=related_link\">",
"      Slit lamp examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/10/38057?source=related_link\">",
"      Traumatic hyphema: Clinical features and management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_37_41558="Inverse psoriasis gluteal 2";
var content_f40_37_41558=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F62411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F62411&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverse psoriasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 306px; height: 432px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGwATIDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD07S3ivYGlilWaFXaNXHLHB6H3HQ55q+ECqREuSeVJOBVGwh+zMxtAGBd3kTAAkO7BJ/2s/wAR6981okp5RcEbCCQxOMf4UjSw1UDgEgbh1A4H41YeMoUZcMCeTjIoT5l2qfM+UHB5JFPwFVUwACRgjqaCrESEq5wGQr93j5aljWPl9o2nBOOQ1SJ8sgBYKR0Vuh+tSFVkmV0OGTJG7pyMcUmhNDGWOaRiQH29GRyCfqT0xUbJvJO6QseCWPT8askJHgsikEjJHA/GgohlzgNIM4ZW6jsMdKBIrssgKq6LuwACDgD2qNSHJCZBhPKZyV7/AIirbxptzsAGclcn7w96XaMBxgnOAQOP89qLjKyH5icgDdkAJg49TTMEgoykEnIYHOPf/wCtVspuKkZ4XgYGG/8Ar1HsRyBgBeqtkZXmkKxAw8tGZ8LGvBLdFx/SmbOFKrk9j1yPb2qyI8YJwGcbTkZH41BbkfZoxMNhH7s46DacAj8KRLIgQrc9CM+oxQUBZXUNkcbgThfw/wAallTbuyQMDkjufWq80iwI7u6xpwC3QHPTnsakSJCzqScDLN9T/n2pRteNml/eLk/NJyBj27Gs77aZ5gtmqzQscGUHCbgOgPduKq3mrJDAA8clxJuSNlxgKCw+9nham5duxLrdzb2tv59xPLG5XY6Rru81mxtBIHG09PxrC02OOL7UIrgS3Mh+03M4IKbmyFRSOwwfyz3q/JdytK0jQXNxf5YqI8RwQ4bqGY4PHG7r6Csy202yik3pCss7EtJNIxcs2cnknsSahsOU0oGEqxeUEKr8vynC5xyfcc1fiiUoGYsr4+7tJHufeq8EQeYA5QY+6Ppx/jVrdvdY8kqOhPXA4/nnmruZtFlVUuzdGJ7L09/6ZqZEC7QV3oxClQOnt9PWktQrFQCVAG4n0A6CrsceQudwJJyByc1SEtCNVVlyGbBJJfAxgdqlJVmOELEYAB4CjtkdqeibkVVByT8ox0AP8qmUbCTnc5bGY+TVFpFU72V/KRwykEvJwCR6e1SeU0nIjKsfu5XPy/Tp+JqfAIYN8wDYC+/rT9oLsDzIw+8QSB7E9KBlBwm92UM+zAyO3uAo4p6wZDbyAAMlivAz3Pr9KXyjJcgrK24gKqRggEDtTtjmaMJ5aRqPmGCzk+nPGPrRcuw5QuAFTeg539AfwpWWMuflwNvPJYY9uwqUDcnCnG7HPU/TFGSSFXBJGNo4x74oJKsiEJIFG0dtrAbR60eSJIgpfzV6qcAAn61YVArYJJkGCWC43VHImPMZnkjIPIzlfxFCJKFzOIpY0jIDuQqhj8uT14H0/Gobjz4I5Jn2OiDJCKVLfQnird26bQ0w2pxg+WcMfY9qQEJuyrupHf5enbHr70yrIp2sqXRLqsiOvyMJvvDPI4HFNPBZSoWRcA7yFH4HHSnWlxMzOkto9uoJ2FnDB/fI6fjViZfOVwwWTA64yPpzRcmSszKeQh2B1LTVOfu+STj2zuoq4s0AUDyiuOwhyBRRcVh0MEkMX7yQOxwpyMcdcH8+tNsI75biZvLiW26qj5zk8kj2xzVxVjY7omieVTnaH4qaMFUCN84cjDBQMH0+npTTNr6DJIy0Cq1vEcZY7pcED/ZxzRbxyxYCOJdvBUv2/wB49T9asQIrZ8sKWX8xz1xTolYSSbyX9M44NCBAMCPdIrptOCWx3pVtkROFBjPChSSc9evan/KGUlRluhZentT0ReWiX5s/OFGM+h+tAmNSOMDJgHmMMkMcmmyKFIDMAMg7SmNpPT8PXtUwYEx4MgDHkNzmieNWiYLuaU42hv4sc4yKQiFgRuZWCbsBt4OG7DpTykquFiIXYABubBINKivIyEbgE/urlc1YKnksDnPBPahgzPkd8lPLD7WwQmVwfU9sewpIoyPnJR33ZZgueD0x6emKuucGJCknzKWSTb8q46gn+lRAKZQynEMowTjB3D/GkIaYhgsvAwSfY1WZBCHZlzHINx2c4boT9D+lXFjkVg4UDA2n1qOWUQplhtOcLx1bPTFFhGRdXHl7S5g+zActuLFRnAGO+elU59P+0TxT3K+b5ZOyGcEovoxUcbvr0raktvklZRGskmSdyg7fb/GqMkNxGhDyxtt64i5IPQnmoY0rGPeWM80LyWk0dv8ALjyEi8uOT1LY5Iyeox+NOhFhJJ5dz+7laIp9nuGyM9GYDo4xgZ9OuKnu55wFi+yLIXI+ZZNiD3JPP4DNUY11XzfKEltGrOZMICy9+D35rN6GiTsR310Hjmur1/P0mOEx/MoATHV1b+L0249MEmsnQGC4hSG5W1jUCN5uWbJLZfPIPI688c1p6jNciW3kvp7WW0t2yywISQMZJ5PbAyO1VYJluJZpYo3dy3zty2T2pbu4culjXgMioxaTaGB2uRyPfHrTkuP3oiihleUY/dp6erMeBWLeXP2dTHa3chuWdQdsQkWEtySe3HJA+laOjpHOgWGK6dc8zTTgEgeu3jJ5/lVJ6kcvU2IJJLSPNzF/FyUfeTk8DGOR9K1k+SMc8dfMTHPrj+VVLe1Qs7+VHnGA2NxX6E9/er8UaROX+6W5cAZHTjitEQkSgNuJOUZscZHSnLGqLuXgrwM9M+uafCuNrKrLxkAnJNOaPI+fBHcsT09KYDCMqRubpgDpg+ooGBmJgzMgB2EjLH19KezBmVusZ5zjAH/16hdvN8yGMxvKD8yBs7c+voPamMeqjyiJEKFxypb/AApFkXzNiZ2rjLBcg+1SeXgKqOoA6D19fekcdFVWx6sen1FA0IrAAbQeOdp6fjjpUM9y0QXlsHJBAAHT06mpGXzcncwYceUWx+JqOW1DsjfeUDO2T+H6E8igpWvqRRXSzRs6OR0ORjJ9iO1BIIQEAHIZdxPDf1phxHL5cUEpaT5toBbaB3Zj05p8m9UIdULkHaiHHT/aPehBbXQCRtZ2VtqjLNngfQe9VI4nG4xRgxuzMcjOM8YDE8/5FWDC3lsAFBP8KjJI9M00g/I8eCjc/ezj8BTYuUrnGNskI8vhSWACHsOlIGiaSSEGLdF1jQhiPwqxEskkeA5cbsZCgAeoxUCW7Wzll5QkKTxuU+p74pByocVlBIVICo6EtgkflRU4iuyBtWIjsdtFOxPKATABVkYL05HBHeop/nglIADFeecA/TNTRhJC+0ofUcZpYYYi4CBMZzhurfn0FBZLCg2qpjIYAHavODjkZpzhFZWmADk5UZ+8RT1z5h3bHQ9t3NSNwo2oCQepGeP/ANVAAQGfeGZWxhlwDn8KauC7xiUAjpluoPf2+lTJGjFRJGhJH8YP86EhBcoIoGRui5OcHtQSRrvRmZ2hKg5wqtkn0471JIu7a7EFTjrx17U9AHzlHUj5Tn+ef61JJHuHzKemCTzzQAxYWDBAU+bkDPf601CJMLHGzFDghgc/TJ4NTYUKpxkjgrnpT5ESTBJKj15oC5WWNyW4VR6A5JP16UhAXHAKEZHHSpSx34QFmBO5VPT0JPalLswO4bcHAbqAf896AGkbQxXnI+7npVJ0VWLknP3SSeo/p+FaEhGGJJ5AHsKruoPI+bikCKkigCRuDgYbtVO4iLwkZZZFHBBH51fkVWBBw2QccfpVVwGDZ6kcnv7GkUlc5vVp4IV2Xdw8Trggk+WjA8dQK5ueW2ukgjtFUQuQok3FGl7lQeoHqeprpfEN3Bb2JLy7TjCkrnJri5boC9SCKUMrS4EpQuYSOcqOmDjHPT9KlRu9T0MPRclexq6hqMkcAEcECOQRDacbmHTYMfxY+b+dcrZRaTcXMsa2iSbn5ErENFJ/EpGf5VD4nl07VIV1GeCVZbki3geEvFICrfNt9+MnqeKxNRjuY47aFNQa5tcboXvYd52jJKmVMFm57jNKdJrU1jhG9Eeiadcrb3a+Qm+NlKRIVwsTYxkDrtPvXZafAfLCk5ZR94DIyepHoK8p8CalfRTlru0klMjKFkMoyyjoQHxjpwM9q9S0+/hCojl1yd2HjK5Gec8VMUjkxVB0pcptW6DCkAbAeM8ZPerDbXjIDck5LkcDviqNtNHNgxyIyH7p3ZArQhGUBKld3OOp/wDrVa0ONomRiwOCoDYqQISoO0lmIPzdabCWPYAjlsYBIqVSeOPvckmqFYDH6Md3ViTx9KCg2EKhCuc8YG760oUwxFVaRiPvSHDE/T+VKyhlRn+5xjHBoAryDO37gdB8wB+77UphdWLHdtJ+RQoBJx6ipyoTLDYFPLEjr6Z9aGOCWHEhHGep98dqYyIRtlNg564zkn2pAp3NJgHaDluCc1L94ocOQQcFeAff3pVQY43AMcHaOKBlCVH8zKHcHxkP7Z6n05pohljUNGgZXb5k3bSPdc5/KtB1ctt2ZVeAc/zFIUQHLrnBA67efUUDuU+JjtV8OhxsfhifxqJ4SjZjQ+YxzsAwufUntV2VAcDakj57LuI/OoTZx5Xek4UKRt3lV59s0aiQwRSZHmRhwvJJPT8OKa0REshDDOBkEYAFPWFYXZCGGW/d5PBB7c9DU5jO4BwAQM9M0gsUMAceagx/s/8A16Ksq1ttG+Zw3cFec0UajsUWj3FQEzg43AfcFWYkKtjfuB/i6Zx61BEZzzuQsDhkYEc+xqZdshIj+Xa2GRjyDTuPUnPO47c8dO5NPWEqDjc2T0z6+wpE7jI3Z44qRMFNowMdck00IfGGVRlW29MEdPxojxlQyqVJwTu5HPSnQMwBZQAAcAZzTwc9eF6ZKg/lQIQkbSFypU4PJBK1Kocgqyg8dc5/lSBQwBUA5HzYJ5FOhjRlONgY88ZJBoENVHPKYDnoKUoQ21CVPVXzkD1qZ1wBlCWP+c04jbmM7QTz9T/SgVyBEWJdvBA6kdT9felcfIc8gcAEZGPSpAR94AkgY4HemuuSMHtyQe9AEAXJG3g4z04xULptXI54PLd6suOo2g56DPOahlQfMcn5uTz0pFIpTDC8AcDHJ5x6VWORHnGVAA3Yxn1/WrUvyP8AORkcgdOnpVaZVAVRlT2CHGeckUjVI5fxY220uMFdkZEjSSLkD2Hqa5S6YX0dwsU06DATch3xnIBY8DP+RXY+KVi+zGK7zJbyMMEfKyN1HPQisiwsIwpEEufUDhCScnGK0hsevhbKld7nAeKLS4kuLCeTyzFGpRUkSRdjkErkrk5YA4Yjg9cVlaJqulrf3FxGZ2eaQ71m6qOm4KCecggn1xXX+P57ePT4IEAt7iScDzDn5Ez6dx3rnoNHtPKiFuuZLdfMjiKjHHVznn5vetZrRWPQjBSppyNnw9rcNxPHHcSmaS6BVYmRsMVPXoeMHknoa7nTbyG3a3SzWeSzdvJ2wIzquB1DHACk8EV5/pumwT3qvHI8drKpLWyMcYJyw49Wxx0r0bT1aO3hjaC4O5FHmRHKk9zt7YrmkrM83MKUIO8ep0FtIGI3xSRM3zMGAHHpxWnEhONw5yTj19qy7aF2cPLEUjwSATlmJxkn0FacasZMKuTzjdkD9KR48kSMxAAHUnB6YFSxDAJBDHgAdvrUduMl03kleRkc5qwM4VnI+pAHH+e1MgVU52gnk7iWPA96f5QYbmyCOc8cfWnIwAyV6nkinswbO7cEzj6mmIhih2ymRdzFj99z936VHEmQzRxZbJXexP6D0qd1mKnlVIGVGensTTyg4eRwy8liRjPtQMiw55CpgDABP68UgyHdw4CjHfgH2HrUispl/dh9o6FlwPy71FdA+WY03fMw3Bj2zyee1A0hGUOm6UN5R52nqx9T/hSNCgbCxqARhfU45xmnSTxLKkYdfMPRBjP/ANakQt55bgZ469fXmiw0hArJgcZJ4bGPzppjxHgDeM9Av60qblViQO+MelSlhuB4PofegLFRsbfnjVsnnOSPzqtBbMqMJCI3ycmNjjHatLH7sg9ByfQ/hVG7fytwjkjiXBzESDubHAX0NIa10Ifsjt8wuL7B54ZMfyoq1FqdmIkC3SBdoxkH/CimFmYcM6rc4jbHmcBT+h9quggGNgGL7vmIAyR3P0FUl2RwuMFj1YkZb8asWM8V/AkmVfH8WMcikNrqi8GKkbtuO3GOPenPw2U4J7gdKiRFPO1OuelTO+wZcjYOpA6UySVFKkgEqSOuOafCoLAFncDjPAyfeoN5XO/geoPSrkYVgM4BxgDHB+tMT03I2dJ3YRSMWjba7bSpDDqPQ9asxMpUsSDx3NMaRWwgIOB0H8P0qWMgoAVDDpyMGkIWSPzFPmJ8nscECkMbEjJJXPQjP5HrUgXbjceccUdE9M9h1FMQjD5sgsTjkZ6/WoJFkByo34P3Secex/xqdsKgVm4Pc1A3UqJASo6Nzk+vtSBEZ2tklRtDYwR0PeoXRwVZQWXuCef+Ampt/wAu6QlVwM5FROzJCQQQ4GATnJGaRaIWIkGY2BC89Ofy7Gq1w5MjYVQOuegzj0qTdE+9UIEx6DowqFwEVkd8NnqT+IoNUjnvEkUk1jLHgFQuWRRnofWuatYLuzvpQyRi3IQo4JYx5B4Pr+FdJqNzH9oePeiBuI2Zjnd3qnpFpLboyvO0xLZJ4G32xW0F7p7ND3KTTOY8WK0tsF8zzJwytIyR4J5wArfw9Tz19ayri3/s8SfaUGZhiNw+dh9Seo9MetdD4nBtrR7lcW925DApzufcPlOeoArLl0tLa1iKRmdid0u5jl167R6H29a6KitBM7KcmopdCzokBiVWCxmA/O2w8/THp6131nGyPbxIqNEUzLIWKsvQ4UY5yc55GMDrXn9jaqSu5rqMsQ6Lz8nPQgV3ukSxm2DnJzgAgYLZ6CuSrvc87MI3d7m2nIZnBzJ87N1CjPAqS3jctuldyWPTO1cfhUUIfO+Ug4+UDr1q2hGQu4Djk1meS0TKByECqD8ueQamRflODxxwBj9agjaNVUyEBenvUqSsdp8qRxjIymP500RYlyFG9+FUZJPapCAxGQGAOck9KjhdJFKhQzL13etP2GQ8lgB2XvTJY9Nu9do3HOcE8fhUSgyORhSAflIGakAwTjII6Z7U4A9cuSfypjQgPDFixUDq1QONyBsKRjgbe54BqdxhwY0OR78fjTRnaM8EchRSAri2hhfiBNy87yADn61I5JXJPCA/dP8AnFOORkgfdyBjjmoyob5cDBzkCgr1GFgRlSBjrjnPtRId2/aAuBjNJdTrBCWJbaMbQOS3sB61V8+VoSQrhjyBtI/MmgaTZIpeYsWUpGpwCf8Alpjv7CmbiN4jjRVzgc4J96SNAxwBsjUDjPDH8O1KzqRliBtGSuelIY7juDn2WismfQtPuJ5JprOJpZGLsx3ZJJyTwaKV32KtEgd9u11wzZwVHUg9frVlUSPAQInzfw4XA/rWdEsKzFpoYxEoOSvzAZPUdxVuOzxHm2nm8r7yqr7sj8c8UyS1HLI5Gz5jk5RuC39KsZM6GF12MwwVJw2PaqSwDEaMd284y67Tn0yOlWfKmdMCRmB5CS4JX3DDmgRZt12odg2jGCAKsDcgXjK+1U7S6cuyTx/vE5yhyCOxwe9Woz5nCzsATyhQf1pkyv1JhImdg4JOQGGP/wBdWvYYPrkfyNVGilzhlSRB1BBBB9qswCYxBiYy3IyFPzUEj4wrcKeR0z2pdpKgggEf3ehoZCPmLAH2TmmbXhX5QZMHkE/40CHkZ2lvmIPpzUTYbO9eRwcDmq8l9Cbp41dJLiFgkscLhmQtyFdR93IORmnSzRM5GJ1bsVjPH+P0pDEkcAsHYlW/LFZ8nmtcRCK4jaNVYlWXc3sM5qxJJMYlZY/MbJIITuPY9KoztKrh5UCEsNpCjAwDkZpNmkURXtmJSGmmLr8uWKhADng5HXnjHSpZGcbshWdWO7PY+n/1qmnYTQlSAWZQFBHOT149KZdusYy+Uznnt+NI0T6HGaxdNHIY7a0uHmO5tzR4X3JzU+jETWiSSMUYDa5VCCW75/Csy+vhLrVu9hIbuRWKtFEeqnOcseK3tMndAEMJVlUF9rBmVckAkd8D0rojsj2ppwpLQy/FaA6HC0qib51V2C42Jnl8jpjg1hPNJGTCI/OdkXy2QgeYMdgehzk12uvQRLpzXKl0VWALqfkYHsB0OT+VcvdgS+RFsG+bOwMM5A5J+gFdVX+GgozTijncMl1DO8MNpbr99ndmbrk7sfyrvdBZ57YSYlddwIGAFT0Udzx3NcXqFnGt9Ass5uIHYKUDhiHJ6k/h3rvPCiBdLB3KGDv5mBjLbjxXDUehWYyi6UWtzdQkrgJgryQ55B9Mfyq3IFRdwL4A5Cd+KqgiSXCEA45cYOB6VMsYAjjbJBBUnPSsjwSW2Rg4MkhJIABA5Hfr+lXYgwb5SSCTwep9BVOzYvGpWQjadrcDb+H+NXomI+Xb15HpVomQ5UzIAG+u0flVhOSMY9ODUSKFAC4RBwQKlBAIyeCOPemQwcYXg4XNID8oB+X8elIoBbcQWaTovYf4UyWZVPlf6x2JBWMdB70CGyOHADNhfZSfoc9KhjmaRWKhY0AIDEcN7j0H1pZcM6iQuNrfLDGclv8AePSnyQxsN9xhtrZ2FsIp9x3/ABoGRLcJI3kwy5IHzMgDfgD06c0FlihOGBPYscsxprlVSR4RGuCfnCdT7Co/JkjI3S/wkyOUAH4HPFIqw2NzuMgWRnwVU9M+pHtSyT4jLEj5V+bHJFSJIkiR7BwPlyRjOPSqt4itBIwITzeWYccDqxFA0LEXRVjRdxQbd2Rt/P1qOUNtDsI0VRkNuKlR7/4Uts6zRRyxoyQuB5ZIGSuOD9KWV0CkSlSGBADLnP4f1oZWxGJ5SAQikHvxz+tFM+2z/wDLOwmZOzb8ZHriikFmZFrNCJ3jaVGc4ZSSQWA9R61NFJFC0nkyNHGcOpVd6ISe4FMmaMorCPM45R45F3g+2ecVYRJjMEmuUjkY4R1g2O3tkkgmgVxLPUBeSSoDFvT5GcOQM+ynnpWjEkxQCcsShyHjwAR2qs9lZhEF1BCVyT5rLzk9ST6+9V4vLguBbq1tMmMKrfKQfZvTvj2oQvQuEyDUIJTICNrhkIweB2I4yD61pQqtwg3MHiIPB55/oaybeQAFdyJCBgYcSow98HI9c1ZggUyMj3AR2A5Q7CD6++aYpGgq7SUE3AxgO+fw5qe1jAtwpV0JzwzHg5rPTyY3/eR75OiyMNwJ9Cegq28bsrFogo4yC/f8KZLLTIjjymy3qAeajkeWPuMHhGY9/Q0qOyuUfywxX5VHGP8AGq11iS2K3K7U3YcdBj60hWI3liDySTBEnkAT5BkO3QEEctg9M8iniR2QIjAbwGw5O4H1IHSklgEsCm4ZF3AKpC/6sfwgfpWdPd4tVjmv7eKRRjfuXKNnHBJ49s5FIqKuOAnlmkZJhGDt4wTg+4z0PBqGJrgP5ErhnIJB3fKRnkbsZz04xUpmithDbmUvO+HfjczDrvOO/HsKhgk+1lZVyjOdyBxglQfvfWlc1S6kojcFzESmSNxjOC3H945NQ3FrCUKta5bHJYFjz1wc9auIHQFXAKjkEZyTVa9YhGMDFXIGCBnNSVHVnN6ppxlRoHUNbxPtVJBuDp1HI+ZSPWq9jew2jCPzTJKzeWnmdQvUFj6AVW1m8ubSOWeA/aLmZiIUjyMseADn86g0m2PkkzRyT3O7ezvHsWRj0HXk5yOa7KSue5Th+6956Grrt5b/ANiRyefJAZbxIwGbMTNgnOe2dpOeM5rnJLySF4kRN5G5OM/IG689jxWx4lkRtL2xQRu0EkMU+VyvzAkrnuRnn06VyVpdMdOSzLxExpxOZS24liSQBzgE4yetdVVe4h0ad438zX04w+dBLhmlEgKh1HKbSdp455B611NrbRJm5gtopRIC4XBURsf7jD9Qe9cLfXl3JaTNcE2s+4YbqpKsDuGOhP512mhXBntI7lvLM0o+UqT5YXsE9Pxwa82rHqY46lJRUjZsp5NymR4mMi5K7WDgjjHoT71oxuzcS27EfefYc4/PGKz4HjFyiysPO+bYeOgH8PsPero/elS8kfytvHB4PY+lZo8hosBSbdi8JiG04DEcAdOnSr6znG9I128EEsFB49KzZw8kLCNYyMZYyA5YZ59vWo7GSMpCvIhhZkCMBwVOAc+nPFWiJRurmmt3F5pXYwZsAkDco+tWQgYiUybXwRnqP8KZHJuDeTmUg8c8L9ahDi1fMQaSIkeaijO0nuP6imZMkiXcqefI88hHyxjAyPXAwPxpUj8mJPMVYUDEFIz1z0ye9Nt/LbzdyqxB2p1PyjpintExeVk8tcggbgTt/M0wFh2rEfLCJEpJ457flSK8ezzHbKDkEjqaYi+X5ckjtMfuliRgevHT8qfKxVgwG35SEBIBye9AEbNgR7gNxPzKeDwM9u3Sq+1DLudd8jNuBl5IPoF7U7y48qZgpmIxvkbk/QDtTBcQ2kLNlFyMBVXaBk4AA6mkUiK9nuTMsMNugbAZnmfARCccBQSSew475NV3huJ2cTzbo84wsSqCOuMc+gHNS3FxJBG8trD5t8yeVGpPLc8Fj2AJJ9aq3LRIga/khMbAZRP4mHTjq2OwFFiloQPfQ/aZbWO6jkuYWDyxh2fCnnoowPbNJdXDLAzyDyUdlV5JcKVU/wAKDn/Jqhq+sw6bHunjFv8AKZZMlInMY4DMvoTgAdc1wPizxIBbxDUXmgMrCRIWdA56kYCFjgAdQM5OBSbsaRSbPR11K0VQrI5IGCd/X/x6ivnV5PiFO7TJBBAsh3iLz4E8sHnbtY5GOmDyO9FPm8jTlXc+hpbgXkMaRafc3cLnZIrqqrhf4hu7cVVe9lAQJpx2s+NrS7ohg9QR90+wqzpgupEM81w83mfvEib93LsIHJ7N64rQjkiyVF1CiyYLq8WM9skE8Hikc97FKC41C6SaO2QIU5yZRMqDpyvDH6Co7K3mnmt0vL+K5cTliwY7SAOm0fd+hrQuNLhvwJBJLJJFlVmhVI2H+zuA6dKry6JPCzXcV8ZJGGN7QR+Z7ruAGfxH40wTRbkjgtdztDFEmdrPEQygnqSMce9JLZMQr6e8cYDZB6qD6A9gauRLemOMi/jdWwB5ltvH0OD+tZ1vb6hvuY3ljtVDjE9tBhHB6gKScenPSi1hJmx9oJtlF4d0edrOqfMD/tKOv1FXo5MWqSW+2ZCAEAbr9DWRbRfZpZJI12Qum6V4QH2t/fx1yR1q4lr8xudPukaQDpnKPx0Yfwn3oIaLSSxSeR84McnABG1gR1HNQO7Tb0idCqNtcuN34jtRGXurUGJ2jmdP9XMBhH9CBzwe4qO0nmWLyLyBY7n+MHhH/wBpSOo9utFwSIT9pjBhlLrgnY6gEMvbKjkAVRv7IyWrxs0EZbmWa2toym3qc7wcZ6Z7VtGNooXZv3mANzr1OO2P8Kos8cTB4oi8kmdsCoeeOQM9KT8y4+RzOm6fDotyyaWBp63UbIkTESR3RCMwJY5O8YPpla0bKZJLG2lyvmsqBiHw28/eVx29j0qnrKzxPpe+EvMdUjn8mI4VGwQRk9Rtz+PtV2W1jJdksYYtu4h3kGM54GB1/pUbbHQ9bNmjHKvlMcuxVyMAdQDwaq3cuxGWTdG2OoPB/L+VVIb7UBBuvLSODam4qjeczAd1HHPsc1k+INRfyVES3c027I+by+OuWzgLRH3mVRpOc0ilNcQv4kRpXjZo4cQEj+INzg9N2Ku3Mty7S20NvHbRSLuaV2G2Nc/eA6l/QetcrF9vufEoL3iB5IPLeJ0D4BbO0MBkngHNdfZQW7iQNGqToQCDlu3Td1wa7qcT2K8FTSv2MLxZGi6FpcVvIZ5VPlbHcDaGBPmYHG/Jzk571gppqRvFdNItsLUfZxFEoJJx34wxJ6Ct/wASXsMsNi1vIJIreadZyIwWj2YzwP8A9ZBBrkrZnvTGlwd0jO6xtGxEcXOS23p93p7muqqlyo2w8Zezv01/MvEXLefHNJEVbg7l2lcjoSPlyfeuj8PX0JhEtwPLjRdhVc796nBVgO/TAPPNZtnYmBp7TyZEiVyEKEhHQ42kjuTznPep7G2bStQikijdtxYsQufNUcLkf3wM49RxXDV13DEctSNjqyZZkQW8TR5/eIGcAhs/ePHQenfpV22m1NmKSlGdcbhDDkfmT3681S8PmBtMt7gH/j5zMkkn3pAxJHHYY7VqtIY1maMxCVepL/KVOME/0rk8z5+fuuw63lmjXdqTLbuz7hGrZWTHAIP67aJri00qQS3JSK2nkLrIF3AO3VSewyMgnjNQtdQRTQDzTIHkKGa4DEqxHGOPu8dulXhN56+SjpI0isCAoGB0O4dgD+dWjNq+5JbXEN0vmRTLIhJCxj7oPfcB3+tXIpCfMDyR7F5bcNn5E8VhqkEdw11LGBIri08qJtpBUDnA4Y4555xjFWby/hilS2tszTSkqY3Ykx8dSMHH0qrmbiXIJl86eOzL/Zyd7P12n+Lbnr9fyqaIwRuDb+WYz99pMs5Pqc9PxrKtZjc30ZEF7FBCohEbKIo2PVTg/Mw6+3SthsGFjdJ5m058vZwPw7mglq2gPJ5ykFZxEp+8FCh/YA9qrXcXnOIQ6RoQcknsOw989T2pFkmNxtI8sEcRb95X2x2OKqzzNlltjG00QHmTy/cQH+H/AHvRRQNIsfZ47b54TsYDDSk8kd/nbLGs7VL9NPgaaztTdsSoMhYJGg7lpG9Bk4GfSnhDMxnmMzqSVjR/lyo6s3fk+vQVzOt6mk95aCGzk1OQuwhjiB2gjC7UB4I5JZzwoHvSbsVEtS6jGbuVX+23XGdykx2kK9gznBd2znaM/hXI6x40vDcRWfhTRs6hdBljupZUDAKcsxPO1B/eJC896fqaadpoebxJqNu1wXI+wRASxQSHBEUMIOZJeRknjJ6AVj6drF9q77NAsrCW2tpSrWsREkcJBUK81wcQNJzuCDeF4VRnNRKRasLpOg6pd6lFZ3l6Y7q8Rr+6mtLY3jgcohM0vVic7QBgBMgd6rX8Ok2NxLeDS7WWKIr++aUSyuAdsksrlslsdIlwMnpk12kWiagH1B/Et6JkvFSGWCNysLMc43upErFehBCpgnjvSX+g2V0sNl/ZXlQWxU2tpBGDGWXnjAAjyCSCc561OrHGWurPKz4a1+4Jns9c8i1k+eKI2TExoeVXp2GBRXqUng8vIzLe6kFJJAj2BR9OOlFHKdHtvT7v+AbEOsqbPzPss8IjIBeORTEABjcpbBGaqr4ns7kzQ+VqsM6EFknsWcYI5YEDaV75zVKbWdbS/jN9oUNsPuS3m4XCKMfcZVOR2+YjrSTtZ3URntbO4vXRi6RkOphccFAXGPwzitrnKkup0Fl4ktpd+Ibu5k3BN9hHnPHBJBwp/wB7FSy60sDRebbavDLI4QIYvNJPuEJxx3rlHvdSO3fo/wBluXBVY5Nvlf8AbURkjH1xW74Xv7+VJraaC3s7i3I3QwjcrxH+JOdwGcjJ6Y70/JC5UtTRlvbyGVpIVnt4mO5wyq4IJ6bCQykdc9K2Uv7VdiCXy5n+6sr48weqY4amwvA6AtBMAcZ3qXGe9ULrT4IVMckbW+nFgxWMMu1v4XQjhfQjjPWgjRm2ifZlLwv5YyQolXKsfqOlOWKG4Duu1LsAhsYP/wCtazIbmfSpIY3Z7uwZsNdKAHhB+6ZUPVc8bx+I71rXKo0ykL5M4yC6rgj3x/EtIlkTq6BZhAZkwd4j4bI7gdj9DzRMy3EChJPM3qCnmpliR34/Kp7eXdEwIKuGHmBenI+8vtVJA8FwG3K0cshyWHyqR0Ax90kfgTTGtSISXMULM58yTOIz5J/dnp2NIbkhNqKZFI3KVOTJ9Pf27VJcupujLGJYnXIBPCsenrjFZd2WiuLS6khl+1HeTJZDenIGQVPqP5VDdjSKuNuy73dkGeNCxLhCCdxPAUH+9ycVPI5ZxBGoRwMBG+6g/DvVR/ttxcxyFI4xFmRhM+MsRtQbRyMAk9etXbgb0VUT5k4wvcD0/n7VO5qZmtTXMUcQRYJ8Sp96XywvPXoT7YzXK6pq7vK9tMlu9uC2AlxyMdiSuDW7r6MLRnvIklhYFRJ5nyAZ4Lrjqf7w6GuOi1ZLec29+7xw7yXaOXPzHgBsgf5PNa0lqergaScXJK9i7p19bNKxmaVljGDAxBY54JJHUAeh+tav9p+Un7iUJGpDeWePlHcsRnNYev2cS6LNdO0Gn3yBpIZNqo0bgZUBxyWOB9agm1FN1rFPdEahMFaaJIvMKybPuhemScnB4Bruguh2OMKi5g8UalaRQWF3AtvLfhj5kEY/eyIfv7hnsMFmPYVW0qa6tLiFW0kxQr8srb0ZBHk7QFUnB7/QVpaQ9hq7vY3mwxSK8c0cqCOZ8gja74yM8cA9qr29zcWSR28EEZa3VonkBVVAU4V2A5Pb8a6qq0IdSycEv61LujXtutijx3C3bSEys24rg5+VcHoACBV27ukW6txM5j8xmDNgZjIwVIz3B657VVa+jW3mWW8gOAGcqm0YH3gPcdqxtR1OGOG8VUupL2YDyTLaHjjG5geec+1edPTcmEfaPY6bwdcQx2twhFnG8czkeax/eoWyDySQecYGRXUtHJIqFVS2Un5WA3SP32hTxj61x/h20to4Y7a4t7e5SEs4VUBkd/vck8jnp+FdLpiOXWe+fy42BKCE/OgJyEZs5J9x1rlnHldjzMXFKbaC8uNXbUTAhtL3bG5aFIvJfqABuyRkA9e/tUtqRfQi+tLtpLiE+RMHj8ueA91KnnB4yDnjBFZ1jfQ2yi9F7BCZZJBJbBgxUbsFznlyNoyB+FXZgdSeC4iWSOWNSTfW42M654Vc5DDvyDilHY57F4RO18l7Es0VyI9lxGcNFLg4GRxyBnD+nWnLqCzX0du8lzaKhDgPblC7HP3Dgqx4x1rJiMiBxd2xClwkOZ97PxkNIRwOTnHStyyntXjZbmW4b5TuWVyquO529Dj25qiZq25pCHysyN5iSHIcM25sEAgc1BPOg1O1iBlEghkcnf8AIigjnJ7/AF98VnfahA4tbTzkBGXd5PMaLnAVSc/Mc9Ow9KfqV1ZQabPc3V0R5aFjJMwUBR18zPGBzxzTuYNalozxxRP84UO+GZPvynA+Vc+vT9aryXCwrEr+X9oLGOGIHiJj7n7zYzlvyrk/D2vTXzy3cMczXl2BJG9zbkQWEJUYZmxySPnwcdQOKj1bUUe5Om2kd9rN4tuxJSICX5sZAZvliBGOv3R7kCouPls7Bq/iSG0sria5uhPE8jl2R90jYICwwxjlnZsDgADJOa4nWNY1+a+KW7RWeqXMaQzJayGM2UC5JtxIQQrAHdIw79uK1p9Jg0a/D3dlb27WEDTXMWlMXkhJwY4zM3zPK24fMMcE9MU5dX0rwvbqupanFLeCQTXcNugm2DHyQRgcEscBQMbsEk9TUtt6FqxmeDvh/Bbotz4msrsp5jQW0du5lac5y8rZwwXIwM56Fj1rv9Oa3EpttNeOzs4cwqqSmdI1U7goRRtDkktgZOMVyF5aeIPEPmXOtyN4W0CRCzW91Jm9ulLAETOOIEYkHyh3zkGt+00rVNHWyaK8to9PgT7OHN1K0kfozkAKzY6MR8ucdKlK2iBu+7LmtubkW+n6ZapbMXTzJbqJ4QVlO0DYP3hY4JwcZx1p2q2ZaxR5dUuZBBKJirHaJHBG1Qg5UcZKgnjrWXHHF/al9fPfXcl0bq3dxbkx7hGhXa+OWIBJZvoBnNa1tFeSzACW1utMtUDeaQUuHY8hGQAYx7YJ785ppAtDJ3+Jrn9/bQ3fkS/PHu2qdp5GQZMjjsaK0n1Cx3tv1vTEfPKyapbqwPoR2PtRV2NubyRx2j2MmhgxyavqUM+39zfXcRaBRnOx/mYd+Wr0LToriW3aRJLmdJcN9m+0KoweCykD1FeeR+I4JLRIrzRtX0a0dg4lmgX7HMzdAkxGDn1Ixmm2JuNIu5ItMmlkhKpIsEupHyxMzkMhk2lUzlTtHBq010MGmz1qK0mhQugnSVsBhLKhXHTHt/U1k6zBJuh1G2Sxe5hO3cEIDgHDIZAceoIPQ1l2d3d5giv9EtbK9lJRkMiTK3H8MisD/KrUvirS9JmbTtYluNPnAI2XFuWjwwz94ZHPTmn0JSZ0NvugYtMLmyLYImwpjIPQHBx3xnitF03CaPzZ8Mh3bjjDduPeub8PW0MmlSS6XfKbI/6yCK6EsKgjgqOdg56ZxWhYpdiRUMq3nkoGhMvyTL6qSpweOhxTE99zS+ztFtfzC9sVIljb5grEY3ITyB6r0qrYQagZIre9FpNpPk7ElVm8+OcMcEj7oTbjvnNX7C8iupmjEu2VF3SQSDDFT3wOo9aZAGhkubcPlJU8yNnOUY9x7HpSZNxYwTdtlSJoACQrY3eh+nXio79DG7SW0qeZIRjzNwDegIHT61BdXYglguZJGQLiKWNl3ZBOBz6c9atGMqZvs0kSS5+ZQOvGPwPvQUkVN80onMtuIbjsjH5WHXO4ev0qtJeQSiGe3HllJQq49T8pB9ADxzVu5lfyWlkcpz+8IbIA6Hbis94re1uJlhEK29yN08UhAEoPBcH16ZqWaRJo5Ht7k21wVwhG2ToTnOA34Dg+1QTIkkIa6iR42bKIHwVPbGOprPnvkN3Ai36TxOjxNCwDyGM/xIBy20jBJ7E5qVHnlSM7RFJtCkyAGT8F6AelSaJHJeJ9YW0SeG3lJiKuJFUE7TjlSv8ACw4IPQ1zsOr2N5bxyRZnYBiftMXmIoGPvL13E9c/hWn4thOpaithbzKAo8yeEjaxAJ27mPO0+341zkjHT2e1ZbGPUnKB7kn92kbcGMjHzA5/l0ropRsfR4eMI0fMmv57KK5jtnaIRqSxt5omxuBwoB7DOSM+gqSWfy4pikn2m4DrIzAbN75yQvfgDk/41DqtzHA8UUckUsYjaEHYx2nuOuGGRwT056isKLznu7OS386WRbclWI8srMWyI89DwCc9K6Yz5ZGsVeCvodHodxi8ml07T4ryVkC2k/lYUQsR87JnPBPJIrSuQ+lpc2biS/lTIlmyA43HdjH0PA9qyfCGpXEGvm+m3NLfWkrEuoTCpzt3DjGRzisLxHqFva3N7BYPcX91bSS3kt/PKoBkZeFVT1jHHr7YrapWSjqcUoN1uV7f1/X6G1fSw3epXkUCvJFBPHAFtwRmVFBaUt/CFHAHUnJ7U83EENjctaQ75Au5I3k8yQ5bG4Hkk55rn9EvGtNJhiWRlmUF5GZDiVmAcsT656E9RW1BbNcLFealAWlmXJuYh5UkRkyFbAP3APTjPauJO/qbwh7N3bujds9UiubSV7e5WVpBskwVaRuMkJj3rrvMtbDRIbvU2lQwqn3ch9/ZI1XknPHvXi1ncpbtfQQrYI0KLF9puflYqzFRiMclzjqCPet6xfS45IrnV5brUr9GBEbeYkVs5+4I1XgYHJ6kk1E3zxuZ4zDqTvE9CsZblbw28dok0xE1y8RdS6u8mAjEfwLk55zn1qVIbZNSu7tNOEF5CgWdIZNqeWwz8yHG7BH8IrPtrqezgh/sudGu4YnaOCe3yCCflDPkMF4Feea/48nlSBZ5EsNShQyJehgwT+/5bjJbdgLtwMdK5rpHjtO52mpaha6Ro91f28APlyNbiK6O3y9vUAZztwQcYJrite8Z6ykVnBpcs/moElY6hbbI45MfLKjNk7euAenp0riNQ8T3YuxfC+vtQvUEgs9kXllFYfO7bgSDk4AHOe9aejprWt2N3fQrKTbYVXvJVlu5SAN8gUgncMgBiMIM455pOTKcltuegQ6/r11o1pNrNxYwQSlWVIFWBPM3jqVJZwAdxz8pyM1u6bp2iS6tHdalLqupXduMx2WpXCokIViPPkJblBn5cA/QmuWtvCup6ZBqbaxqf2bycRy203kG0lj2KUxuPyNzyQSWxzUWkeKo7+3ZtI0K78QapB1mtIC1raOudpMpUAgDttIPAHPNV6nK9Nj0ttSfVrORLL7ZJHuR3e2HkxQbjw5LYMrgciPB7ZrA1nx9pPhaRdK0+x1LUdVhbc0BQGQLtOGmOcKWOCSeg6CsDxNrPis6YsurXMel7HXzbZLhEWInCtLKc+YznICxDB6HAArB07QEnZbY2lzMkkhe00qGYI91zjzpXPO0HILvgE5C8UnJ9BKF1qUrbUfEPiWBYY2nW1WVbm6eycPJdXJclf3p53EkiNB/dBPrXoHw/wDDH2XX31htMs4byH5bQXE73n2SXGGMzrhWnIJz2XgDHNaul6fZWUkWmJZ3mqaw0RWSC0ytrZKByoJ+WNmBxvOSfmI7CurayltpAZ7iwggQDyLbToTvUA5IDt97IJycDJoUerFKXRF2Cyu5A99d38m7AJlZYY4XwDnAw2FOfXPFcbq3ivS7y/8A7MsoZNau4XXz5vs5a3iGQBuYACQ5OABwcVyHj3xHpfh7Vcz2k11O8ZnsreK5zbsBn95Iozjax3bwPmIK9qfpev3v2K3sYYhDbTE3CnyMykDBLw2gLSyOeokk2qDzxxQ5IpQtubGm2mva3qqXukCe1tykkBuLydXYor/fSFAvzKQQuT0yK1bW9tr1Utor271jGZJ5J7ZyJmX5SiDbtABB+VTn3PWo/DVg2u2EE9/cXU0wl+a2m1DfOqfwmdIwAjHHCDgZ5ya6ax0iW3hkliZTG24mP5lQ4IwevyseRkdcZoSaByimcddeK9JS5mQafLhXI40kEdfUrzRXV/YdQi/djVbtdny7WjQkY7E96Km0u/4f8E154dvx/wCAcBYeNtIu79Wl1GyuY7eEILGW43xu7L/rI26K/QbDwOSK3UigNutylnPA0iiR5redIpcnBOV+46jA69ccV4q95qGhyyx/2XpMsbnZJBciExq7dCrLhkGBn25Hetvwz4u1sWzJbWLRl23RmHVYY4zjBZUO05PcKcnHrVxnfc5NbHqOq2NrewLBLrDpHMBtb7VHiUZ5AUjr+NUrjU9W8IwJFbNFrNlGrIyeVi5UdtxG4Of94ZPaufTxtqThrefT7SeSbOPOaNoXfqATtIL+uOmM1u2a+K7+2hnS6t9KQg7LG1ulRyR/eYAg8jAGRxV3T1RS7MjtLK7vL9NV06O10e4lQ7fszPFtbOeoXb3OQw46YrbfxhcWywWviSybS9YhYeS8ozb3RA3Fo5E+6COx4/lU1rpEV2kxnGmzBiVdZQ5kbpu4LEMQ3cVjeIvDz2dlIdJj1MXYJKRQ3bxqQccqkhZSM/3ab91DdpPU9Etr2HUvst6iQvaSr5sEqPh4iw5QsOx96sykSosErzQyZyI5mAYd8Ajhh6Ec15B4euNc8KWFvBMYbeG5lZ7C7uwrWVwNxzbyshxE7HJDHjtXpul6lbazYf6Ta3FtNEczWs6AyWMg4P1APQjqvI4pp36EONmMkvVkaSSN38lGMdzA6HcvqB3x0YH0rViuuFt7gLHcqflckZmT1H9cVhapFdT28oE1vcxFSVBUsVK91YHg4J49KWyjW5tUhuIka5gdUKRkyK+37rru+6e/HIIpXNOW6uT3t5dwGZw9tDaO5jjmIJZZMceYpxlM9xzmqdpJbM0X2eWVGQnzhMx3I3Q7SR1J6DpV27soZbadTc31ykkZV0kcSKAc9scc/jxWNpjXGnO1tDd/azIfuzqZDnbkb26gFeOR1FSaRtaxpXi2cTfbrhLfzI/lWSUfvNrcEE9RnpgVi6n/AMSjTGe2mkhWBm/cbvMU57ru5GPTp7Vc+0TXthMLaI7WjO+3ZgQAcjcp78/h9K5LxJrkUOjTGDzJEMH+lJKQrRSdNxXOR83XGeootdnRh6TlNIxbm6Ooa950ZnS9wZfOlxliwC8KPvL14FYOup9vfyFkNvdeZ50c8QDIygbScn72SBkDpisfV/EkV0t0fs00X2ceXA0TMojOMsxI5ZT0IHOM1j6tqomswsso8yRl+024JWO3kPCNGOoXpn1z61s6seVo9+Xu2t0NyWa6E8rS3EM4jP7w+VsG/GcEA4AwKis7h5GX7EWKrOrjb9+QkYKgZwF9c+grAjczQkyO85VS0Lu2GznB3D+LkEfTmrlpIYLae/MVrJBGxeU3SeakhC9B0ySdoz2OKVGd2FepaOm4keuahfajIYLoKllHIbdFJZUUj5lJHQY4yRiqaXLXkxjnuE2bHJjYfMpxhVyOMcfTimWdk8cU7yBBMWUjyUChRjoGGB3wffiql1/oZaWyBIaUb1kfIXjsfTnoampzRXNJ7nP7VXsjZstTeHTzN51y8fkrlWB2uowNo9TjI5q94dnvb6O7kjjSc4YrBJIVYoOmOCTzjAFclaxSG0Aa8hggghylxKwzGpYg4BPDZ47n0qLS575mjurC2v7t4fuebNsjbOCXIyGIJHbAxWVOTbTexnVxfJotzuGNxaeKbi4a+sbeSGDekjWwuPmzyCzf8tBnsOnpWS3jS6Oo7I7hbeeF9y3KsIwvHJIbrnqc1i+IZ7i6BlvvEUTvLgmGKNUX5j8wAXkAfh6Vnre+F7SWQOHliA3pHbIV8xgvAdm5XJA4BxjPetrvaOxjLGSSfNZfM0tV8YeINVcW2m6jcb3wHCzhnuGAPzDAyoAPc4rV8O6V4W+16dbeJr695LiRYkZYY18seUD/ABFt+8knjcF7Vz/hPX9VtbJ4dJhsiLuT97GsJeT727cyL1UHpn09K7rR7JvFN2P+Ejvprx2k8z7Jezx6XbuueZNp5kHUcEH61i1bc8qU3P3jmtW1rw7YvJFotzeu+0RiS1lMnnDjIdGUKUJAOCc5pynX7xU02S3k02GaaSSL7XavFIXc5LY4UDIHTk8V9F6CbDTYjFYeHbqwgAZIzpYVoX6ZJcAd+Mn8627nUPtbpY3KLNEu15bLzI5ZZGI+VdzZwTySRjgdRStbYltvc8Ji8J/Z9XguPEt+t7cowVjNJJfvMxA/diMIFjyDgljuHbmvQVh8RavbWmnJorWdpL81sZdUktA208xojKGxgAqCmAoJ6812ul2Wl6IYv7M0RPPgykUVhGJ3gU/M4Ds2FBP8We9bEt1qUs0LGCW1VicmeETSElCR0OFAz74/GqS7kya7Hns/gee0ybrVYRqMt0JYLOxs4jHEWPzkSSfekZcsZDkgdulbuhaRYaRPDp9oi3MZXZdO6/u7lnJXMsp+aVgeCowo3dBkVJpbQvqet6pI0k1taq8aS30e1XACb2A4xGGUAKOWOav63bMVa71fDLvB/esR5gJI2BVGSCCDgdwvPFCSWwN30ZdvFl/s+SK/jjjs2G1xDILYIoxtzJn5TnoAciuF1HWN8d1Jcxz6jaTN9nSaRFXzE6BVJ278N1c4z1WtrURNaQS6hrOrXa2Ue2ZGuEjdrWMdEgGDvfPBZvmz06Vw+oeIrG+1AQWVrPfMszTWcDoWkkl4OY+CFznkt0HTFTJ2HGNzm30O91XUNR1KaKyt4E1Brea2t87olj+WOJCBtWMn5SV3ckknrXZ+GYrvSLaa21vR5jqUx8sajPeeesyH5o9pUA4ULtMYHVQSOadoX2uw0NdSu0hhKM7RQs7pbYbIkZyTmR+SijJ9QO9YesStHqVhPe6t9muIXMaRQxyxLEhA2iNiC6tlsHd8rcHOBWe2xT1LDTzXdxDeX11/ZN99oUO13dmGWVsH5AoXiMrj5W5zgZHWuh0s72uJtV06BbyC3+yqZJWlSXapZtsSthGwQRuLbgcg9as6EtzYXNxYXq3V8qwKsksnkQqwMx++m7lwBljyT+VaM/8AY9lfQl9cSxS6UIlmSZYQAxKMBjcpBP3sjGcdKVgvdl2z8MeHXs4HjjhdGjUq32p1yMdcbuPpRVLHiJvm+16Nzzxc8fyorW/kZ28zzSGa48toNJvdN1G9gjMK6ZqttLDLGDjo/HBGdoyR6VzEdrB9rkju9MNjJeTRGIOceWFJ3MoPVx2BwSPY16XeWPiV5pA9npk8RiaCGLUpY2ViMYkQKCUx/dz9K53UtP8AGGkXMJuprJbaFVuUTzvOQRxEBmBA3oQG5I5I+lLXRkW3HWHji3h097fXtQ8QQarbtuZI7ILDcLnar7UzgYI6EHORW/4f8YeE43awtbK6mEAzJJb2UjCMHJ3GNvnwT1AHUit9fB1jYQNcXWmpq04VmM7yh92cH5M9VOc4JrFm8I6BfTQlrW3IMvltHFL9kubVh8ysnUjGOgJGelXeVydOh2NncWksCzafGl3byp5sTQxAMB0LKP4sHhlByKuW62V1psUtgYxuIBjLFSpJxjB5U+ma8s1NNY+Guppq1nPf6p4cuzI17ZXEXnOFzhmDjGT/ABbwQcj5s13+kX+n+JLODV9JbdKYwBOVUvNCMkhs8kehPzA/jVKV9Ch90lrpJkt9RitZNLvpGaXfzHIrttZXjb3wTjvz3rhNZg/4QXxfp9+t5dT6Dbv9lHmlmmtIZOBCz9TErAMhbOMkZ5r0Oa2t7iCytA/lhyrRCVd0TA5OV38g/L0J9awfE+lLc6bf6Xf3Cq6HdG8D73jDNwqq/JQnsCcHgdqmXkaQfRjH1+w/0y9uL+G2tIpE8mBmBlkYjJcjugA4x1OfSmR+Ib25gjOkLZwS3Fwy79Yd4y6nOCEQZ6DjJ5rnvBc0dzpNpe3WuhYJDJC5W2jMqiM7cAsCxLN0GOvArbvpo3jjMRnvZpg0ruIxLPOMEBSpAww7EdOlTzGitsNvfEms6Hcsur2treW0vEj2mUmXA+dsEkNgc4yGxSv4ktbr7DrVhdCWSz5mZx/r4AD91hjdxkgHnIxXC+I/Fk0M4FrLOz+bGv2S+RTNE3TerEBlA7qxIz0Nc3p13He2n+n6zPpV2c/ZpY18yFlEu07gMAbQAeBnqaXP0N1GNrtHrH9oWVxphvXdIJo42ZrUMw27sspZR94MuM9h06ivPtf8SWJvkgQTWyNEoRigKEclWB5OOxXnJ9K5y/15L0QDXrltQjRXYOIwMY4VlK4JH94EA8Z5Nc7Mss8sQilgKBA4kSMSBE3diSCBkjge9UpdUjtoRUVzdTS1zVdWltreymnjgVh5eIvkkYNnA7lAR16cfWuW1lE0qcyQJDBJxHKIWJTBUYyD97g8nrmursWW005UuYIp7t42SQzREyIp+45IOMegPYVj6hardMFeFcuzOcKVVlDDbuT+EnuAenSm2766l1LTV1v0fYu2nk26lJY2thGRMjsmcZHQA9eT168irOs3V1c3WmWFvazNy0zW8XAIXAQtnnk7ifU49KXQLK2jMokt2kaBs+c4+ZeBgKT09Kp/Z0uvE+oiQTBPOFuQspXAX731PNaRvGOnU0nFySuai3f7jyprgQSBxsSFt7Sk8uG9D61iapd3jXWLWBdP8w7XeRldm46iMdB05NbEkWk2VsscTrbPuIKrIJHbAyWIwSCfrXL3ZnffLtNp5mxgZPmkEZ/iPocYwO1ZTlJ6SZlXUYL/ACKtsEjktrmSQy3TkCJ3PmsDuOWVenbvwOtMutVkmleKwR1PzGSaZg+wjkkEDoAM8cZNSWVpZl1tRPbosmVe6MZ+4p5I77j6DjpmtZ7e3ef7PZrFbwpAZZMYZjBkEjsQxx9cdeKE0vM4lGc07Oy8jCtNDu9QVbq8mcWqMEcviMuTzgD8uSK6nw/a6Wtsoa4urC5gdkF1b6IkxEn8JMpkAU9uOKPCulSeJ7xhPdNaaSTIVeeTb5i8bQVHIPHbr+Fbdlrdh4ZvJhqH9n35RmFvAkDCGc/KBuDjG3GSd2MHoealzd7EulDdI7Dw0U1+60+C+1nUYLqc7o7HVLJk+0SqpBZDEqoU68E89CDXUxQaNHdxWVzp0OvyJEfLiiHnOAvO1CeBg9F4IHtXD6d8Tmu/Pe08Pie/cBlxfyPHITgKDHGMZAz1bgAc1r+Fdf1O6Mi2Wm38FqknmTW1rYyT3i4wDIskh2LtyeAScE/WhtPQiztpsei6XbNHiWKyi0lgcTIZ/tUyg8hSpyqcE/KDk44rTnkYXD3t3cbNOEQDRyHy2cqeC5Gdi4z8oGW/SsK11NoXNxo/g7xDJKG2mZ1iJOOQTEJOPYgZq4/i/wAOWl1BJ4jl1+LUNweNNR0uZEjJ5CjCmPI/vHJHPNVdGMk+x2GnFfsokFndMszArgZXZg4bPA/A9OKi+03DeYy2sNrBgIZS/wAockcD1Jx19eK5XU/GWnG/ttPju4b/AFec4t9O0hDcTsrEHfLIQFRcYJyAAOmabLo3iDUgP+El1N/syq3l6daRqZpFPQK6kLGeB8xyw9RV+hlydWa/hyykIme41F5Bu87f5KgqOMDGCc7skYwecmsvxgsAhuJA5ub542hkWK8M5ZsErE+R8oBXJAx3q5baRrKzRxmy0mzstoEUU4murmMj+JhuCtzk5Lce9cz8TTPHYGGHUo58bBsUrbRWyudpdlXr3JLH0AHNTLYpL3jjtOa88daZd6veRpFBBGn2WwjbY90MlGIZPmSLIKnGC3TcBWxptqdHjuobTToDdStb2Mk8dz5+2B13SF8Mdke/5QuBhefm61n+GLB9Qtbbz2jF48ZubbFqwhSJWKSRxrEd7q5YBywAUZ46Gu2X+z7RkudQsoNNmWZVnIQBXKLhGk/2dpK4weo5zUJX16lN20MvUW1FZrWax/sRbtSEa8usNZRMo4WOTk5A+6qgNTdR0DXL6e4EbSJZRTxzLLFGg3HOdqIzkv3PzEYrsprGyWK2it7Ix6esLXcQijEduZGx+8x94nBPbFVNLsPLjsLOxlto4VUl4jIxRRnhhkBux6AKScnpS5dbMfN2MGGz8R2dpBZzardf2rN8tut3ZRzRXTk7srIuWj2jOSeOO9eh2JnFo6XPkNG6jdcRZ2lunIIzwRWfILU3KQX/AJM0l0NgiDbzJgc5KgcAdDnGTSRXV9Izf2eLZLWKQo108jGHI4ygxw/YnGAR6012JbvsdCkMgRQoyMcHYpork3iu2dmYSFickrfHH4fu6KrmYuTzOMnvL7RfNj8QaBeTuWU7TF5yKA2WO9OWzx2GBUl61hrEE02k6gkGlpIpnaebzoFbOPKdDh0Qk8np2Nbt34bsrfT7u40JoVJiZViE8uFx8w3AlsHPt6CsC9s7K7itfLFq37tJPtiSNGZWU7iiuAQ+GyNjfnxQrisnqjTs9J13Q5JI103T5RJuYQ2c7KLgHncFc4Q49M5wKnv1lu9Ptl1LTJzbWzrKtxEgzCV6AgElGwchuQeRXNv4ql0pbmDULi5lMbGWKG7tz8koyfkOPl68AEj6ZrrNK8V6HrgUpqNrFenKyeRMYpACOThiDkY5Uj6U1aWxm1Z6nL6oiWNhKYrqe90biR0huJBctvJDGRF+WRCe4AYc9a5jwRc6hoWhSrYS2rvaSyxWIkUNDqUB+d4VmHVkb5lyMjJHTgdN4xeOTSbuC01+0t7iPaWeONkLvu3ReVht3mMQBjkHrx1rjZNE8RaZo8GqXsDala3bi61LTt/kj7Ru2spOAY5F5BcDk+o5qWtSltY9j8P6xp0ii3jmZnW3Z3spVErRsSCzBQTlMEHjsaxfG0j3tlDFowmtnMTy2ryRlEM6AlAu7jAfBwcDArA0nxQXaz0W8fU7DXbV1Ed1dwRQTq5zsJfO2QADGRxIhPANdmobU9NivSsE0+57e+skJZbYjJDKrcYI7kchx6U2rqyHH3XczY/C+qeHNFtI9I1SymhsYEhUTW+CQAN7GRW7vubnPWqVzJLNZzSSaN/aFu7tIgsLgbZIyMgSB+jZ3fdOBxXWnUbAfZ8SGOG8fZEYoT5Ick5RyR8p45DYBxXJ6xpHh/UWEt1FYWGnTExRPC7RiVsELLhCGVd2Rtzzwe1TKPQ1i31Ob8R+KbfWdKt7YrO8c1sZbZ7qBfN2qxBWUL99FwcsCOnqK8zs9YsNM8QWlxomyDDu62kbpKuDGAQ6vxhm7c49zTvFWiWWnXbzby9lGzgwwloJXdhgOhyS7ZwxHICg1kpI2nok2o6fYTjzXRj5ozA/GEk3Aq6/keTzU+Za006Ewlt7lJ7W50e2upZSHVzILV8biSR0Xg5HBP0rC1OK01GeMLHY2cEY2owu2dEySdpP5/nXWXWoaVqVwkFt4GtNN1FCTLDcXLpb7j0bDfw+gBGeBVDV9C03SrmyS8hki85fPYSIqRPGAd+zk4wcAdckc9KtNpHoyjz007XMvRtPtbuzS2sb6RmYFrmOZcxkrwNvrgkkEHvWo1ld6Yqv5j3FnIBEjKyq24nI6nPGSOenFSWNva6lJNeWs3lxRs2MRgsDwMkADJKjPHpnNbOoWi3cUIZAs8iqgKueWAwOMnEeMkt9KLtq5th6F1e33FrS7a6s1ZopA++XG2ZgSSOM+nNcp5CahfaneZki097ktGhkwCw+ViT1xnOBXR3MCx2/2Xzr83bRt5MsCD5lAwrMD0XJxk+v41y+gxy2tgLjU7aVo0BiLhA3lMDz7KPWrlJtcp0zWsU1sJPe29tbi006yCk4+dRhpG7bm64/TisDdLNqkFxcust1JIrbZVypJHcdh6VoXGqpczMwjMi+biOEDamDwNxHJye1QwoJlzLdsJZXPl2cCFSx6Fi5GB3GB09qxu7nPVUZGiJrxGeSeG5hjiSKAltsuzcSUjznksQTtPoSeAaW3hhuDPPe2yz6fvYlbeMJ5jbcElj8w2sRk9DgjpViGwt7O3eOa3EwiB8pJScSTuBvZueRjj22e9O8Nf8AEpuUtrCzbV7me3DpbtBvSE53mTb/ABjaMgfnVtoy5ZL+Jt/W56Q9jpGgeGJtXu21KWQfuLRGvf8AWTDG0Iv8QJPOOi81W8IWMel3n9u6olnq99dwkG4uo5LtIxu6xxkBiFPB68cjvWboOj6bpsq6rqSxvdQeZ5sM6sCzOcosMOBtIBJ7KK3V8UeHXikjt7zS7TUgqyLcpa+X9nAHCIw5YgdcAZOanzRzyfM9dT0Lw1jUQdWe8We8nbyIYtOlDQpbqOVWNeCc5bnnoO1bupW9tYIv260l+wMwctbz4MD5++SPm6dT06cVxfh9Z7xhfJeaff2sBNvHfNEoUyYG7e0IDOecA49c12+iWMEd7Kbe/wBNJYGVYokPI6bsFjxVrU5Z6dTR0TUI7pfKjvNHubfG+CeFw8zx9Mtj5dwOQfzqbV/EDaXZGeKdb66uR5Fhbuo2u4B6beDk9ScAAdetY+raDp2Rd28Fta6mELLcWN6LeSbs25FA3ZHBJBIrGvRaRTrf+I7a9nCQB/s4uGuIYlGERFAx8xyeCPm6Y4qrsySTdzW0Hw/Pb6NLCxt5by9H2i9nhfMl3MTkh3G3ag4AUcBRgZrUtWn0oTOc3E85ZvJtothhROOHJ2nOD8zY9qhuJ9Snikd7m5sraUq62doqvc7iAQjyEbVx/dQcDvViLToNMnneTU7hr25YXV8ZZRII2C4AVMfLwAAAMn3qvQiTvuNvdXv7W1YC23TuBssbf57iQ4ztLngn1JwAM4rz7XfCZ1LUrceI7q51LUIP9L8m+O23G0qWxHG3ONwGGyx29MV1mt6xeXMlwNJjnjtIrWWNp7aDDiTAK7d3G4EHJPY8isyb/hGba2iWfVLxrZkMjSjAEc+SfMlcDG5jkHJ9iMVD1GvdM3Tl1fT7m5s31C7s9Li/0iKaygWFJJpmyY1d8kDr6nPGRxXVnRbO3f7ehddYlCyvPc3e/ZFg53s+cR/gMnpXluo6ld6uz3sGuafp9nODLNaNdLO1mWyFEoOcBj0jXocHGalSO/W3Ntrt/dWejyLse61BBHdaljqwydsSgYIL/NxnGai6tqVbXRm1NrNv4X8Rqth5R+1wGKC3lSWV5QW3loQmSFBB+8q8cVr20mpvHcaxf+GYPNMQaaXUbjbdSDGBlcFYk9EOTg9jVDwjpcX22aey06SSyG2Xz5Lple+m4/1n8TKoUEAn5vvHriuru0nb7ZIbFfMzJIZjdeVjK/dwex6/hSSbKdkQLq8k9rd29vtEzkLcQpMrOoxxGAQCMngAADvmmJqBWIQ28ccUaRgx28IKNjqd5JwEyeSM/jVLX7G8v9Tjg0p4PNuFAbUY+TbgY3EuOoxwvX5quW/hVNNs4oRHp8u3Iaa9zNK3vuwAOfQU0m2C5UiMa1dqMf23ZcccI2P/AEKitQaDpRALQ2YY9QLfgfrRVcrFzI5LQfGEV5M8rm1t9SYhSiMy73II8yJyPmTjuMjoRW9aX11olkNPuLG5fT4kxFPYwcbCTy0Pf/a28gnOMGvBNQtdR8J6n9jukS5jRjPZ3QyZ5D0yp5WZAeCDhsdq7fw58Q7R5X+0XbfZZWVi8bMXUc7sepHA6AkcEHrUxn0ZDh1Wx1mua9eXenzTnSWvoLeHct1bXaKJAGBwVbkMCAT1x0rG8RaXaa1c290+mysmqOIneF4yWmxzvwcq6kHORt+lbuj2MV3p815pWordRNcSATRorfaVY5A3AdgcHOTkYzXE+IbuWHxEBpl0ItWnWPzFxtS9EZyXHGBIm0Bm4yOOeap+YJK+hpaT4a0O71Cw1Wy0TV9Ony1wDfBWjO1dm8KW+QlgACMnPbFdDqOha3Dpn2i0uZRbhFS6s4bkyXOQevz5VnHQYA3Z61BomvjVfCltcItrLdpKZruImRQJC+VmA2nBAGQFJGa6iHWoNQu7OdZd9vLhWbyz5btn5WSTGC27AKduT2qrJbCep5t450W48Q6XFc6fOuoT2BLo2DFdxlQ26F4wBtAOCAQMEkdCKfoov7Tw1c2888SXdwYQxlkk3qrIuUZcA/IxYAqx5HbpXVeMtMs1+2a0sso1mN0YSRn5x5Z+eLIwWBHZsknbgcAVe01ptYskjuU8jUbWTzb2K5jIeJZCH8uROMZXaQ6/xDtzSa1ZSeiMi6syEKXl5d2+pOghjuBPLJDOrn75zw4PAKtgj2puoaEmp2lxFqWjSQ3UJDj58MAM7Cu3IAJ4PzZAPPrXSavazQwz2115lzaSgstxbIGZVIOGdP4sHrjnHNcd4iu9f0SziuIrizZmMbxyznzTLx8yIF+8GUYw2Dnv0qZJGkW3sV9a8G6Va2qajFpNzZSx27vGFZLmPzCpBXynye5Bxz71yVvr+iRzG11WwtLaS5YWcrbV8qeI9NzNnY4ycbuORzXUeJ9V12WYmCK601p0LrITLLKyvztiVAVTjGS5H6V53q/hfxBqWrPBJrE11qAVpjHcL5jxDGRlsEv6YBwOtS7J6G6Uraia7oUccS2SXs91Zm0eXT/typIyKGOYWIwQw+8rKdrLxjisGLTZ7uaTUNVkn1LTbRBFNdphVh52qmOW8sE5baMn9ayQl7YWH9maqtxBNCWmtGR8qGT7+OdhHJzjkdCO9ej20OlJY2kTmf8As0w8hF2+S4QhlbgFgxJO7Bx9KIrVndhoqpGz6HKqZtNvLrT/ADDHOCsTps2xyQsPkm3MTjcvGBjtir1ks620LpZRxi7BWOINyoU4DEn0PYnn3p8Om215pekbrZmuQUR0kUjAU4QuD1yACPbFSLM/lrJG7eVbhvKYrlWYuSAAeMgDqPSmtHqepRpPl0OlkWDThcwS3UN5rMjjzmkkL/ZxgAs7gBQ3oo6DPArnbvS4tH02Szlv/tEcqlIGU/dUAk56bgc8HgdRyaiMIbT41iTIDmSYZ+Zsn7zEcdcZ71q60LbUbe3jieSW6ns2WR533LG+MIqnGdoAHH4V0e0uny/1c0qUXyq55BaxFV8/5ysb+XEZOmc57dMAE55rotLQfarFkLzZhIRjGVjVAc4QZ6ep6k1lxo0kYkjjHnLcxA7snL88/jz+VWLOO3NmLm6JMs+REnYZySijp3HHY1xc3U4KcOWdjWv1WTUk8iPzFEG9cyAKx6BwvX1z6Vd8F6o9veCSwWa41mYmCztrTDy3bDqp7LECPmY9QMAYyayVUeXqB021Bkgj+Zmw42suCrY7k8YyAO/OK0vBF1p2ialeXt3aRzXOzyrW3tlIkMrkfuo89dpA+bPRTnrVxte5zYyUk7J6G1p+iXet6rqr+NNYmtL2VEZrZmCxPuztiIzuKhgpyeOM812UWoad4a0zTbDxDY2tzblmitzZ4NymeDIiLyw46g5HvmsC31rxeb651a0u9J06aVBC92YRO8qcMQ0jAhQvHCLjjAru9E8O39vqFzcahqdxd38mRPc218YxdHnAZSvyheyjAFPRvQ4Zaa/8OXkGk3cdnqnh29sbW+c/Z4XS8Ec91jnypY+0oBLAn5gcZ4NdF4eg0W83XcOix3Bl+Zrqa2LTSHJJLbh8rAjkDAB7VEqadYyJekLFeAhXe5iV5pRgYBZB8xyB8/Uevat6a1trzyZ4pp7C4YgyMkuJASMYZTlfQE9a0SOeUm0WdTS0aGUS6YisqgtKkQLru4GCBkHp3rnbE3muXeju8LSaZFCZrlpJdky3cIwQxHUK5IwOp56V0epSPawvbxXKCWbEYEuXCsfQDqcc4/OsO7tHs7tLnR3hTU95aFpSXLOQBteNeqMowdpBHHWq6kLbTcztaudQ0bTLd5zLYrBE1xO8am4ZFEiAsrL2I65BIP41LqsUOi3Q1TUXt4ES4MUaREsyO6kbU5+aZ843kk5yeAKi8WajqjabJbtoq2xSFIi0lyBbxM5LOTxuYLgdRjnmvIA9z4jm+1+Kb65vtKtXaO2siSsDzAZYsUGduCxyvODn2rNzQ0rq53B8Ww3sVuNRuLKxgt2cpbR36xmIJkFVIbc+fmLTdG5A9a4W8l0K5v5IoNGtrmB2Iki02/a3gCAg75AAQVPy8gAnB5qveeLLJNJa2t9IWYu3lSfZtPiWAIhz5asVDOF4OeAOM56VBaarqHi+5j0Wz2Q6YSBa6bZN5VuSpz++YY3JnJyxHJ4FZydzSMbBpOif2veSPo+mNqapK4jg0+MiCNeRuklYDc7dv7o6deOq0Dwhe2cNqj6LBOOJDBNmQxknkpuJjYjp2IHSuo0/w1qVlYQw6ldXCwIhLRR3Cx2sJOOBswQvtg/Wq9lB4lZJ4rDUrCC3ZRHbW6JK7TRk5LKeNoHIyACeppqHcOa5aSObU7h0uyskjMWe1MIt2ZTwu+T0GASVyTxnNbbaDZootzcXMnloElt7efy4QSf4iwDN7k9u1La+GdSCRJrV0+oSmTfmI7Xjz2XnoB3PNa1po9tYoFbT2vXTAV7tizHng4YnPXqOa0SJv2Y63hjsrZ/tWp3TbwIy3lKkIOMKqd+PTJ7mqNrfaZb3txb3mpIjFE3Jb3TMrKFwGdTkonrg9eTgVsx6LDPObq6J+0hQkds+Gt4QO0asOT6scHHpV6ZbKCzEeoLZmMDAKwjDZHoOfwGaqzIuimsNqVBjln2EfLtjDDHse/1oqBtP0pGKqL1FHAVI5AAPQADpRQBw2taRJe6CZo7rTb9i4uImQqksU6jhgV4JXjKgDIyeteb/ANgt4gaPVLG5FjqJj3iaOXMm9OquvAPzA7TxnjJr1ldWtfMtb3TzbPZXJH7+GMFOhU5xzG4Pr6EHFZ2sWsmka3brd+WmmXrPKLgRBf3+wsxYjmPfjGV4JHvWco63NE7aHjthrureG7m5j1CK8srW8mEk32dmWC5Y8nH9xj1wO/tXomnafJqtm9ydVstb0zdJiJ9TW3kdG/hfK5yOQU4HHBrofE2m2uoaU2nTW2mzvdxIyRyfeiYkdD16ZIA5xmvPNS8G6t4MuZ5tOsdP1nTFcyS6fe25Z1A5IhL8sV5wAc+1LW9pEtJ6ovzXd74XNu9hfiwhVkihFzauWUngIpXKMucZx1HvXU2vivUtZUaBqGg6Z9t8x1DxagFjmZUJLxIwyec98qeDzXHaJrFlrL3H/CLfbrGWOxkkewgmxFEg5dmjkyrA55QDdkcVoRlp7i1ha+FpPJMy2Vz5aQ7ZSA3mFhgoXBUHjb0B9aE3sJo6nRrDWdYtbW4m1BrbVNoR44CJra5EfV2A+dZVACbz0JyAa6mK/jKn7bZSxMrqomD+ayqwxyRyV3DBHPrWd4T8Rb1uLfWIVsNbR9t1bPhW8xOPNicfK6sMHHQe9WBqEUtxcstxbfaxJskjVWMMyP8AcLqRlMEcsMge9aL1Fv0LlkIzZ3FvFbCUQv5kSpMEwoPKh/ReDz2asrVhKzyxwzRwWzB96XOZfMiccKAOCS/AIPAzWHHcavpGuyNrFoltYSr8stu/nWyKoJZ2YD5WAAXkYO4VHf6hLqevSPoDWUrXNul01xDEJjlUZURcttVgSWxjjAyKltJGkY66l6HULuFJNNur+BNRNsspihIUFCcKqMf9b0OTnisTU/C0/wBmaS6vfEOkxIvmyTW6wx73C8YJIJJ/unP4V050CSw0yI6npTKgTISa5DuNuCGJUDknJKoMCububu0v1SRrO1dI5WV2upyzQrzvkSEtvjKhfukfMDlfSh+Zsnp7p4d8QYdaFwXvbu4kFy4uIo7+2EMzuqg+bgDazEcZ6nkHtW+uuXviizhnhigsZbiLyHmV1llmVgA6RqPutxjnkA103iHTW8Sqlw+kW13Yz26CEW8s0lvbxtnbJIwYFJm7BlOBjNcV4O0eC203UbSJ5NL12yvHiluWbOI+nlvETtfnHzY9eOlVT6o6sLdVVbZ+f9fmaumaUdHaOdJla6e3ZEt1lOSuckIzH52C9MYq5qzfZbby9wKBvNbjGVb/AJZgegHUfWs2OUatDC+w/b7cmObyY8iJ1JIaI9AMcgdxVozXOopZ/aY7cyj/AJZO5IYk5BUfxN7dAKiezUT6KnypLl2Zuw/Zl0MOjIrLMYgAAxPGduR0+tZMZ8qy0VMb3jnli8vhdql9wJbvwx5NdadPu28IXl5bLsWKbLp5eVZAACwfqWUlfbBrjry2kCsBlTneSrckHHNbzi48t+w4uNRNJ7N/1+Jx+s2YtZrmGfy3SMOyMnyk4Pb1P096zo7u1SJoHMQjkBxKqOeB0UZ4JJGM11XjC3t1jlbeUWOJZPnIz1Axgf55rl5YwumWMk5kDgb0XktjPCjIOCB26fnXFKHK2mclZ6+61exp2yJa2dgLkyvZXELfaIWfYNgOY8kD++T9cYNO0OGbWdatbidvscMy/ZrONCd0amUozBv4SDkntitbQNHl1HSZnvN4jikljh85+ZMtwi4+4c8H60ui6KjrrEd3qNxPDaGeIpAMsYsgqNxGQCxzwBuKsKpPQ8uvFtq2x6Z4PtvtF3e3v9pyz6HNCba3VrdWvLi3X5QXyOEdtxXADHqe1dJo0OpWrh5Z9Rk02KNYrczrFLIEBODKRhmPQDB6Yzk1yeh+aog1C7nmn0544rS0lijQySFUw7bV5y7DYOygHpXYR6zqBZIk0m9uSQYbaOYqIpXA+bleCF4BYnGeBk1bZxzT6GzbarFaHctvfvalSGa1sJP3fcswIwB0FKPFf22eawtriJL6MbWigAnaL0LuAUVjx8uTisHU9CvNfmi069um+zti4vIVIQxxggeWm3hVPPJycA810kNronhbRWudPgWx0u2XCJbsw3EnHygn94zHjnJ9KpN9djBqPzJrGGG2upH2XUt00IUyufmSMjLFc4TJPB6dPwqxZa5b3kM0ei2X2s5KM8haKM+o3MNzn/cGO2a8t8Q+MNOuJLP+0J2nuBODDa2p8+GHblid44efHU/djz3PNeZeOvidf6vPNDptzdi3kX7MLaK4IVwD1bADMccYzihS6IzlHqzsPi58Q5Ib3VtIvIbGfNv5O21kZnhwckM3UbgApHtXmVx451LU7VEgWK0B3u8kS7IyzgBlCgDC7flKjAIAznFVbHQL3UEXfaExxysPI8rHlk88rnLHgAg1eh0m8n1BFh0oJdTqyRQgbmTGMhUB+9gnANQ7lLy2LPhnQtQ8TahBHNI93awhYTIblYFjTBICKfmKjHPHGR61754Pt5tG0xNPtNNTTbW6O8C7ZN0rdPMVTyS2OhHQAgCuW8F+ELqG3W1mtrKC4MYJ+1yqrxITlZHj6AdMKckt1wK6yPRW0a0e6t7SwtrVZvMlk/tOV1TKgGRs9RuCnaORk4q1G2om+Y0L+SK0D/Y9G+3XMR3pEYVZcjHBzgA88e/0qW1i1ZtUN/rUMkG+JY7ePzubZP4lm2/LgkjkcDHWtWJhJblHFvG5CuHAK7mJ3bc/w8jpnNOud09vPdtZ7S8ewFl8tioPJO7sMluODV2BNFmzP2d47eG3sJlC7cbW3r+IyD7ZOelTXG6aVCrraeXMsZBjI3Mw6ZbjjPUVy9gHsIZYPDt3exqJN4kuH821nbPKncAfmz1TgY9q6FZ5ZtHM222vOApiWcopfOGUj2OaFqS1ZjVgmvLqOKR2DfMWGSSiAlVKtnAJIJORyOKvW2m29iDIkrB2wWukGxyf9oDgiqmhyQWMzQyCWIMf3TO7Euec5zwPZfStK8nEkPlDbNLIR8obHGeSc9OM07Ck9bFcQ3+OIrFx/eww3e+M8UU8TSqAovoCBxnYP/iqKdvMm553b3suhG+umhvLzSbmVZ7mBrNY3jDLgzLj/WdtykBsc881keLIL6+8Oiy05LhtNlliH2uK4BSzUEMGUMCSPZen511i6DFHbSQwW9nHDJ808KkyG4Xd83zdQTyPbpWRqhh8LoLzTWks9NL4eyhYhY89TFEeTgffTpt+YdKhruappu6Ks82pTw6pa63pMmoXglMk1yY0SORGH7qWNumMLg46Ec4rkNQvLqe2Esul38DXys0N8+qmRbeMPlJdoywdjxnjtxXbajpiW5+zpPIyQs0NhMkzDY7feiZAfmjbK/nVLTZDocVouiadfJZl3iudHuoEPzj+JGyXBJGQp+VuOhqZRZSeh47r+g6iZ5L5rTUjNE257qA4RcN13bQck+3bNWT4+uLy1vbTxXpFlfaiyEfbmBV3UcKMDAPc5GCe9e3XF7Yanp0P9uXl7d2M0jZH2KReVGSrqvzEgA81ycej+G/EFlcaOyW93HzPDdLL5LncC287gWIBGCP4emOaz5WtA31ZPZXF3qOladc+E5n1WKwhWNraQOHiyMdXXcVb3J6Y96pWfivxJY3Ut/Z+GXScyCG4sYJUzhOGCxt8y8c87gT0rzTVvDd94L1aGS4mjv7BJN8c1vJkQE/dbGSNpP8AeG04Ir0vwnq+n+IIodJuPCGg3ud7hxAtv9rVOSEx/q5RnJXPQZGRRza7hy6HceGfEHh/WyW0N0ubuVS00S7YXhjGflkiblwMfNgE564GKxNQ8Htdakl5oc3hrT7iNSIFiikRjGzZDGRGHz56ZB2nFc3rfgLw1czW+oaPY65pN0P+PhLOcs9o54WUB8lwDjIBGRzkVqaD4suoL2DT/FsVvBqForfakkhOzVLb/n5hOMJJGVBdO65YdCBe+4lpqh2k6jb2d5Ksnh+W81u33ed5iyvcbM4Escw3Ky5BB6ZI9eKbr8lvq8FxqVn9ht4YYYrW4eO33PtkfDB8AbiMcE42ntXQ+LblLPRptQ0x7Oa6RzMk6uWZX7B1U8xsuFboMEN0Ga5aS4kk1qw8Q+I7J47B0WCJ7GTzEgIB+aZOcAbiuDkKed2CKT7HTBLcP+EX8JtqN/GlrbwFF+3QKJ5I5VBGCVdGH3B/CM/erznTlj8M+MtUW8D6gh8md7qdhJOm6AyEnIw4wckdSASM4rs7u6t/3ltDaPqEFvJPZxXF3cqUgUqJFc8ZynQdR0BNcvqNxLHPPcXj/wDExkkgkgmjIIuLiLIQkD7haFpFC8jce2BTi7G9JNtNGFq583WRPpl1EZZpYcbZCqJMFALnaMkY6Nxy3euztX+yW8rIRMFl8uNMh37AS5xkccFv4q5+zsdOubeOe9uW/s+w3rHdxkp5se75Y3xzgHaSD0PHeuj0yCOe1ea0s085c5eZ9q4ByMYBJ9QCOTmritLo9jDa1HfY6TStl94V1KWFtjBms3aMNtlBKuVweATj0z8vPFc5q+1YZWyqCMDe7HAHPGfeuj0w3VrBcI8bJaqsciRpcqVmk8ogOwXOB83XuRtOMceZ3+pfa42a7URPG8YmiIBMkpUlQM8DPJ9qupUtBX3L9oozfa/5mV4gm+2LbMYmaPyjDE5OCzl8k84L4GOD9Kp6nJdWWqw/ZzNK8lvt3uSrGPkNuB+7jBPrx9K3L60t2srZ9QZSjW7B0Zeh4Klu4yeDWTpF5cTWtxp9/MrxsyuYZk5KKAoG/qy9gBznrXK9tTkxF1U06nf+FoodT021Sxa+hthKGeO2k8tE4+U853ydDuwOfWqzXc+n+IbTTrGS0/tdIZrTc0nlfbId+Vjk7CXfgoRgbhzkHFT2T3miafcXV3FD5tqgjAJKsGcfu8+ozwcdAKoQwHTLWGLVlWX+1opA0ixiR5EUrlwT1YjOwnG3j1zQnynLVtJ2NqxlutU1nT7fSNK1ex08J5UckuwQFo2BnlTd8pdmG0gDqScV6P4XnuG1O+a6VreaK3MZ8whU8oNkEMpwODnChcjJPNcLYaTZ2VvbSS32padDcFltNMguCVCHDBFd88DkljgZJrS1DU5dKtldrgampmiSGxWZJgQCDveRfvngcnGBwOKq9nc5qiujvopQ17JPZ26mE26pPOc/u4lLN6/McnJHYY6nivMvH3xHhgla5lm8+1g+TTrcorCaYfK07Aj7qjIXGckk8VifFf4musM+gaTHJbzSuFuCzo2UyPl2oSMk84B+teOXY1XUb6b7Y0txLCPKEoHmCEKDhAFyAOeg4FVy8y8jinUSdupr6n4v1rWpbi1t7lY4nUpPOFCBo88g7R8q/wCyuK0/Cuiie4Vx9lknZdkLXUpSMs2AvlhR/DkHnGMjrVvw/wCEoG0Qz6hJKY7fLIsG1Q8hAIBO7dnnjjrxXRPpsuiackd7p2pz3zTGJ4o2BCxEbtgXGN4BDFm9Pahu2i2JUebV7nV2Pg+6tHhtZLV77y2wPs7nIfoWaYgFBnJyevGK2LDwzJpkiXbTSW1u4C5Bjkc88lW6q5Ppnpk1W8Ka3r7Rpb2F/aalEY1DLqSiOeLd0GEAMmOnUj3rqtPjeK/SbWY4lkLMmIpw3lx4yHUNwq+pUkk9z0q0h3sWtE8N2r+Xc2tsYE3MwuNivIxycszMTkE+g5HXFX7iC+kso0MkDvG7HLoI4Wz0OBnkdcdOOtUrq0E88g0yaGG0kTDFiXDMexwQQeCSenArQRYiZLaJb6SN4xueR1lUDOMqem3qSKdg13MvUY5f7JDWM09zNBCpV5fnMW0/6xsEbiSSAccE88Cpr3wtcXwSGbVNWlmDKxkNwWilRQC3yg7WGOMkDk9KvRaT5d/9ovSsQjZBE6knzc8AkdMY4x05rQjtokmtifMhAmK7kZlUHBHPYjAAI7U7JhzW2JHt57faLd2mijZfLjYYIGOgOSCfyqpJFZyy3Mn2aUmOdZLiEgIhYjqc8Z6GrMS3UKnz75ypYkbUUKPmPXPIyOM+3vUkMRlu3uHYeePuI4A3R9kIHUd89c07E3sX7KRDaolwrMz9E2l1T0GccnvmmPG23dF54Tqn7xVwAfXBOPb3rQO+RQ0G/awB3M2Afb1qo8V0bZQyQiIdY0cqW9Tnt7UMzWpFvQ8tHa5PXM+D/Kir9rZQG2hJsUJKDJaPk8d6Kdg5jgxpsmo3Dw2lhp8scc3nRST2qRGKYdlxzu6ZPFc14s02O2M89yNWS7jhk8wwSEpIpRtyDH3TkjB9D6Vs6NPZeJNLtmheKeQRr5lusjQTCRSd+eQcK2R+HXFV7/Tr63W8/wBJmZ5XQyILl5kjhXHzRAZIPGGU8nPBqWtDZMy9NuXhtbK61SwvpdNeCFGuHUSrH+7Ub2kX+Feh69M1s60LGSyt7w2Ed2RmFG065BA3D5g6/dKEdSenBFa72NlDZRRQCaVpCGVXd4Q7N1KbcDbjPHtVA6PLZyTXemSCOOVf9HF47sYMEZjI7qfxx9KGugJ6nDJq11puqu0KMumy2yyutrcHzYPLI3P5bdDgHno3OKq32r+DNU1wagFimMcLSmaSCZ0V8YXzgB8mc5JAPTOa9BtXn1XUmtr+Kwtrm0jFxL5ZOWDAooDkfdbk8E+hxmoLzRZ7VJJB9jNiq5KJZySPAP7yMWyoBzlRwM5FZuLt5GnMum556mgaT4i8P6jN4Vsba3Z32SWmfPhldT1R05VGOdrdOoIrz3z9X8F28cUgltUuP3ixSAqodW/gkxwVI5U9u3evUtca6iuPPi0aL7ULdGaaxlDxzqTzvj+8wOAc4DKecnrWJ4uVdc0SaVtN23/2czMILrz1fDFSssbcMVGcMuGHB5rJ2T0K33Onu9Stdd0mOZrq5S6kC3KPEQ/2ckcOQRng/KwGQRisPxxNejWbKG8lhtb94A9teWZK7bklmSbIBGCE2sp7E4B6V5z4P8R3WjLPb3BknsIDN+4YHaw8wEkMMdMZyOme2a9AvNTXUtJN3FcLJqqlbqa3MQlinTOcqARuXb8oHOMEHBJo5tdAirpXNbSLlLvSvttjZWcEtxAypYkGMw3C8vbbh96Ns7kDcYbbVbSNTC6RDf2NlKLKWLZeTTxbOUOPJTPAYA7SeBgdziuW8NXUEiX1rHeX9nbWkXyXM1qTHFHkFOh3N944yCRwO1ULC5ZPD8TXlw2p2kFy0cgdmQSF5PllBBGV/h+YHawwcginc2vdWL1o1nputG5soEuYLW5KRRIzM0UpbP2VM5IDKrmMkYJBBNVvGSwr4sa7SI2ttItvdFyVG4sw2M2OmB14GD9KseP9Ys7W7GpRSzLI9uLdFUgS+WFXjzMYJDhiQTn0NcJPc22o3sfkX8NnL5W7fCPl3opYKB/EzEKN3Tnnmny9hxq8kjo9K8qeSSHULtZDHM0sr3DELy5LkKv33chQD046V6FYtc3lvLJZwQQtK5xIyZMzdyFGPXAJ9a8503R4LhbScQs1iLlIpVjALXHyBmbcCTkAjdjjnAxzXrURh+xi5LNEjMiJI/OzI3Dpx0xiuvDx0dz28LP3W2hbe5tmguLmZLuMwQwssiHyVdw7BlcH72G3DPQcYrzHULm3TU5G8lEt5pBCZJQCvyEg7exxxuPr0rttYvDZ6fcmGaTcsbyEJtKMIyW5I+8cgHHTPNeWS77iLTrUXY3xx+apkfKxkfvCuO5JcnGM8H1rKu3sc1Woqctdbm1czlr426RwQJlk3wIXyOm0gc5IOcnr07VgQxSRW9ykGnok1tOwSYE53lvuIAck/wCzzWprd5HbJb3D3LCaSZTNNEVB24zggegxwT0qj4d1C2bXpJYVS6tA8bNApYyPhF3NHj+Mt3+vXmsGrkV68bK71N7WINU1kRRXMsiBZIHminGyaQs20Rgj5eBluenINb82rXsF/NIIRHcXcvlWsqqCsaR4DKi9F+XDEnoPWuVGpx3OpWU8jNFpk2cXgU74nDbsMScMyqxG4DOSK6PXrqygTT4LG4DSSpO8NvbzAhN6gNJKxBK9FLE/f5AHei7OJ1Endlnw/GY9Z1PVL++YLYyhLy5ubnY6I2WTAPyru64HsOtch8R/HUMtlPa+HojHbyzYW5yArKBkhVxySSSW6Z9653xfrIjv5ooNW1DUb6JFR5mjWKLcvbZzwpztP48dK5e1tpr9FkdjKY8RpEOvrjHbv9SfxrWNNJXkcNWu5PliT6FFcz3wcErPNkR3EmflI6lT3f09M12/h/SNVhv2i0+ZRPcW7RxQGJRGwUcjk46c59etTeCdBgYpcw26z6fIvluZZSSckuMKpBU/IeenBBNdPYwWMz2ZvZhE7S4zLb/u7bcc7lPQAcZIPOSOaJSbduhnCmkrvcf4b+2XWqXUktpp8Vw0IN0s+2OIxAYIUEEZz1KZPPFa3heArqEh06whsrYkS2ssG90lUYLINzbSw5Pbjitq20Ow8Sx3Ooy20F9Hbq8Qu1kMMbOByYgnOARkEdeBV7SdEmfRYbnVLhJo5pVVLgWqq+CMZIz8zt8oDADnqM0kmXcr6A32M6TaT6ZLa6xM0si3PmBoZYyDgNkklNoHyjBU9K6wpdXOmm50myl82yIJtpiJbdz3Q5+YgqcjoM7eKs2ujmeSBbiYvaWMZFi7AeZG4I+dz3OcgEccc81a0tiLiab7KVkkwJtp8sSDkEAZ+Ygj071olYSYWUFu17Atu0VnFOWaP5QTMQANrHgDngpwRW1JpZm2y3hV5hg5jYxoCMkjA7dsVUitC8NwL9Y90qADcNqtt+4SOgfgcj2rXs4BLBHcSnbI33SV+UDHTH86ZMpDUtoJLSSMt5kDOSF378E9uevsO1Ot5DARBdRz7JOEk2fKw6FSf72ecnrTbWwVpHkZFjMX+rwMbgeSR754p63S214LdtzDBbK5ZQP7rf3Tz16UE7jp7OCZF84QEb1XzT8rBQejeuKsBFdRgMJlwyGXlhzxnFR3O26SNIwjXJHDJ83l+57EVAdUhtWkgvXVbgciNJAxPbcMdB9elMWrRpAyCQDyOC2eGxj1JFMCmZIJFBUnn5ju4Bx0qhZ6quo7jYvG9og+aTzV3lh1AH14z+VXUVhGGkhcRMM7B1+hNIWw4y2+Tidcf9dBRSeXa/xWUYbvmIZooDQ4y90S3mnS1u4oZlaRmtSA2YH6sQ6jIzzTWj1nTZ4I41vZIBIVDI8SjaQQclhkfXv7VusIhLPJNcvHFcEAZYqIiPulffv9ale487SXE7xSXEakMV6OR0IHYnrigvmZmaXOrwSwLG0l0BtaKZxlh6oAflx7VW1C+FjOyXsDQoV8zMsLMmR/ErDofbvWvp9itxYu8yIhabzVfAyPlAyD+dUr2IWoillvoJkibLGWQoFzwfXt2oGnqefar4guTcq8OlTvaQRsk93LGYYRE+DlFBL9Qp45B+tOm8QC/t9H8yK21dpUaVjHK9qqkDcF3E9SOpI7dBXUXukNq+RFd3FrCTnfbRgB2yCWVcZP1PGea56bQpbC5hih0COazEsiGQXKxzySsv7rfJjOCQTknGTzxWepqnEiF2PtDLd6XdWbCIeQH2F4RjOI5FGJkB2sOhHPGKx9ensbnQLjWjaySi18xJJ4rXaWhcfOpIIU4Y8EjIJHrV6S/vohdvHpqNCp3NuutsTFcgluCEkHK7l4z1xXN21/Gt7Lb6ncE2l9cRIbeRw0NyI081S7DgSZUIwGMnBINZy10NOX7Rwc+jy6JYaZqLyi3VZLhpoftBdoiz7d6kAruAKhhnkAgisK11eHS9RMcly1tErOFKRb0RiPvp3CEjBXt1r1TXNQs9OivrKaJIUudzSFpeIJWXLqY/4Du24OCrjrgiuB160urjSFtbiKO9jt40RFTHnrI26QbVyWAIYA4wMioTSeonF203Leka7Zaf8A2zFrEULgC2WIRoWTBXLNwdxB65Ge+Kff6vos8wEN61uXikt5ttwVUsWVo50AHzJ8o+XGTyODzXntneX+lW6b7dJY7dw6scHYXAwCR1UhTx2Oa2rR5tc1dpIIYbKKVyXgjRPlHA3BW+6zMf4eMg4HStHC2pEazeht3d7f3Fk1q6SyAh3h/dsxIBO3CtgqGPPmEZwuKq6Dd2c/gyeK4jthfWP+qtuDNIhzkknspJbB6cHFV/Emi6to/wBqgfbHdBRHcRWU5cSLu34kJPXI4Uc8HitKGCCGK9sb6zjhDwx3flzOssnnrkFt4OUDIwJGc7gDQrWNIX50XND8PXM2oG0hvALZo4pZEjkKrbySMo2EgAbjnJXoc9sV3l7d6cq2AijvI44SovhPGWML/dA2ryMKD74wKy/Di3MSSaffSpG058iO3kYDeqxsklw7jouSfl+8TyTxWlp96WitjLdu0X2Z7KSVIw7S3AO5Ce2cDCvzkr1Naxujvp1eXYwPE+sLd6Xb/YGklWe3kiiijXG4BgflPGM9cY6qVriryRbbVx5pTZapFaK+R5YkwzOOPu7ucnJyc846dQ5u4r+WG0aK5miv47hCWURTOmXcbhxuDce+TxXA+JW26c0+5rhLmYhZ2TYHbhjgf7OSv4+9U05anDXq+9d9DM1GbzJreNIpFjeMNKpXcQ+PmOO+Af5V0nhizmnsby9tJTcD7QqBCqoxEeW+WY42Hbk7Vzx1I4rmo7GR3kmnjRrdQJmjLlSBvXckYPVvmGa6rRHK219dhvs2lQu7Law3JjYMCVAcYOA+VUkHqB2JqJR5VZGCqOcnKQsjfZormOeV4LiNVKNCBMsrysrq6DG0ARgDaOdzc1yOt6pcCa6t45bkLPs+0Cd1dyy5AG8AErz0pza1cRWpErF7h3I3bhxH3Ud1J6Z9Kx2cSXQmmUFXbcyxkDjPIHpVwp23MKlTmehJZ2wnZpbiXZEvLMeST6fU123h9ItS1y0t7R/+JVbTZEtwCA8pHys2OTk8keijpVbSdHWe306382Oc3VxGRZwk4285MrDuowMV6hpmlWGn2tpbW8Yna6Y3Dq82IYkU7QTjnAAIA5z1qZyuy6cbIxFtre11DV7UT2ltvdpofK3RxlADvjwT93OTgjjt1rs9Cjn1SznsLe1aKIARXFsrc5DBkjUnO0HgknjtWB4lhtdQlubDTPsjx28bXE5EShYUGEVQerOWOepGTzXZ6PplnpNtpNtahzfxWhN2YjvdyW+Xfg4LAk4P90VEUavdWOk8Nw2On6et1caeI78yF0jit8Eb2IChV64A4xwB7Vfnjd5bZTugeJ90dw0nMsa5KoyjptJ79ccVr6KkP2aIiJgY4goMXSP1G4HGaTUGhubzT4XgL207lGmJ6Lt6f8COAK0M09S5ptvMwR5IhJLEu0SsTHu5yDt6985qxZ2/2d3ncieUuSrSDBAPB2DoB/OqFsktkWt4Y43UjbHFPIwZSOnzDJx2q1PPcQ6fG9y6wzplfYk9t+Mfj7VRLNCeWMNGsrAOeTGwBJHpjuabb3p2MtrBKsByymZSqhs8gH+lVoRCoWNitq8oyyEb2dfr6+tT6nDFJaC0DS7Zv+WauQSo5P8Au0Eitc7w0pikkVTw8XCJx1yefwGahV7qFHlIRXOGa4Qh3APqox2/hqTbP5ojzCIo23K8hLAjHr2IFK9rZXMdxEsJMhG6WFejE9Dx1z2NHoXGwI8MzRtLKsSlGzJHLtEgU4O48Hk9u1WIVtzbCG0jjSB8Y8pAFkH16n+tZOlWkttLC8f7gKHiMb4ZnAKsOx5AB+uKt6obmGWF4y0MpLBJrYb0XP8AEynkcc0Da1sjXuraMGNlCRtuABWMDeADhSOmKYbe3UmREkiZiCXjJBH1xxVGz4VWvpnmucZLhygkx/GAOAD/AHR0pBJHa28JVyOQrhXL9einnIPagmzNBoZcnOpzg+mIv8KKgEaEDOnxA+nBoo1EVriIxkpDcExttURYB2gdgaiuLCWW8W4/c7Su0OsYLNjpls9OcVJumIDGNpVI9QrKfUqOMY981JFGEjZXVwTySW3IwPUg/wCTQFyGLBYLNbRCQLsG5sfd/h9BTUhgvLhpESQd2Mh4/wCAjoaq6npnlW87xSSOpGcffCj+8oOfyq7aXkssKRuieao2qwIRXI7rn2pPUprS6K88c0d2nkTRvEwK5YZkUkcDPTGfbise6sX1K5AB+cXSvncd5SLgleMA56cetb2pfaJVj3xqhQ8FH3N9TjtWNfTNKYYbRZWmmVgGUYUHbwu7qByRxyRmpY4sg1aSW0tXeVBPJC5l5XImibPDD+F8Z9iR715xd6RbyR6jJbD7VpEqG5Mdv8gMq7vs7D/bC7s+pwOtd80Ae3nuLLUrWykiBg8t4gyZxlkdc5+h6/nXDaHqraRM9jcvDCqy+c4TDeajLxGoYgKMAYBG7IPXNZy31N4aLQzNR0678SaJNZAyPeQSeXC3ysrFFUqM43NuDDlsAbueaw9P1CQeHNR06G3tJI4FazuYp5BHewsjZXf/AM9SOcEHsOmK3dLmt49SkfT715ZbwyXCTqxiksWjYZWROhVlVQV9uRWYqaddXFu9g0k93BHeRT3SW6ceYeFIIw25y+OcgHtWT7mrT6HEajYRltRjksEjjmt93kSkkxT5OUJGMN8u4A5+9XMaHqgXUI1vZhFiUSfaJ4BKqnAw5DdQwAyDwTg8Vva5c3GnXt9bajBC1nLbC1nWNmO2QY2u+OVcYXI77MHmuf8AFtpJBfrEZbZ4kgJiuIlCJPHnk4HGQfTqAOK1gr6HNVdnzI6fVJg17otleaighhZpJ44YmAVedxBySx27mHJ44FdVaxR3mtacdNivLu/nSSOwuifmmgjXDE4wv3OM4wQcdRXlN9eiXTY5EnZXZ0YRwMESMgMSNp6MGwcjqDXYeH5bq00C3ntI7uyEkoaG9t5fnWfYcxhRziQFuAdpyM0WstTSlUu7WNe3SCw0y6tk+yI6zJZzlnMgmcuR5itjGCh5x/EpzjNWdZ0Z7XSFlsLWa701pEs7WW7nCi0mY4aIDOCvynac4HJNWbVNPbT4Z7a2kYuU1KYLLukgiRyoQYHVPmJGBnJ6YzWK93aiS9t9Za/liku3J+yy+RbspUMJVUrknOSFGMAYJPdx21NpNIlleGWe+mgtpbXS7OZ0aMBXNs2zaAVXjqWAIPA55rzXxJclTaW7IRd20HltggqSWJ3Ljvt2j1OCTXRXGrXLo6QXUlzfArFcXccnylDIpi3AffYHAwPbOMVyt/NJBrMiBpg1tI+TMV37sktk8jJx/wDrroicFad9EJokrG9h+0upijwFkPzeUWYfMBnG4cnnj8q6jxrcRqslrps0SW0UeyRIJEJZCcqHwcM25eMZ4wTya5gZht5LQxQNJcDzxO7/AClCOMJ2bOcd+elVtSvHvws9zCqfOVaVEAYnAAHGOAFGBx35pct3cz57RsupVlFxFGkspJScZUlgdwBx09Mirek2L3NxFFHCs00kibMnCY3YYMegHIye1VoI/tBitoIAZizEyckkEdMdBjk/jXW6dCi2DyzXChZ18oyAbXtzyAAOgB49cjNE5coqceY3PB1ve3d+1qv2a3MLy75k+YYA2lx64AJz3OK9BtNMntpm0qJXhNwGFxfXefNjUjchXHAYjjb24Pesn4cxR3Vvd7LaK3nnLIRIpG5UCqEz04Iye5Nd1rLppUc12jSy3l3+93y8t5jAIv0II4rBJHZ5GJb+G4bSex0S0SGe4niEt4tvcyHdBuBXe2AEDNjgdcHAr0G1hstHuE07T7GLdyYto2RvkAH1PUDPc461n+HUuoHmhtbcJEjA3t1OcmaQjkL3yo6dq2FsDp7wW9vMkcUeQJJPnkQbs4weCvPA/nVpdhNpm8Yvs8DOZkhdUDzeVFuV/YL1PPAplnMrXXlXkRglMZVgcsudwwobscc47VFLNFaz2cCpsnnnIbCMzS7VJwCeAAOeeO1W4ZJnYy4t4bMoXDTOTIZCccqOCCP1q0ZGvHAWgEcy+fHjGSPmP1rNuYkbVrOLZNIIQX3g4RiOiv8Az/ComjuJdgtUiVRncRkZH+ySeOe/NOuLK4ghR2ZXEf7xU8wtsPuf4s0MEtTTaaOH5IVjDkliE+6x+vc/Sqv2uB/MaW5dJomAkVlwVz0zjII/GnwtHPGqrbRj0QDgbvUdjjv3qvqEVvCV8uKK3uA6pGpH3+hJOOOB0JoEuxdkuQ2lJMEMoXCxxxDJLE85HbrzVmCeV9iyQ7CMbcEbsZ6Y7isfVisEkM6Skbv9amFTemOXJ6YHXsakthdo4mnaKX5CYyu5mUAfez0J9hjNUUrco6+uLuKza7061mkLPu8lj5bSlScYbryMjFJFqUT2y3YjZHnXCpHGxyT0Xdnk9s06FHgsbXzL4q5ADNcx7cjGe/8ASnySyveSRPatswoVnYLGWbg8YJHGSDj1pBoRWsUskcLJct5AG8WzxghDnDHrk/yqaO83pEQ+3LEOZYtixjoDg/e+pqxNYQBg1tBHBOhDIAu0nAxwR146jpU80qS2xmVnWWJsSInYjqv48UiXIhGl27DKyXhU8gjoRRTxpVo4DG1jO7n/AFhH6UU7C5vMdbyIzlFKqzHIx/EPT8DWfcToRPbxLHPLGA26RiEXJ7n1B7Co52kkJ+y3FnGE+bbcIVJA4OcHoelLp2oq22KSIR3L/vFCMPLkyOik/wAjSBaFtbeZlQpeYbYcbFAByPfmsqNbkL9muYLd28zbmPKFlHdeuSPTg1rLc27Ksc6hJG4USEYPoNwqncGONIsv5hWbeGVhu3AZ2+4oGmVrl3WRUNz+9f8AdqIomwOOpJ6/Tr1p11CsCJNCjyPGwZpCPQZyF/M1Yjvg8KO0MzWox86DJUtzuI9j+VLHLvt33KzFHMUrr/COzEdelJoZz0sck9x9pso0tZ5hvnd1DnPRTsPJBAx1Htg1yM/h5Y7i6uLe0e7F7Monikiw64wVkjZxhCSpBVjwrcV1Vxozfbp1uLuVoZYiR5ZyfM3fMD3IZcZAwMjtVC61TU9M06US2UlyIZFljSxYvOF6FJY2OGGAcOpNZyRvC/2TjrzTdYk15ZtWj8i8n/fQSkx7FORuVsZ8wBVA3nJIPI71S8T3c2kwWb3uji5micz/ALi4EiPJv37tqnj72cMP9nOa9Gj1C2u7R5IWh8lFEkUS4ypx9xgPuyNyuBWTriyalp88UkMFlJsE8SRzLgSLyFfjkqcdODUuOhqqnc8q+I2gtqGnNqNtbSIjozxOJkVXBPQAdc4DYPcYryjULn+07HS4ykgW23Bt/AAAG5R0y3BPrjFe2X8KXNharDshtblpPNaSXaizDIO2PsQWLeh4zxXj+sQ2tg10UdXWGXyI/MQoZIGB2yKp6lT3/OnT3Ma6MOUxS2scYeEiJncyNHsJ6naWH3sgDAPTJ9663VPK0e/tzFdypp1zCrIkk4kMJ2gjaOoKtnr0/I1xNtF9rvY4ixSOTpgbuBwOPwrrL7WJLvS7S1SxMvkxvHM7qN7blIJGeh+QdO68da0qLoYUna7N7SDpklv9nki8+S8uJo/tRuGWK4kZgodj97AA3leh5Heq89hby2siWtuupWriaK2hvJH8+yjR+q4O0lgdxABwMYPWofDriW0ea5iv49ItP+PfEXyJJIFVwzHnZtySFOV3bhTVsVk1Sa1udVxYtAZ0mBxLMrkkqqnh2ZlC5BIB545pJPY05k0ctevHPbyFHid18tkldSjgDK4ULkYAAJ6HjPWspHQXLLcAyoWwzKSC3Xkfz5rZ1ZrKKYT28FvJATGXhfKvwGG316Y3Hu3I4NYlvummEYV3aQhcRjc7H0A7k1stjllvY2Z5oo4LGyi+zNBFcbmdB87sQPm5PK4xj+lZV4wkm8m2gZYwdygr87DHU/hz6DNb0slveG7n+zCKGzto4FlELDEigAAAdGcg8k8YJrnbmYPdySRlwuSEyxJC9AM/TihEvUtaE80d7E0D+WRJGS2M4G4D8Rz0716HPamCJbiW6heZWaGJvKDRRB+FZAe+Mnnoa53wzpBnRGusojIdy/3R2J9xwQPfNdvo1nb399ZrdJJeXEe68kZU+8OODyBlsLwe1c9SV3Y6qUbK7O+8CJHpWmmCOPZbom0iUgkAEksc4ALZz681Ynt31LWdLe2E8VrF5lzLcs2El2DIEQPOwEg7u9Z+iQXOpWov74CNMs0cMmGDSDgSSHo3Q4HQV1NrbNqsyW8xEg8sSXSMMKIFACoQezMMnuQOcCktTaSUVc0NOMtjpenW5gN1LkNdncEOTyevBIO0YrfvLf7ZLavHu8+OQsZODwAeCPx4rNs7lry3CQtGwhjMktwoBjQg8D0Ld8e1dJEqo0Thicgsuf4zxn9K1Rg77lCOxvDDcKk0TiN1Ea4ZZCFwTub0PI4ArRhsoXdrosMP94dSAPrT5Cq3CL5ojkZS5J6Mvcfy/GpxHHclluxE/G7ywM8Dpn3zTFdksRgjg85zACwEjEMMKB0GP881Xknaby90y26bt7MZAAqg+vQsfTtTJ4YmLeXFGo6ljFlSB0yPX0qzIbeSFIkEJQ8AAAoV6Hj8enrQFjPv4oraci2vzIrON8LZfcMdNy8j1HXFUo9ds4Liee6uJkEW1Jke0kbZweAwGByRz0re2PBD5VufI+YAyxjncvJPsCOKq6fHJLNM6XU0UYBCIAMFz0+oHJz60yl5kFmsM8AaeRXhjdZFBcM5CnCkr1Gf6VqXBmmikQQbrgD90ZG28kdgO/rUcVkyozuqmZMYnEY808cbvbOenSp4G823kaVmWYDeGU8jPcUEyGad89lG4ihukKjcFO5oiOGT5+nOfSq+qMsEKzwM8XlDIwCflBBx3zitOMK0kqFFDSkPuHG8Edfr61AGaFpViYS/L5gVnxjHGM9unegS3LE8qmItBIXjZRJHx83TICnp7fjVfyJbiN/3kkDuEOFwSox0b1xTbGJTHC9uuy28rKxHgBj1Ht7Edau2rhkQEHaIlDAnG0D196BXsYP9p6lH8hhgYrxuMRBOO/3qKvu0wYjbLwccLRSuMrrYwAyqETKSZJlG4tuGfvHkg+lRQSfaY1jQFngPJznABOB7njg1ZJws+WXeTtViMYJ4/SnJDFbRrHaLgJGVA6ckjr655qhk0K2l3A8jQwbhlJBgZyOuaxSk/wBvcqu+0jG1YXQOQccEA/eI6Yp9+sjyxXNvazgs4DBduOnO4dx2q0IFijRIo/s4VDld4wAec4PvSaKUeVXZFp5SM3aLIbiAEyGIcbFcEgFc7u5x24xUkSmVILu0yJyvlyROhRmA6qw9eBUJgtzfGK5gW6LqCG8vow5+Zh27gUs2lWxlSSKa5WQqQsyTs+H67wCSOP8A61SyR8zh/IeF8li5VmGO2MN6HJxiq15HbXMbRzIqTkHarRfN7gcYOT6Gkhmu95fURDDcsDDI6D91dEcpLj/lmT6c49xim6jPEkasxML7xFuEm3DE88DpSew1ocve2q2JsdPubVBfGN/InVWTIA3Eq6g4weuefqDUd/LM80K39vCFkjVYozJlJSTjqvfG49OK07bzZIo7uyeSIvlkiL/vJgMjaAc4z3ZufwqpcpJO0MU0fkXsQW43shAVweQvY4GQfY1NjojK+jPM8XP9iXGl3sUU9kk5uBIQF8qMuyOquc7mA5x15NcJ4r0vzNLkuvt63JidW8uNAgODsIHXlgeT644r1exjDwR288CSMUkuIIhysy7yzIN2NzHJYDofrXJ+LNMEF19r09EktTbsIwvDRTbl2so7jGM+mKzSsOaumjw60tJhqjwvGA6hg6sc7R3zgjJGa1NNuRayajFCsEmEBV2ykhwQF8stzySNw9M4NJ4otDYa+qQKs87HdgKHVw3XgdTncD69RxWOJoXtmSbAcvuLBPnHykbQc/dzium11c4L2ujUsropJJateG006SQCa2R5BG4B4LhevXbnrWhqM4uvsdzHvtLu2AiiYMcRJGxAcE8ke2M/KcVzd9JbvBCIAwljBRiSSHXsQD069KsatdQXFxDJG915ZiRdsrAsrYw2DkkgHpnr7Ucoc1yPVrv7VIqp5YRT5eVYszkdWy3OCSSB747VDp0ck17BHbiV5w+VEYGcDkke/FQK6qXLL5rEcEk4HHXHr/nmruixRvM4m4XKgsJCpQZyWGOpwCMerCr2RG5fu1khguIYpPNtYW85yjAKzkDq4+8V3Dj/AHqyIUjuCWeTbK0qqI1XA2nOSD0GOOPereuOEc2vkPC0EjJ5fAWMZJ2dMkgkjLHPFVtPO1wVRXZnWPaW+8D29fxpPRDWrPSLaIotjBbBBI0ZQsx2ozfdUk/r+ldR4M3TQ2zMZQl1fTK/mja42ptXnsnzAYrktO/fS29tE/moIvMG3kqwIAHPfAP/AOuvSLCGaxtLOG5g8qWWUBpC4by0UqcgD2G36muRbnZ0OtSGSBbSwtJFgj2AM5UbYFBBZgPU4x+Oafp1nG019PdxNb2c0jzvGXZ2myQqKTnJ3YJ2dfWo7IO/MwMSSMGSFF3Scnln9PYfnW1YQO08+oXCiPy8C1i3bjtHV29ZCSceg9a0sTsdBZJCllHbNCqRCPa0YTaDnsB6Y4q9FG5hRQgMaYwWbBXHTj2qnBi4hSWSN/mUHkgFfwrQh3SAsxwPu7egqyNgiVEIDq0szptOF3AHOc81OJVkJAUq55KkkdO30pkanLscgMchd2eex+tTIAG3sc55XLD15/XvQgQ7BWVFkRSjDbu3ZO/HTH06VGEMMjyFY4wASQMfKMcMT68c1LOomtghJ2uQSyHpz61HqERmheF5HXeMAovOcevamCZFqHnOm2BWI8zLu5yACMnGOtS6dErwmOdWDqACp7Y7/jkH2qKC1NtbWsCM2VyMbsgHPX8asSiSUedDmO6jB4JyfcEdwaYy6y7P3mTlRhge61TRGVrf5QpiyCoOODyKmjllYFXix8oGQ3JJ7YPH45oJCSESRTdOGIBz65INBN7FfUt8caLZsjSg+YquMqg9c+nXinlMRKLiUgzDy9yAKufb8MnFRaVMk8DkfaEnlYyMoiOG9xu7DgfnVmOPdIWuFDNGSUXOcZ/iz6+3ahBfoSuvlukcEu1RhgG5yB9fzplo2bh02H5Wy3Pr0P41ZdN8alSr/NvUE9T3P5VQvWKSQXcLOioBFLgZ+R+jfgcfhTElfQttFKzEgNgnNFM+0XK8GK8JHGVVSD9KKOUfKzMs7gSSPPMpaGMtxtPzMeMj1GB1q9GR5Z8x0Ck9zuH0+lVY50eJJBbyLhQEXj5AOOeevY1YgVEaSQEHoXXGGX6jtRYpiyTokRAu4VCqcA8bfrUFzLDEjLMRISgxwQx9etWmkbcyxqr5PO4/KffHemxxSojNHdMGySwdAwPbpmpZDM+GWS4UkW1yHBaURll3Y7EAHjI4FT2DQzLMbXIQOCEIxsYgE8dueCPWlEWFDyQM0hzl4zyBn06j6VRxCJkFqx2u5OHQgH1AJ6tnkeozSK3LEgMkz7JJY42QrJHtzznOeR9ao3ViI2WeBmc7cPINq7079ByfQ9q0nV3RfKnlXJ+XdztP41XPmRj5kWXJ6D5Dn/69A0Z8VrBFvmtlCSqMvtOSwJyH+vv3FVNZZGaMsFjmiOY3zwhI9fQ9DWla7UuZYl2l1Cg4wNq7e47c549qwtWEqvGqzQ+S0Lq7ugkYD1X/AAINSXDcwvEenRX1iLKdCqozGOeE7Wtio3K6t25wfzrhru4u5JZre+SBza3gt7l41KNIWjLI390bhnI7Gt3VLyCS/iRbeSQuDZXUty3mKUI+RlI64J9B1NZviuJ0luhJGrPLMhNwE4eVFICsucBtvQ+9QzR6aM8O8XgxzQgEJbCTdExXDhWUE+55zn3rnW2xeUka72I3MHUckiu4+J7yXGpfIMBo7fMZALF9vQd+hU8f0rkSsIsY4FjUXBmDJcMSjEEYI9MAjr15reHwnFNe8yhLO00eJCCwOc7Rk8Y5P4Co+CCSTke3WlIBbC4HYnP6009O9WQKMgZGcHip7XOdyKpkQcAjOevP16YqHcnk7dh8zdnfntjpirdosSxNJI2wBSDnnc2MgDByM+vQUAR3cvmxxY2A/NuAJLE5zlievX9Ku2lxJHZG0lWJFKPNGzRDexZQuM9ccZH/ANeq0du8unTzr5IRJEUb2/eMTnhR3Hr+FaWmW15cLameMvFlVjMjY2Rq/wA2M/w7jj0yamTsgjqei+A7SGGa3kcJ9lAWfKKR5m0HbyeSc7j713uhbdQ1c6hM2VjAaGPHAAz8x9Oct7nFchB9maBjCFSOa5Vzljt8tT0wOM8HP1r0Lwzny4lkjCG5feMZ5PJxjtgAAfSuaOp2LRHSWkaxq7RSFWkHlqR065yfU5retI0URs2cxdM+4xn+fNZ8Q/dhhkA/IoPTbnr+J71fjB3SOAQQoG4tnk+lakN3NC027QchkI+oOfSp4WJdlDbWGCy9SB2IqvABtAYBUjOFBP3h6mpZWEcDSrgt/CQOVJ9fzp2FYmclnSH5pI1OCFbn8fakfCOoeErGDhQgHI7806CRIypJwuN2SOM+/wCNPJWeVSuGByCR0x3z/KmFyNYASJYZJUDfM0XTgeg7N/OrEPyZXe5fOcsfXoMUSDj5QWwenrVd45DsDYeVAWUgld6jqrewpoCeXLPDGmXkaQgNngADk/h6VPJaxKUKI3mAkCQsST7ntj2rORR/aD7VQQlDLGq55BHX+YrRhcEAMWiIHckAfWhA1YdDMIovLmyo+6WPIU1ZVCd4K4KlkwRwwx1qlNIIF2ysHUkgso3A+mafAAAER98cqlly2cAjnB9KRDXUnsgFtVtyCRCgQEnBI6jNTFeSduAVHPTB9vWqTTMkajYRGi/LhTkD3qeOcuqh43JPKuo+XFMdiZQVDFmKkEyegYU2PLoysThuNp7cdKezRyRgwsp4IJHQetIJ1wAE6nHpjIwTk9RQAxYY8DPXvgnFFUpNP8SGRjDdaasRJ2KYmJA7DOaKL+Q7+Ys8YlfMakbzzj7w9SKpyxPGXaOWXf8AwOeVx/tg9q0mw+CGAOPvZBI9RVaaa3tlJyGbIG2P53amtBxdgtbhMljIhkxyDwT7D2qeOfdGzMjIgY9Vzj6+tZxvoYLr/S4ZfLcFt+zcsRHqw5H16VoQzQvjZcRuF52rIG6/rSYpIldlEbFiuMZUr/jUC+W6rasQ+VBVSc5+lQ3ULzzoH4tGfO3HU+hHp3qaRI3LZKiSI4wB0PsPQ0hKxVtDKomjeTciSEKSo3D1BP170yRSyOqn5uQCD0wf6U23DLdyI5XcfvBTn5u5P1BH5VKBneRk7mPt7UizDjZrfVrtpgT9qCRkoMqjKDjPoCD17HFS3UaBYn+TYoKEDnGehz+dTalbI7t82yQ4dJfQjqPesG9F1cMIYJFtYVzvuECszMSMBT/d7E9e3rSKXvHHaiJ4LoGcRvY23mASs4K4cgI6kc8ngg545Fc74rmlv9CuNPtdxlRl89QcrEpyAHPfLYAI5GOa7nV7BLhppE22++NVkjVeGZTlTxwOn415/wCJhNIpjaSAG9lDRDmNiWH7xMDqrFQ27jDAetQ0Vc8s8cT7rlLmJlJUCKOQyBzlFw4znOVLYU9wM9q5aa7WSADBGwjZE2XVePmYZPcjkV0vi0xpYyotsiRM4EBUblRVPY9ic49+e9cYpAPIzW1P4TkqfEPmVFYCN94xycY5pYY2lMhDopRC/wA7AZx2Gep9qYxHy4A4HY05NhdRKxCf7Iya0IL32Wf+z5Ps0SyqiCa4lifftQkBQw/hwevuRmqBx5f3fmB+9n9KWAM8gRGwX+X7wUHPqTxinS74vMgkVNyv8x4JyOMZHagSViGuv8L2zLeW/wC+AUKCY94G4nB2nPrlTj2NclGpeRVHUnFdjoSiJdNuLjIiE4lldz8xCjCAD0PH1rKrtY2gup6BZW5aW1sjtXcgmnfOQAWxj6cV6Bot/b3t5Jtmigt45XjgU5BlAxk57DOBXD6a0MA+0zLtvHOxlDDfGW+UDHtmuqedbExwQ3CQOUCl5BvYD+4B05/IZrGCOjV6Holr+8cPg+UgIyTjPNXcxyxKPMJRXywTpuHIz6iuN8PQLNZRTSzzXsilioklMijk5LnoWPT+VdDE7RjcF8yEjMgZSN2eioB6ccVrchxOgiTK9T8xzjIORRO42OM4whbPuOhP5VWM/kRRy3L8lcYiXLE+uOvtiliSV3V7j90g5WJiHJPqSP5CncRfiJEUKsSXIB9fmPNPNxtXCIXKqc7T97nOCe30qtdFg8QU5kYkDHQZ70IoEMaKj5XAOD3HXNMW+5btbrMQea3khJHK5DbT+FSNJH50W2RDsbpnnaf/AK/Wq0pDqTNDhFOdznkY6MAPSnw4nlEF0FfepZdw5Ze+fegXoDKYJVHRQWCjB+XIz19604CdgMincfWqDQMEMET5QDLRkngdgD6+1TxMJCDkHaMHBO0/Udc0DepZnyts6xHLKDsA5A4qOSNI7iKVcYWLDBecgEYP4UNHFOrRMWRtvbg49j6U2ICIxxSk9CFJGN3sadhEzPDu3CVfMOMPnOfb6U63cgLwqPgsR2B/wpy4CAsEZVG9T0zR5Zm2g427SRxwOeKBpjZYpzh4WHmqMhACqn6461YBJQtJIXTGWJUbQPrToSzRng7l5J9fT6U5B8mxwGByWwCFHsfWgVyFI1KKULBCOBgHiirCwRKoURxgDgDavFFOwjEEUYKhoAm3sACp+ntU8UKQjbFDHAmMjagyap20PloiRpEyYO4sxLZ9ee1WQPmdYvkI4JB4DGpLGNEWcbCyggqrqfmJwadBGJlWRhE77ceai7XBHrjqBUUYcvt+dWAO7c2CT6gDtSvHOhJt52yTllYDYT+A4NA+gT3KxxfvXBAYDJ6n8O4P6GnJKZEIR1LYyElysi+mfWq0808AnSayZiQG86Mrh8HnHOQfwp1wTdAvJaj7PgMjtIMt74pCsAjdf3sjfvXOSwUgtjtj8aexHAGAuMbc1FAwkUsAVaJv3qsx3Z7Z9B9KZdPucbDuc9W7IO+T6+goGQXCyLArwAb1O5EYkBvr3rHuWzNm3cLE64Mi4ITB+b8e1a8kW0F4nkVz8u/qfqc9awJ/tSyXYtTbAKVCb22ozNy2R1Bzgjr1pWGkYGsLILqFIJpYt+Rv35BOeSQR8w2/yrz7XWin1q3aeVbpzHcs6KmxhjComOxB/wAa7LV/Lu4bSS9hYSRMHUiVyBzscP6HnpzxzXBa9b2lpqLJHKYjtW1kcFpGCbjI5B6g7c/hUSHzI808RuzaDaGRPK2RhFQcb2Lks7D1OMEdiMjrXIsVO3aCOOcnqa6HxPJcJa20DSTNb75GUtJuV/mOCO+ccHNc7k4x2raGiOWW4Z+XHanu7FUTcCq8jA6Z60wsSACeBT0U7dyngHn1FWSOtXMNxHLyApycAH9KScLkOpjw+W2pn5OenNEkm6fzT8zFtx3AYPPpSTyGaZ5GVFLsW2ooVR9AOgoAlQxsbcQxsJRw5JBDHPGB/Su50+N/tsLSvD5rN5URbBRTwDKR9eg7YrhLTKXUJ+T7wI39Pxru9JVMmaSVd6sLSIsdoUkjPHXdyee+KwrXNqdjv9Kgt54PI3oLOWXdNIwzL5bEKN2epyGIPoc9q0PB9vLexRa3fmRlO9IF65UNjc3fnA6c9zWI8kktlZWoKvILhUQhcFEySQe5AHP4jFdroapFYbB5aJb4to+OEDHJY+p5qI7m/Q6bSZo/scUMQ8kySOpReikkljn17ZrcUqXSM7VVVBVT/CexrB0nZHbuY8MAf3fbKt82fbI5zWxbhJiTxuceWeDwMDNaE3RZtpA6yzEjzN/lDGfuDnj0ycmtNSBFtb5j1wvBz259qx7KYGYpbfNDCWG4L3HGAe/fP0rTtxmMHgM/OemfTimtRSFMFyWiaS6WNgSPliDcHsc9/erAS5Tc0MyyZ+YiVApbHuOhxQGVCoG70HGSSamdWEg8vAZRnDdCfSgzvcUSJOgBVwj/ACgMMY9RRcNE7IsmTKemOMk8AVHNKIEJiHzA7nHcE8ZFMSSY+bLKscZjYBC/y5wM59M0y1HqWYLF7dSFuZZS5yxd+jH8OlTJ51uQ9wAA3DygjGc4+Y/1qSJ5HCspRs4OD8ufxHWkdkikxdAsHG1cjcAf7oHrj1o2HqTyL+8wzkOp4YOCAfcelPb96qj5XQHllwSDULo4YqIjgjjAWqn2RGAKhIoeIiIwUIPqRmmCRoymSGABBG4yTtbp+lRRyymYq1tjONuZOPrSw24BXyy0WwYYp0OPrVmLcMKWLKR97IyT70IWw1I2LMypIo+6PnznjqAKlRZNhIJVCBs2tkg985p0K7SxLFTn5fmxgnvTpAyY2kseTkdQKBeRF9mlPJdz+VFVPttr3Mue/wC7NFGg+VlNd7Arcjf6NHnYP97vn3qVJA4PlquMAhux/wAaiHnG8dZh/owX5UHy5Pv60qRtDu8uRlj3bthO5fw9KA6EtyxLKUjy2Byrg8dzzSQzJ5oQHY3QhxglqgllYo6KRFIMYJOQxz0B/pUqfMSjxjYVyc9G9vaiw7aFpnPnrgZeMEnPHJqvKywpkfN7KO9VJLmWzbYoa4Qn5VQbnT6eo+tSSbpiBJIEixxEFwWz/eb+gqSbW1ASRSTuMBmVVBI4A56E/wBKgm81AQoIiByQkfG3t75qY+XbGSRyqqoAB6KB7VE9yioWDF3A58v5j7UylvoVyzlFkDKYuofPJHrisy5SJZ5BOyybojIdw6AYxxj9a0FLw5VMOGJdAD94kdAO3IP51mySRRqwTYW4RmyBkE9DjsBQUcFePcWkuovDLK8BVpzaqQI2aRCuUyMrhgCfauDvzFfXzDKEFN4QSEHCfL5mRxwwxkHJ9K9F8V+bM0LRxCCa5Z7dySfkgByWPq2F4FeQeJGms7S2nYRW8s0bW0UqOXdDuyN/bDYUfr1qLGc32OC8TSSeZtml8yfzJFdQDiPD/d+pJyfwrHufI3J9m83bsXf5mPv4+bGO2elTTeT9ucykvAHxiNsErnsSKqjhtwBwDxWyWljAbUqo4by9mJQwGDkH6YoiceY28KQ/BJHTJ6j0qe8muJrh571y9xhcl+pwABkfTFMCvK7NKzEBWz0Hb2phxgYBz35pCSetJSAs2IZrlI06yER/XJxXd6YEFpHCAkgybgySKMO5JOT+XT2rz6M4ZfmK8jkdq7HSJndZLpZSsBGydWICqp+VcfQdfr71jVRrTZ1vhu9e5nkuHCyKrYgVSdoZgMkeg68dvyr0rw/vN41u7eaQwdMYCr8pyfpj+deVaRMtpfyvbr5ccGH2lcLlvb1wueemRXoWiPJHcNsDF5R95znGeRkj29KzR0eh28bytNsTau+MBflxgjoMVegnm8t4oyqpEwLSk85Izx71l2lwHSP7NH5skWSWbgKc8qT/AHiOQP5VfjsoYnmuJH89JyGbeMDoMEVoZ36GzpkKxW6RgFPqeR3z75qfR5fNgUSD54iUYehz2qCEldsqkYP3lJ+UgdMehos5mk87awCCRt8bL8+Tgrg+ntViepqwyMzswXG04HuKsQbt+QvOe/fjnFVImw21SHPtxipftCGYp8xBHPl8gfU0WFYmJLu0qnKpwFxyfr+NO04xukmFZvnxjGS5xzntntTYQFGNjKg+bqOfepTNHHIp8wfPhSAOjds4oRVxZREiBoCY2ByABgMOmPTnpVyBW8sSsMvIoyfT6UwFfMGGH3sYXnB+lIRJCrEAOhJOwHBA9hQLcmcjYQDkKR14pNgeRpAQZCMOM9qr21x9pti4BG7gArjI9afGSQuGCsxywHPPv700VYlt2kbepKhl4ZucMKmkfMXmxDBIzgjjFNdvLBbAzjoOue2PelVH85iylRjGG6qfSkheZPG0bkgqxjXrnjNKpMfIUFAScnv+P0qK3f5DGefmPAOQPrUiFkiBZGK7jwRkemMU7EMrjUdOx/yy/I0VN5cP+yPbJoouXoc+0siSbVcNFj7vJ6dcVMkseMbnTI+VSu0kHv7j6U9Yn3OkUziMnI5AK46k1nf2haCc2wj3E/M21N4wf4s9hnvQLc1Ym3RiMBJJAvzA9cfTvUBZ4R5azALjlm6oT2/wP51CYJxAqWgRG5BS4y6ke2DkfhTLe3dIjFIJoRjDRSOJFkHordhQgSRbkMYhcQzbOhYBQT9cj+dQuyvMY7YEbv8AWMznKt7g9SR2qUx4twQ3luAApXrg9j/I0xl3qYZ5SykfeTCsD9f60AV5IXWRWeOO6U8DGQUI/ug8U+TN1HGyHYAerJyADgj2Jqrqt59jiVEbzrudljgBBIkcnuR0HcmiQCNwguGeRlwQ0LKBjqcjkDsKRXmVrs+ZqscSQsLYKzysDhc/3CfQ9fwx3rP1CCO7WNnDx7MzI8IwQAcDJHOP9nvVqa4jeGaEgmZWAETIRlv4c4HPqCBzWDfPbC4fZfXUDs5cDeVaRFGGDZGNp5wOAKBpnNavqLTanB9mVvLiWVlmct5URII+pBYDk8AZ615l4ogCaNaRyI0jreTHzIwCDkFk9+o/Dj1r0Z5g7ahdzSLKhjSMSKu1ZVJYg9eoyBtHAFefePFm+y3DRw+XMUaZkY5yNpO5uwOOmOvegznszye6jl3ILhI4MwrIOB84xweO5H61BMJFWNXUqu3K/LjI9ff61oWwaGeF0LfJjEqAdCoONrcY5PNTwyyGODzbaOaMSErDu2PgAsdo/hXk59SKu5Ps7q7KFjJGHDFVARlJ3DcrDI4YZ5HHarUxjurlruVoh5r5aJRhAxP3RzkAA9egxU11YEWgEixyTKiyb4Zt7EPjYrDpwPT15qMmyiKmCTepX5ty7cDPIbHXIz0xxQncXK0iHxDb+VqEsiAm3kYiJ85DAY71lVe1WUvdvlHTjgSD5gOoqlxzQQ99AzXRaNO81u1nFuSKWVd5HfI6fmM1z2eCOMH2rovDEe6/h3ghdmGI4wCRyMd8H9aipsXT3O7sFFnFsjiaRSzttdstMdvOT39a6fRtVM80RWOWNnAMpUgBDj7mf4fw6Z965K1cSJMqYAd9iDJzHGTyef8AJzXUxCGESyQxhlaLEjGQrudupOehxisY3Nzt7CU2r2eY41MAIbYxICMcDj1z6+9dNaSn7lx8rOTtUc5zjp/s5rgtMuPtEK286zLbov7t0wSwxjk9R64IzXUafcTSWMMcqzSXlsA8chTPmMvH4ZHb34rRaEM6VI/KYKcCNeRjoD/gaezpAztjJdhuRRkkjpj8KpRyyyukdvEqTMu5hMceWDyCy9T6CptNe5mkvHSe0eIMFQorHpw2SD69sVe4b6l2GWSTYiphcZ3McE+3FPDXDBMCHYRhYgpUf596jj3wISyKzMuS6twB+Panwy7I1aUBPP8Aug8EAfw/U07dQsWbdL50Z7gQrGT8iQfKoHqSeTUd1bz3dsyQzvAAwUsiAY9cA1aDCWMqxJUMAVA+6asNtI25A5x+dJIadtSG2kmSGOJwbgKoTc0eGY9+h4NXBcoh2SearAHGEOKr/dRWQiKT/a6MfSrEjGSANnI4IBosHW5FZyCMsgeRtrbg5U4Knsat20olumYNGUK8r3GPWo4PkXgEN2U8En0p1xCjSb0Xa/P7xeMfU96Y27ssl8qcrtxwABz/APqpszAboE+aXZkMOMVFveJUMpaRegfGDnsKSGNiS0xKtkkEnHFFgViS3geLOMRpkPtAyfoc1bRwRJjHXjn7o9MU0Ou0HewA54Gf8ihXOBIjbw3bGeKCG7k4iH+cUUgeDHzAE9+KKRN2c3dzpMHjQsCDtcxnk/Q9qzbi4ihm8tWmeYJx9njLAL/tN0rWe1jjhDukbsDlcjI/AdzQ8Iiim2MQzqc44A+gosXFoS3EsKjefOc/cbHUHsSO9SG6WO48ss+/G7YYyd2fpSOiGMtHlDsPKNjv1/OlCmBWczSEuwLLjH0AoBEclxEj7V3BVILx44Y/whT6n8vWqpv7eUXDGOZWiIRzgEEnBwMHnHrSpZC5vme+tQBEpCLvyCT347+5pLuCGzU+XDAkTkBl24aX/ZXH8VBVlsUrueKXUXlSRWht4/nWMFlDN3GO6j+Zq7dzTG3hliE6EbWLFgmBj0Ocn2xUmnj907gGCZ2JMW0AIDwqMB7d/XNRxFjGHlUqkS/cUAnfnBX6/wCNArmZcRzxb7mWZbVHjwfs67pGb+HLHnPPbvWZLaLGspgijilFvggjcVUDKoS3qeWNa+pIsNu00iGSXfuhjQjh+OBnjcfU1iateiDTd62ztcSEqqeYMJIQQy7j94gZ6elAb7HnNti3sY0lKrEJyXTO5Y/MXEeD6kbs+4WuF8d3uoS6Td+XIDbeWq+YF2gJnBQE8t1GSPQ16HJZ3CxIoljVI9vm7IjtOVbc+D95hgDPQV5d45uo20O2jj8wzXp8yWV87VUYKxgDoB1460WM5vWyM7RI1RpT5jeWUjgBumUdAXAOOi8d/bpTPFVyY7uRpraPMmwDed5iwxZcDjqOMdwaj0G8ljgFvLbyHdIX+043sRwCR3PAxntWpcwEaRdXa6eHtGCtA04wJFCkHI6tjHB4xUve51xV4WRzX2prw2SQlGlgceSdpDqByFOOTyOOtUVQyXpWKVZmTPluqn5yOg+Yd/QitWys4Wt0jlkVplz5ojx5h4ACDJ57Yxz1FDw/YopoTcAIm9oRGVbqBncep4PQYwc9xVowlF9Tn752aZiYvKDHds5O38Tz+dVamuMNMxQuy9iw5qLafQ0zne4V1fhaGWGeaN1KzoTDsPTk/Nz68CuYjGMsc7lwQCuQa6Hw67hUggJV97tIyjB2bexPAz0qKmqKhudfpb7oWOHe2aAIpUZ3Hec/hmuotBanViL8M5hldwhHyqQOTx97H4iua0WaETRRSXcDbnT5RIAqqFPzZHA7Cus0y0abdD9oZ2iiDEo+QMnJIxw3r71kjdbnSaPqUFtO6OJAqoLgP5ZAYk8Ekjrz+NdLaefKiGzlETcGSYjftY+g6Z9+lcraJeSagkQMMVy0UgWXkjYuMtt7en411Gl2htBLPC8wt8CNYN+Iw3Vto7etaIlrW5qwT2tmz25nj/et5rAsWYN3yf5elW57uJDBMs6IBnfGOrqR0C/3v51B9ispY0jNujxMSQdm057nPWnGK3jhLvCnmhx5UzDLccdexFUHoWmnla4eIWlwisgIZlCoAOgz3PtirLLLMF86RApxwsecenWmWkhKbgS5UAb243e/rV63jKuhwcAc4PU+tAXIlufL2/aGjSRCVM0YPA/2l9D61btpTOpkz8wOCqkEY9R7GkuG8qLzCBu/iOOo9KhGnxeaLm2cWt7t6x5CsPRl6EU7h0uaUWSdpwCO5/SnqpgVywLR5ySvO3j064qva3Hmhh5bRyJ8roy8/Ueo9DVm2mKMSwJPcnt7UCuxWkjcIyMHVOjDv9DUkT+fEQVBcdQTgfhUSIyIBFgLnJRcDcP6Go4S+X2HKnOCVwV/CgrQtRqXUfMAc8B+VGO1EEocZbcrEkADoKjic7GZ24I5/wDrVK/ygbOWA+bA+97ZoIe4+IbS0aN90gH29s0sjqHKLkL/AA4OAPqaI1GMqMFvm64GamPzA5UsD6jH50DuMElvj5uvfg0UCSTAxNbgdhtziimB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An erythematous plaque is present on the intergluteal skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Goodheart, HP. Goodheart's Photoguide of Common Skin Disorders, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2003. Copyright &copy; 2003 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41558=[""].join("\n");
var outline_f40_37_41558=null;
var title_f40_37_41559="Neuroendocrine low power";
var content_f40_37_41559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Large cell neuroendocrine carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power photomicrograph showing tumor nests with an organoid appearance characteristic of a neuroendocrine neoplasm. There is an abundant necrosis associated with many of the tumor cell nests.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey Myers, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41559=[""].join("\n");
var outline_f40_37_41559=null;
var title_f40_37_41560="Linear porokeratosis";
var content_f40_37_41560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73545%7EDERM%2F50928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73545%7EDERM%2F50928&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDSheFURVDiTqd3PFIXaRtoZuBjA4qFQ4lBQYPqa0rKNPOxOcnGSfSud6n0trDYo1CgyrwB26mpYX+bb8xHYNRiPziVLkdiwqzHBEy7wMt7mpYiLyDgggfN6CoZIGIUEkjHHtWgkLb8nBomkMQbgFsY+lTe4r9inAGjXDY24xxVlRuHyk8jFRKZZTt8sjHIxT41k5JfBH8I71ErsUlfUmCsFGCePSmEOW+Ytt7D0p8ciZ+ckN6VL8j8Bj6jArOxFrEEa4JbAbPrSkPtILA85HFSqyckKGI7jpT0we+T6VW4mRRwbkC4HvjrTEUgkcYzjk9asDfuBQ4Hp3FNuFLDphu/akBE0DgBlwQeOaieHGQBj0GKlQOrZbPtnpU0vyxAycFuRjsKCXoRIR5Z3DIxuzjpVWZFcH5yuOmRVqR4wdquVbOScdaI44yW81j90lcdSaNxIqLBuid2KhlI4J5P0qLarAqy4I/OppkJ6DOOhBpMHYTt3D1zQUVwHxgjkdDUF1Gj5KHtzg1bkKyYAQKRwATUTxoTnue1AFMAKxG0uMd+op0EW1iS2QRxx/Op1XbzwPUEcD3pSdzAYC44z61SYhjIBgbGB65U8UFW2HYAynqpFWAq4Us2F7n0pVRSTtZSPc4Jp3sSZjw4JbbgH+dRmEE8na3btmtSeFkw8fIP41SlgMg5GSOo6GpuO2hVeHe2CNr+vrVOVSshDrgenStRIzHGyEZyO/pTWgMqbW5I5XPXHtV3uK1jJKgA7RnHpTAQV9versttsIPIJHB6g1XZPm44bPQiqFYiaNHGMDNUpoAy8itEqM+jD8jUcsfzZJ4oIaOelgkiYmMkVdtNUdFVJBjHGfWrksG4n0FUbi0+YbePWi9gN2yvllXmtGKXJGDXGL5ts2VJxWtY6gHXDnDijcDoyd3BqKSH2plnOsiDLD61aLbgMcjtTEzLubcY6VjXVr14HWuplTeOKo3NtnkDmqRLOPO+2myOPWuu0LUd6qpPNY97a5B4rPtpXtJx1xVE9T1W0uA2MHmtWFgQDmuH0jUQwXnmumtLoOFpWNEbCHJPpU6KSvFUY3BX61fhORz+FIolUc84ApzKCcU6PGMVIFGfpSEVjEDnjAqF4vrWjgVGyD061aAy5oRjgcVTli4NbkkXHHJ7VUmiHpTaGmYM0APOOTxWbc2/Xiunkg6VRngyCcVNgOYltvaqVxbAgjFdPLb9uMVQmgHP+FMlo4q+0/k4FYl5Y8HivQLm2DdulZF1ZA54FJk2OCbTwxwVqndaQP7vFdq9jhsAUGx3dRQiJRR5ndaPgEhTRXoVxpwIORx9KKtSM3TR6Kk3ynADJ16c5qxbTBRgxY9SBzSxxyRQZEI+bqatLARF5hUq3Ums22ezoQyODGpEeffPSpLfk8AD6VKtuTEXGdvftzVZn+zsON2fQ1EkwZfwCM96gaJWPJ+tRJO0uSeB6Cp0fkEAMSOhrNbkWsRqD08zAJx704uY22JlvQ+9Kkq7jlASpycjr7UMSz5jHB5x6VqaJDJmRtufv9CBx+tSRROVznG3p7VCxj3/ADZGe3WpfMdk8tWBQchemKlxTBx7EpwudwXr94VJGyI67149j1qtGzdCVI9KsrCxj3njnAHpWb0MpICy5JQEk9cinEkAHkUn3fvY9M09Mgbs49xSJsRvEzqWJG0dT6VAyMR0B+v9Ksk7nIXoeetNKBgw3nnkjtmgRGkW4H/ZGRnrUZXK5Iwfc1MYWAI2/L/Wm+USD5mT+lAhm0MVQ53HpiomTEhQY46g9KsTxIvEbAgDk+9QfMR83QnqaAQ391tLNt35AAxxTXCctInyjptPenvGScNgk4ANRlNoII5PTng0DIsABRkluwIojMIDiY7Pl+Vh2qVUUISGwRjAPeo54yy8Jwe3agVhQfkAXB7hgOKckCHkjHPI9KjgjeCQhTkjqP6VdjwzZQLx2zzVE2sV0iAYmN+D27GoJoeeQw4/KrzxAZYkYPVeuKhJbafLyDnv3oGihJAT069jUZgIGHHB71oRruOSOO+D0/CnsiYHzdefoKQMyHDBsE5A6nHIqvPCrPkE5B4H9a1prcbsg5z6VVeAb84z701ILGZMgLYIGc9aR4vlJA49qveT82SPfJpvl4fGOAapSIaM54gFDDqRyPWohFubd296vOu6Qc8L09KTYOcjGDg1RJl3NqG6DPrWdJblWwAc9q6B0PzZOecVHJEoByMmiwjItJ5LdvUd61ob3JGGx7VXkgBAIHNRiA7sjpTA6CKfzUXpTpVBBrEgd4jyavR3Oeop3CxFdW5OCBWRd2u4MSvNdE7KxBHSq0sIYEUyWjm4JZLSQE52jtXT6VqqtgE81lXVsMkYrMkikgOUJBzTJvY9Ps74MBzWvb3WQOa8r0/WGicCTPFdNY6ujKMN19aC73O+hnGfWrCOCeelctaagDzuGK1YL1WA5FNIHobAPanjGPaqC3BznPFWElBxzkVVguTMARgVA8YOcg0pkXdSNIMn8qdhELIB2qvPEvYdqtPKM9SRULsCDSsIy5IeR6VTnhGecVqSctxUMiYB7mgowLmHrkVny2+c9K6C5j4NZ0iVDGkYU1t83TmgWvy9OK1HiJYYp/kDHAoBoxHtc9uKK3PsuRxRTIZorKWxFEhYDqSatMJ2AU7eR+VZ1kJFBbOFHYdTWpbguG3Jj3apPSatsU5NyuQh3fjxSPgxhWUK3XFa4iRUcOq+ZjgtVNovNYll+Yd/WpBO5mxZE3AOD7dKlEhfzMDnsatJiFykqDPp3pjGMk7FKgnn3pWDqFvFIVBxj1qfYqydcc4BHSlTBHyHfx0PFOKrtB/iHUnoaZViGWBSGbkehpFt+QVBPo3rU8a4k/dk7T94GnzQO7L5ZIAHc0CbsQpGrSExKAvUZPerMcZH3iTRbxBQwbO49+1WhhFwBg/zrOZnIryQjGRkn0IpioFB4K1a3l8K3Ap2Sq9h2z61KsjMomFsDAz9OtC7txBBwP4qutDj7wwx6gH+VI5IXaI1VeN3v+NF0hlcrjbz74NSokbkq7hcDIJH6U8wnI547U1rZ9xyRgDqelTchlaSJVJXBDHt3qDGwn5FORgE1dMYEZYuPoetRhwrhyARjoaaGUpEByqqfYU1oduFZuT09qszJuyVyCfX1pBE20BxwPXrQMpNEQc9DnuMCmsjvuA+U9xnFW3GNwKlh09SKhRTnLZK+ooAi3EIgYcdAR1qWMogycEDrxyPpUnlnO7qMdMdff601YyOAMnqARVCtcf8rZO047Me9NaAlSVxjvU8aqUKtkE8Af3aUKUBYfe9RyD9aTQFUx7QQcBSMZ/pSLGCmCMEdjVliHYgABvajqAP4v50h2K7xqTyeDzmoHiIJXuO3rV0Rgox3E46g9qjxkr0yODQBQeE/MvXjPSoJo/mBBIXjNakqbiCuRj1qq0QwQRk+nrRcRneUQDnBGf0qOZNmW5IPFaJj65+oqvNEGUYHX9a1i9CGtTLY8HjnvTSMjpwRVmWFSDtJHpkVAyY4HBzVEkeMLz1NN8rP1qVkJ6DFSovpgUCK6wnjA4I5zSmNvoa0Fj+QEGpBCCfXNAGdCmOD1NTEHGeKvfZ1AI7ioWiAzx+VAii8e8n5aq3FnuHAFbBt+AR1PWmNDwc80XBo5qayUg8VVkilh+4TxXUvbBu3NVLi1wv3cmquTymZaarPAfnJxW7ZeIQcBm5zWLJabgcqartZFeQDTTsGp39trUb/wAQ5rRh1RSow2a8rBmi6FuKsQ6pcxHDZ2+1WpCPVBfqeARmnm9zjp78151b6/jAbINaEesI4zuGD71SswOz+1BufTpQ9zuHXmuVj1IHo3FWY730NDGkzoFlUkUjOCDk1kLeDHFOF1nnNIZcmIP41UdPm4p6S7j+tTKFbkipaGnYqxwbj0qVbfHbmraKMciptgx0ppCbuUPJ57UVf8oZoosTYy4WO0MEwDwMdamjaUybskkdjSYjD7WchV/u9asJcRx5MKMW6DNZtnpD1Jlyep7mlIAfcCAq9vU0I0ssZAlRVPVR1qOKJmc7gc9uakViOV8sqMFwerGgkNNtTaRgUXMbJu+XLdsc4qO1JlYjYMgY9Kdi7XJogHfYXwAfvCrTwCNQQ6sc5welRWqr5bIAS4PNTK6R/K6MSegpCe4qLux8iqx7qasZGzBI+Tp71BkZwqndUkWOQxyM0r2JZJF+8PzKBVhIgEIbJz0pi7FIA6kdKkSUDI3DI4rJyuZsZ+7j6glhxzTFQKCrkbjzgjpU20lugPtTSioPmOcHNIkE+ducFfWleNc43Dp09ahLufuAYPBGKarbThl+hpWY+UkbbsO05Hp6UhkMsYUgAKeSKlIWRSWGenI7VEUAfgkdsjvQKxDISeqjHqO1QNEME8HNWmjIjycj8OtNYMSGGR29aBpFYocqR80Y65p/knKFj16fSrwwvAQA9xjrQygnKjt1zQIotEAvBBA7dxVdkXdkZXHT0FaDxtjdwM8EnqKa0eHIZV2469jQBSAx15Uevao3T7wIJx93HWr0i7ExtyOxFV5UwuSc56H0NO4IrDAIIJ54qY42sDlWHUf1FLsLHgjJ6cVL5WHHmcZH1FFxkQQO2QoJPp3pu3aSQNy+lTKMHCDABxtNIIct3GeRmnoBCeG4ODj8aauzJB6nrU8yKWXgg9waruAmGHPYj0pMLXFlGVDIQai2bW6dTkH0p0cuxirKCp457VHI/VVYYXuaQcpBIoaTC5JPOKikjDKepHTPoacX2tuB785qKS4RhhDgn171UXYTiQyx4BDkA9MH+lVHQ8jg4q4UBJxyCO9QypjHIGPftVqRDjYq7OcjIHbP8qVRgjd0J7VIEA3ANwelMb7vIx7iqTuZtFiA5A9PWrKDCj61RgcrwRkdM+lXYvT9aALQi8wHGBUPlYOOxq5bfMNvP1qVYQeVNAyn5O0DAyD0ND2/cDitFkKkZGR/KmmPJ4BxSYWMd4cHjGaieA4+YVuPAvoMVDJbhehzRcdjnGgdiSBUJtpCSWFdFLGpGUGccGoNhfIC/jTuHKc89vngrkioHtAcjbXQyW5VclQT9KheAkZK/lT5hOJzFxYqCOMVUmtpIzlCce1dTNEpwCmTUTQRkcjBppktHNJczRkZJAq/BqfYtzVq4sVPIxisyewOCU6irTYtUbMV7uHDZqzFdHcMmuTEstu2CDj3q5b3wOMtzTuNO52EF0OOc1oQXIP0rjYb4L3q9b6gO5qrhY7CKbn+tWVYYz2rmba/BI5rSguwT97rSEbAOV9qKpLcDHB4oqhWK1u0WSHJDduM0ry4IKA8VNGyJIWiAUsMEGo2Leb8oycc4rnPSi9SWG4iAXcMt0yB1qwzw/KPLOcZPPWqFsmX8yTIXoKsoi7ODkH1oQWJNx6RfLnr3qB7by2G7cWPpVp0CDlQABxg0+1KzO7SSfMBx6UxoWAARLhM475qWTDEDbg00ROsYYsuw9hU6RwMCRIVPT5qQiDyTtBORnketKSiMMltx9qkEvlyFWfKr+tMdw5csjAfw0rBa5PEySfeOGHFSBBxkgn6VC2wqhQYPepAw3Dtj1rKUbGTViZQCfT6U6Zl9O2M02IKASxxSgM6nCkqKRJG8WY8DrjPBqGN2RwrLuTFTpGxBUcEnikw0krxEDcvJA61qtUaIQnYpbIG7tUkQfbtIHrj1qDyiygZwpP5Vci3LwvI+tRIhogljBYAZKnsexpogK4POB1q66k4II2CmBSBk7j6HFSIiEew8qaVVIb5cf8A1qlAYnH3v50zJWXjBHftmlYBkwyF457eoqBFw2GyTnkdqscliwOQe3pTCcgZG5fyzQA1k3ZCAjHODVd48jlTjoR6e9Tszg8Hb2+tPXD88BvT1oApCFQwBB59KBGWyvJHr1q6EBbK9x19KQqEUFQdx9KAKDMNwDn5vX39KRpD/GCSehqd43UnIBVj6U2RCkLKRwOvPWi4Iqz7lHz42k5qORSU6Y54NTbCfmDA8dOuKa8iIiEqW4+760NjKMqO8hXOPTimNhFxJj5RwaS+llmlLK27A/hGMVRd8MA6sM9z+lGqNFEvLGZow4AB6gdc1FPCditIo2ngEU+0LQxsHBAboQegq2xzGSTvycZHQj+lbRWgWMd4Rj92T9DzUEuQ2xl2t6HuPWtZ4whBRs45A6ZqtdQeYPlOQrcHuOKm3YUomd0xyAB2qFWw/qKkmgKONjkkngmoGYrJtbv3HeqXmYSiTY2uNoq7CxIwRg1noMZHQ9xmrkDKSMcnpVGWxqWpKuCOnStS2XJIznFZFuwXp1BrVtWIkYY96THuXPJG6keEYOOPwqZQeTU4jDx4xzmpGUVtsjLVD9lAJ9PWtV4zjb1BpVtvkxmgZimzwxOMmlNsAvyqPettIgAQ5BppiCHAGRTC5zskXBG0ZNVymE2sgx61uz2qsxZOtQeUCxWQDFA7mFLbKVyq81VktUfIIwa32twxIBIFRvaKwzjmmI5uS1KDpwaqzwFRlR17V0kkHGCpzVSa1LJlRkCqTJkcjeWgbtz9Kxbq0eJtyk13MtuCCMVkXdvuG044qiGuxzCSuDhjzU8VwynrT7232McCs4+YjYIOKZPNY3ba+Ixk1qW2oc9a5KKbBAzirkU5z1pl3OzhvsjANFc7b3ODjNFID0O5UtKoWPbxmmMrRxh+VJ469aQ3OXZlB44Gae8okRNyMMc1mehYczMECnaQw5A7VAku1hGVOB6VaWWDeDKG5H5UReX53ysAowdxpjWgEeZtyrKR696shCigDCg8HjtT2KmUs0q5HAIqTmRDuKHH50BuQu4CiOPcFHepY3PG1VbjvULr5g2jIc8inRROu72GM0h6WHMAzcYGD09aeyKZjnKqei05njKBVXJH8XfNMb/WLubNJsTQNIQwVAOvSpir4yWBFV58BgAcc8U+Itgrzs7ipXvC5STlHAYHHsatJJgHYcA0w4+zEhcc4AbqarRs0TfOODUyjbYlxuX2JK4A+b1zTPI3kFgd3rnrU8EqFgVHXjFWVwx5HyjjA7Uk7EN2KcFsQcnr2qyISvzYz9KkL/wE5HY46U4lcYJx6HtSbuK42IKwwgGfSlbIUkjpTUjwpJIU9RjtTmaRTg/MvqaCbEBbchwNoHtUTKxKtgY/velWTt2fNxzTWP8AdwQfvUxkGwbznPHTaetKX+Uh12n1xU23bzyD2IppO0Hfgg8dKAK2zf1HzYz7UwxsoBA57EVdRDxjBUUssWBuXB74pWC5XiX5jnAPseKJUIIK59DjtT1C9Au4eh6inspKkEDngEUC6lNwTuDdagCkIwADAdjWg0ahdrjA9fSoUjVuT1HSlYaZUkjVIw4yDjr71TaNyxY5JIyAa0zHkkZHH8JqCVcDJG5evuKCkZqossrKVI5+WqUkW1vKkZlfOBuHB9q2gu0hioIfjj+Gm3ZzGUCIdxwC3b3rWMrlp2MUfu1MUwBHbjkVLDIyxKAVxyCrdCDUk1vIGUykq4HyMR1HYVAVAkcMoJYE4X1qjXRiHIyDwc/dJ5zSTbcLLyHPJ9jTZAZV+ZhvAyuDwcf1oIKR7zgNjBHtQKyKlwoaU4UcnkVRlQFWHGAMAnqR/iKvyNu5weTwD2+lVLgqD3U56etMzlEz95Hysw3JwfcVPBIEPB/Cq0uBOSTwepx3phO1jtYHPekuxySjY6G1lDkYznvW3ZNk9ea5CxuMMBniumsJfmiPbNNqxJvRZ7gGrcRAOOarwZIBHWraoA2QeaTGTxxg4JFSxwg5JHBqOMnOTkgVaGTjHpQBUnt/lJQ4xTYkwNpAq+QNh71CIi4+QAY45pWHczpYD5nyDIprW4ABwK11hBUbuSByRVaWDB4PXpTHczGiUkDHWq0lvtcdRW41rgZPSoGi+Y7se1AXMS4hyfU1QnTblduAetdDJEd/qKo3kPcCmJnMz2x3E5xWbc2w3GupeEFGBUZFZlxbHaWHammyWcfeW+OnOKy54QRjGK6i8gbnA4rHu4SATyKpMhoxPsuWJHaom3QtyK17Ybs55xUd5bq68DmnfqRaxTt7gZ4NFZUnmRTHA4zRTvcdz2MtEQD5mWPPpUyzh0XcAcHjBpphgAJ4zjrSSW6i3QIp3Mc5rI9a6LolUwsW2Etx9KkjVFVgCpAXOTVK32syxyrhCetTmIAEgcDgYPWgLCqdgBIyp/Sr0SK5DAZ2jntVN4DFGu4de2aRSoQsJH35wAKY7FiNJy24LiMHr7U4SFYX5O8noPSmoJPlWOQuD1HpT7aMguHj3H60BZEQfewZAxZeuOlXIlWU7jnJz26VLaRQmDIfbKTyD0xVmPy4EkYYcngAmkKUkUhCGcEj5RzViNU3oJQwU9xUyGJUXy2PJ5B7U4xhWaQSKRnpStYm9yK4jUSARvuQdFIqZLYAGSV13fwLnNJExcv5SZz3A6Uy6dgwJjw2ME9jQKxDJ+6O4DD9wKtQvuKnOBVdYB5ZLnmq/lMjgglVP3Se9Q1roHLc21UD5jyOp9qeArKWQbh6VlwT7V2Oc5q4rgIeoHYipsZtWJJAM579waemHTaMsFPGai3liOhHqetPUguSOD+VCEJK23AC56mnYUoOQcjkUDBALZ3CowQJSc9P1oAkA2HDY/GkMW8eq05VDE7gffmg4QkZI7jFAiEpgFCME9D6U8IRHtZhx0p4YMSHBH0pyYBHcmiwMRkJxxgY545qNgDklcYNTBnO49QOKaUdk5BB6/WgkrDcUXeuc96cVBU7QNw6EVKOFCn7nsOlIgG9jk4HSmBXeNcKAmSCefWq8sQysZ+XPUk1eYb39NoqMxDy2fIJx0qWhorCEjh8bemfeqMkG1nz0HTPOa1oY2ZAnT69/pVYxkpkEEqTn3pdS0zLmeRlAkXoO3YVTWBXiDoGS4zk5PBrbki8xGJyrKM4/wAapXEIYoMfP65x+dWpPqVGRhz43NkGOQde4phfauJDuGcFhztPatGePzFbem4Y5x1HpWXJGyf6vOW4K+v1rQ1TuMuAElG0blJww7c96ryW52L8xIOSKtBEOGXIKkZDdvb6U45i7ZRjnb/UUxS0MmSDgqRx3Gaz7iERy7EctlQwz/KtycKDxkADP4Z6Vl3abZd+OnH0oexzzVzPjnMT7T09a6fSLsSbMkc1zNyuM8cdqdpNyYpdh69RQc9tT1e0JaFWz16VoxgEcdR1rB0W5WSFQCN1bsB3J05oaAlQ7R71ZiIJ4JJqoo5IJ61NHnB29KRVtC823aOBmmdGwvBoTJXGOPWpIAoPPOO1BOw5VGMjvSyIpHqR0NPY5GVH4U3cobDD/wCtTEV3RsEbCefXrUTQbmIbjHNXwNwO3g4pkkTHbhtrD2zQkHMUJYgQBjms+SH5yCDmt1gADnrVGdQZFIoGmc9cW5WQjHWs+WBgSAMj1rqbmEEkDms6W22nkZU0Bc5G5gJJBGKw7y3IQgjvXaXkGXb5c1jX1ruByOlNCZxkMe2YqelLdpheK0RAFuGzUd3ASOKEwaOXEYklO4d6KsTwmKf2ooTDlPT7dmeMKQoUmpt8+7am0lOAaqwqVcrtz3FPDsjfKAM8c1KPRsK0crI7kjaD0p0YkMeWcgCnKWeBg2NoPPNIBNKikr8o6e9MslDDd87lgB0NPSFJRg5HNRyQhpgSNntQ5eFwAflPFAFox+S58l8gDrmp08zylV12b/4qqGNVAO7GT0rSth5p2lwT0BNIGycwMrKUCttweDwakjYTzmSQbF6EdqbcR/Z12KSHx83oaI5MDymIWMjnHNBky3sjEbzJhWHAA7io8DafMTluc9qIyrQsqnDLwCOpqOISRwFZch2HBNAItoFW1xC4WT0HAqAM4bbPuRT0zzTVyAqyL83HIPapWZ93yIWBGMHsKAWg2dInnKl8Lxz61Gwlnk8uNlaGE8BqUhVicH/WZxtNVQDGkiksGPp0pgiSQIkYYhlds5GOPwqWzzja5yOvNRecytH5g5QYUdRU0Ssx3k8NzUSsKTLAKD5eR2FLLu2g4/djvThEVA28kmnAHyyrfdqCBtu/y5Bz7VG+NxK5IPUe9OWPa2AeT6UTYXv06Gi4hqMyocHK4+9TxKWVlYAt7CoWc5G3g+opY92TkZPfFCCxM5O5BkYx94dqTeFbkZJ4FMI2k7M+poIO3jABHftTaAtQyHIVck9MGp3IwACC315FUIw4H7sj5e+asDJbAJJzyPSgloQ/Nu55HAHrSEYbav4092PLKvI6ZFR/w5z8xoEKRulwuBgYz2qOYDlRjOafGQHJJOOi5HAoZQXVVOMdzQAjEPhVG3A4qBE3Ic456+tTSgD1yOD9aa6FBtweeSKATK067lUYyelVZE3dzhR06Z96vP8Af+YEH1Heq02eeg4xgUrFJ2KEyHzxggZHNY80TC4kyF2k4Kt1HuK3ZVwgOcEDge9UrpWMRYqPMVs5A5q4msWYjIVkIxuA70eXgcMcE9B3FX50RJAwPOMken0qpgglVJHoO4qzR6laWNSpIAwfSq0sIkABXI/vVZViMpgBmPyk+tRyN5T5C/MxwcnpRcxmjKlt+CGwcZrKniaM+YPWukkiwg9f61TmhDcnkmkjlkjQ8OamNqkHkcEeldzZ3wljBz83tXj+Xs5/Mj+7n5h6112k6oGRWVuP5VSYnqegxSbgKtQAfjXO2N+HXhu3Na1tPuU4ODSsBqxnkr2peEb+tQRyjAPepC+4ANxQBODuG3cR3pN5BxjIHU1CmTTyRgA/jTQixE5C0hJ3ZJ+lQ+ZgjC5z79KkOTyR1/SiwhMbh83NRhRkjg1MBtwDRhQfb6UrAVmQYHFUblAEIArUkBG7vVKRd3Xg07AY08ee1ZF7AGHt0rqZIBsJI5xWLdwhj/WiwHITW/7/ADimyWwK471t3FtlyRUBh4ORSWhe5yOo2I3bsdKK6G6twyYxRTsK5oMHE6FUJyO1DuuwL5fAPOaW1nO7IDcDrU8b5+YJnnqe9SegMEgAKLGAXFSCWQxrHtG0dKGBIDBRuIzj0pBHKSBkA+lBSJDIodfOiOzH41EXjdyuCE7EnpVhSRIBjPGCDT47dXkYSABscZo1HoBSJpIwzLgDrT3KiQiJwRxjFVHiMIGV35qVY42Az8uR19KAsi/AxKOxfJ9DzUkw2wIygfN3qtCgG1WfaTwKnQvDI21PMHQE9BSIYNKuxQBgKOT6mkjuQ7MJVLAj5famyOoiMYAD96mt4NyZx0HSk5EvTckMyKdwG7IwRSRzFCdm4g9qVYgvQdatCJRgY5pczJckUy7MhQx7s98c00RyYIJyD2NaUUKq3IyKmWBT1AFK7FzmbHaszAt+VXoo0U4BAx1FWFgGMnkVPHEoU4XGOlFrmcp3KroWG0bgPpVdkkVvlFavHLDsMVWfBOQQKdhJlUKx3Evhj3ApXjDD5j1/UVIEUZPcd6RiNpO3djoPWkVcqzJszs6dPwoimRRjJzjFWgqsCTxnjFVnhAY54xS2GncdvBbJ4/rUrkEEgZIA6io4EAHOWqyi7V5OM9M09xNlcL8mME+1SJn+IFSehFOKNICTkY7CkRdygEYUU7CJCjspfpt4x7UxV3tsGMEU4ScbCce+KjJAbd0I9eKdhWGujPwAeTx6UoG2U7xg4z60RM7ZLDAHcUyQqszBgcgA/XNIZKw+ZdvHYZpr5Ybix5NKW4IP3jwOelMZ9oPynjt1/GgBrD5l7+oqBwCjA9eoNTo4x1AyO/pUci5RcPuxyAKAKTRkKWbp96q0iFo3IIJ9c1oSDzSAp2Dq/tVS6wRtxkdcjjNOJcdzKaHeQv8AGoxwPvCqrhg3IOR3PUVsG33KCrEkjI29RVaSMNySfM7n1qjZsxbqJi+04PQgg1UPzEGXkY/P61ryIcHBBA55qnLGwLg4DEcrigTVylGw3MjcFWxg9qSWIOMevOafLA6hmIVs43Y657VEGYHaQeD0PaktDnnAoXNuenX8Kz8y2sweD7p6rmt4qrAtnK9evSqV1bg8jj0qjBqxf0rUw65DYIPI9K6bTtT3MAW4rzmZHikDRHDZ596u2OotuwTtf0zTTGtT1a3ugWGCDxV0TqQR05rz+y1U8c81v2eohsZPJ700gaOlSbn1qTzQw9KyUukK9qEuMEHNFgsbKMoHv61IrgkHPTt61lfaQwAJAq1HLheopEtF9ZFY8dfSnhvcCs7zjnilSXnnpQTYtu+Rjdz0xVdkPU9BQJQScEdaUsMAn8qB2I5sYJrNuYcncKuTSEntioXYbTxRe47GLPDg5HNVpYsDpWvIu4cAZ7VFdW0cM6xSzHA/1jKv3fYetFh3MOaEhSHUg4zgjBorS1OB45mWRzIcAh/7y44opj32My2JjkYleDUsZA4LYBOOaoJcOyAgEetTbTsDYPzdDUI9D1LuFUMVYk04naUXO4nvUax4KbTgH72alChVyPmZTyfamBLOCu0fxHjOO1IIW3gBt2asQzfOrSKGGMVbjhtjEkv2jaWP3R1FO1xc1iobcQDcGHuDVOTKOHb5lJ6Crs4DSEZLqOnvUUyR+acA4xn8aLFKRHE6k46EHjNTTSusu1DkHuKbIBFCGwpY96S1XzSGwaibtoQ2iVIWLBmPJrRhVlU5xnOKI4sdRilDENis0Ztkp+8AODTwgLg4wRUcJO72PrVoLgcdRTRLYrjO0jGR0qaAKG+briq544HIpA5EgI5xxzVWIeppEAgg4wD2qNJcMwOSoqBJ2Y/P+lJhWyobk9qNibDpHHO3nPFMGC3XpUanDAZ5HOaeCBnqQeefWgq1ibaGABH1phjAYooIPcmnRzdRjr1pksmDjjceKLCvYaAUfBOQegps0akkg59qSWUbxt/h7n1pBJ82SNx9MdaLDFGIVORn0FODHAyeAOCRxUYI37iSMcU4NxtGcZyM0kraFFmFSUy4wfXuabIu75lXAHUUiMUQ5JI65pZJQFKE/MeRj/GqsRrcruvLMj8Z6GopSfN2TNkDB3D+VMuJTG4cdzjH9360sN2ifKxDMTg5GQfeqirl62JvNEK/PtyWOcdMetUpJ1EvGGAbHsTVnUvJ+VWbYT1I6AVSiIeUwSBt2QoGMbc1TgUlpcs3B2Mp3bg35j3qaEBiNxAQ/nUeoSJ58MI5Kr3OKfGrYdgvA656ColHUl7CyRp5h8tRsJwfaoZE3lRG53DJ4NW1UBVGR1596a67JH2jA6bqlohMqeXuZUOM9+2aimUPgKgDdPwq7HF8xJzjIy1LLGQwJA574pItSsZTR4bAAU9AckBahKE4KljIOoIyCPatFoiZFDndH7GonLeUyBQyockdTj61e5pzaGPdW+3G5TsYnnuD7VWdMbRKm4H7jg8itkRqttzhhnkY+7nv+PSoJIgRhCS3UADP5UFtmFNCIyNwOw9h3qC4VZAQ5AbHyuBwf/r1ryBVyilnQ9j1B71SlhYMwjw67eP/ANXrQFjNCqVO0gNnJHSoyiMD5gO7oMDj61ZMJZsA4YdmONv0NLIiqduRuPr1NBhOBj3VuB93njisueDHOcH1FdDLBIpLR4bH8PU/lWfMBKcbVz+VMx5bGfDdvEQJB9CDxW5Y6iBjLVjPEGJDYBHr0qAiWBhgfL2pphc9Atr9CMZGelX47kFl+avP7XUNuOc1s2mpBsAsB9atCZ2CTDJNWBdZxya5+3vFcZzVhLjnrxSaGba3IXq1SC4G3dnFYUkuehpYpm2gZ4qR8p0C3I79BSG43L3rIWU4I3Yp6y85yDSuBqxyhjg058cHtVGGZQODn3pXmwM54ouJrUllwDx+fpVxoDcgST2MjSEZJD7Q3uRWYkhZ1Oa0rqJJrhnF3EN3OCTx7VUSJozNTEguHM6bHIHyj+EY4FFJex7ZNquJBx8y9DRSuWtjmYwGAVDj8KuiX/RvLdeFP3gKopcNH8yx8DrS/apJcqoIB5xSTPQtc07cGZMZ5HQetTwSwwyukqHlay4rm4UnCEEDA9qGvXIIKKW45PWi4KFzWdAqxtC33v0qhKX84gZ+Xmp4ruL7CiEsnPzYq1YWsZuUaN90LLhiabVyb8u4y0nUyoSM45walOJHdpQVVjxgc0Pb29iZG8xZWzgDPSqV3qDsFWPBc8EgdKXMkQ5Xfukj7MLDGWPOST1rQtQFPC/Ws+1jwAzAlj3rQjbYmR/FWT1dydtC0WPGKUnaCcDNVjJ0GeakRtxAz1oIZdt8bQwOT6Yp/mEPzjmog+2Mjpg8YpgODu7dxVIlu5ZDJsyM+5piuvLH7p61GpCqATnPGKUdAAOp6n1qiUywjqxHYetKyncCGUt3AqvHtO7zHIGeo9ac7ABSO/tSY7kmc9sDHNOOQgOVzUZcMNoIIx69aiM6MynJ56D2oBkw4YY4HekWTILqy5zgA+neq2/dIodsAk5NRTzgltvyqOAtA9y2VB5zkKeajKshGDktx9KrmfYOWxjqeoJ9KVbgsSWYA44x2HrTsUolvcAQh20BuT29cHpWYt3GJNowzZ+lWC+1jzyeh9akbVjREqvFGykMvWibZsYlydpwmBwTVVbgxYWbbtIJ+WmiQurMGKrjKimhJMfNaSvlpepHHPX/AOtWPI/lzDG4RJ94E/yqWaczOqfOhx8zbutVJN7KVkQsB0I71orG0U1uX47u1mXB3SSscjHAUe9TxS/YomSNw8pOWbOR+dYTQpFIxjYxnoxP8verMURjhEYkVWJyjA9frV3sEordGtAikDJzM4yWP6/hT45DtzuPlk9M9TWbDcS2/mecpeQ8btuVArQWQyosgfBPBGOVqGrkNFobxjOfmHHtVhIyBtABOPmJ/nVWCTdKpUgdic88VbXG1SxJYnqPas7GMkQA4mKAj35qXJbhuewYHj8qDGCGk4DMcZ9qYDhCCBz3qGAht9zD+76gVAEiDMpHI+76H2q8gLKuV7cVW8kKxfBBByAOacdy4spSRw4BXckx+6M559DUDQ7JcH5GHpwAR/P61oPERI0pX5WOQr8/XNV5kUFmyBs5xyeParNFqZVxErDJbljg4/nWdJleCoOwZVgen19q2oIleRmO87QTnsB2NVZEEv3kGcZBU9PrQWjGucSsBt2dwVHU+9MaAbdjc7Tk46j3q5LCVBXB744qLOGxjjofemDM8+YqsqsSM/ex1FU5oS77tuecela08XluGTDBhkow5qtLH8weM57DPBz/AI0eRDRkzA8ApnHfGM1Wli3IQPuHtWrLCxXIyM9yP0qgwUD7hznkmixhKFtjHmiKkbO1MS6eJwD+dakio3VWK9yD0qhdW4JJQYHamnYz2NKyv2JGTXQWd4Gxu6VwKF4Xxzitqxu2GBmrvcLnaRujc5qRXXJ7ViWd5lc5rRhm3Hmk0UmXDIQeD1oWXmmAZXJpmMHOKhoq6Lqz7cY6Upm9+Kqj7nt60g4/wpAa1neCEtiKOTP98ZxWjFfKw/49rb/vmuaDnirUU56ZxT5iXFPU1pWWWRm2Kmf4VGAKKrSSIiDy5i5wCRtx+VFAkcxMW+YBcKelXLaMjyySpyOwqEGPy8Nnd0pgkkAUDhc4BNLY9C10XpSRKdy7RTDDGzKUwG75pwSYLmT5lNRun7wg5VexpglbYY8kaxvGAC57itLTHWSyKujIwP3s1TtrRCwCnLnmrs0b20Jy4VmPSnYzqSVrIrLaiTexJBB9aetoVO5VDAU223jPQ5HNTiYxqfmx6isb3M2yfYVUDGAOTmnlmCds1D5paMEuvPTJphk45IqrEXJeMHPU+lAlYMpA/XrVUz4cZK8DvUDXCkjBAyccdqdhXNvdtUE8E8kZp24yfdboOnesdrklgfNDAHHvT4rvDZZQTnsaBGoHC7VJy2eTU6SoCFPUnv2rIN2SSQyfLUf21sZD4PJ5qgsaTyHawDAHrgGnG8ZVy25gox83Y1lG6LqFADHjqOcmmzMY0AwUJGWOe9A0XxdFumBu9e1Oe4QBgDtz05rKM24sMjPUZHammfZlgVwOgPp60rDZpCYgOwIkAGAFPQ1As5GWycHuKpCZI0IPBznKnmkZ1YAq+WOeOhFOwbF5bjcRjrn7vY5qdpt28P8AK3pjjpWNBKCxLcOcY+nqasPKOd53jJG5e1FgciZmC5XA55DCpoboq48zkFSBWe8q9CeMDHrUZuQGUbgy5xSsPnNA3TSu0fZOme59KmS8dUC5BYnlfSs6MB2yp/i6+laNpDHwABu7n1pWKU0K6SrMGA+Y9eeaciEuS5d3HOFHSpZlwpjcYYcDHem4ZF2oxDdOtNFKdxnlR5BQFnH8TjOaoaqyvgnh8fMMc59qtt5sfKtwc5qF9kuQ+Q3Qccj6VXMaQdhiSXdrbgmRVWRcc8k+1SWly+5WjfDjpk9fWi4hdlUSlVG3I2n0qhGxdtqqFUfkKbZaSZ1NrMkkiKwEbqBnJ+8T3rWjk4JT5iGwM1yVtLGF2zAbegfPI9609OumLbZGAVPutnG6pMKkGbLA+Yy9wOB6H3pIoQ+7dj0zREcscAbcdT0/CrUQEca4IwecmoaMHoQABcAA+n1FAGEz0OOR61YMRwGJHqOaApKgsBkDHNKwuYpu6hAJEP8As4OMVUuPLEgcqzlThhuxzWjOAhRmI2g4JrKuwzE+XuaJSGYge/SqRpDUY+0SKCuRjJAGCp96qSxlg5iRGjXliB/T1rQVY1dWlO13JBI5Bz3H0pssBZRLEUY5CnYMF+cZxVWNL2ZkOitv8xTj7yOpz+ftUX2dZXYwnZkYwTkNx69vatCaIu8YgP7zaVJHGQD0Iqo6eW4VVKhTt255x/Wi1irmVPbnaDglBjPOSBVKVHjye44Poa3pYwwTGR6Ejn8faqcsSl8Mo3c5I6H6UIaZkGIlcr1PbP8AKqzwq29uQSMYz1Nak9tt3KHVj1HPUeoqg8Ll/kJyOc0+hMkZvllC4657+1VJIWxyvGc5IyK1GOQVcnIHcdaqTIR91mH0qUjBxMq6i8xSUXkdaqI0kBG+tuaMLGSSu70HeqUoWQDI5x6VSujNxaJbS9C45rdtLxeCetccVkQ5Ayoq1a3+OGJyKtak7HeRXCv0PParIZdvbPrXH2uo4ON3FasN8Co5NOwXNpzgkD9KaTjnNUEu1YdfxFPM4J60nEFIs+b8wBIAJ610DxraNczR2y/Jtht1YbhITzu965MSBmABznpW1drBbW0n7y5eWykjVm34Az1Cjt9alaDk72LOphYr1kUBMhWZB0ViORRWVqB+zXpRXZ43CyKzdSGGRn3opNFRWiFa2aQgjAI61JKqvEqNjI9KlRPMcYc5qwigyDaKlnZchSR/KVAvzDvUMvmCFmcZNaEkYIBTG4dqgdpJjsxgd8UFJkNrIscaSKTvHrQpe5mLOTjPemGMK5UKQnersEYOCoyKTZnPe5LFbrjg5qrMi7yuc9jWmBtXgCqsiK25gBmotcyZQwiqFJ47Yp82zyV2S4J5wetQXwBjODg+1ZT3DeVgA5B61SJZJdTFfNLq2exz0qmszLGuQQM53eppsLxzzHz5GCu3OPTFOMabdpLkA8n0HarsTew8Sktg456nPAqzHOV+6ME4AOaY9uzHCp05bp096Y0QyQXX5B2BG6i1gUiz9p8skYyV6gjgmo/PTAyDuPT61VwwyCMqR9ePWkYrtHJJBxg+lCQXL8d0olBVyFXlsiiS7G5mJ3AHdlhjINZsg8g/e+bdzxk9KY0qOygk+Wox9RVJaWFzamlDcADJUElsHaccU6S4DBUVyAOGz0HoKx5JCDhSRkYY46HtUDX0wBCgYGM5OMn1qrC5jaW5Mgbcyt8u0evFNadOdrs3IPzd/wAaxHvGZeSGOOoHv2qKS7AOMkAHAOcYwKdricjba5Bx5m5Qc4br+dN/tALwWAB5BHQ1zE2o7clXzgc5NZtzqq4O2UKT/CTxRykcyO3N8pHzfdxu+lRw3iyZyDj1rg7fXI2kbzXHoqA1safqKspJzlvSpaLjI9DspNuwjGCBn1NaUbZA7e4rjbC+bGzacgA59q2oLo4XJBHYA8U7XHc3ZJdznI3DsDSg5weADjpWbHdq5XDc8cY6VZiuMlSMluOvak4lqRbt0ZgQcY28fnUc1sNxYDDZ/GpI7gEHIK8dfxp0jbjkscZ4qGi1NmfKzZCS/Op9T2qJQVQlEAycn2FXXjDKQTtU87tucVVUvCvy4OSAT70jZSKk0m37pO7dz6Vo6c4JzclQ5HyZ7U2FY72QBI1WfoAq5z71TvPlkIwqy56dAPpTNLqWh0EV2wl2s+Qh+YDpittWZiAenXjtXF2V5C1vIty6iQEBcjAI9a3bK+QIFTDKThWHOKT1MKkLM6GP73zDJ7D0qxIF6kce9Z1rMu/Oc7fyBqz5gZicknHbmk9DmktSC4h81wwOFxllBqmxaFnTnpkqe4rSlkXBOOnpVd1jmwSuXHG4elLYtSsZcriSbaPl2nO7qKdLKAp2L+9BzvIxVx1j84AxqGXjb0zUxtf36E5CgYw3OPxpqRfOupi3yyysCgCoOfl4+bvR5Xkspf7vRyRwff61tTJGxO8gcYIA6GqF9hYjETt4BMbdz6g07jjO+hQlh82IMzfvgRt2/wAWOxqj5W4yOHbHIXA6e4rRjQPGWkBPBx9fb3rOuIpNzRROofrkk8+gqi0Z9whKAtxIP7vcVRYLxgfOP4gec1pM8jZkaNS2dm0d/WqM6gOQhzzkL3pFIyJUJfdn5SSMk4596rqhL4fHPOa0J/mViAARgnIxmq4jxIDtDA84poGitIjbQcDI4qu8YchX4zWi0RycdelUpkBOOn9DTbI5LlL7K7SEI4I9ziqN5Zuo3MhU5xnHBrSfPmYfClQefWp7ecTQyQTkbe2T900WRjKFtTkHvWtJMOcCr1vrS/3xip9Q0tJJmTG8FefrXnfiS1v9En5VjAfutg8VcW9mc9T3deh6bDrC44YYq2urJjG7g14eNduFPWn/APCR3WPvY/Gr1MvbxPcBq8YwqsBngAV2tvJqMsJW70i3meUKS5uAvmY+6SM8/hXyzH4juVlV2JcAg7c9favUP7f03WtROoweJLG1t5NrG3uWZJbfAA2hQOcHpilyi9rGR6HrKaisrXV9FtLttJUgqvovHTiisgeJ9NvLfVJ4LvzBc+XDFERhnKYzKR2zRS5TohPTU63epUCPqO9W18wKhI+ToGqC1ZZGwV2dsVahYqxXG5R2rE7riMoJBD7jT2HGRkN7UxJUSU71Oz0AqYXaL8pGRngUBqVpgwXBBz64qe1BUc5zilmmjuplZRtx29alVcAAVEhMXaxOTn2AqPYSp8wEMe1Wl52g4wKedgHJyB2oRkzFu41+YbePWuZv5xDvHP8As+xrr7nDdBg1x+vAs7YxgdTVCI7YM8QdypRn3MQOQfStaGAxMBJCF8wfNu6+oxmsnR5I/KKsfoPQ+9bTEYjV3JD4YdyPatImMmIytE0peEKowMg8gVDJEFtl25z97B9PerEjsnnxqy56gtn5h2qtM7NHGWUjK8HGM02JFYRlWIVhyM4jPUelKC+Wz5ZO3blhnFKMJ/q3OAccjkg1GLj5sv27HnmkkNsrTojPycqeDjioWhXA+bCgHrx9KtXDs65cqBjgY5xVOZlPXp1q0iXIryb2cFMHJB+9VR2ljClvYjNSz3cMQIwgPriuV17xLbWakGT5ugVe9Nq5LnY073UEjU7zz37Vy2qeL7eBiI2Mj+i1x+r+ILrUHZS5SLPC1jdjVRgcs6/RG/feKbyckRYiH61jTXtxMxMk7tnrk1X/AJ0mPaq5TFzb3LlpqE0EqsHYhexNd14d1wT4UzEc8gmvOqkikeJg0bEMKThcuFVxZ9AWV55iZByfatW3usYIJB9DXkHhnxWYmWG7bbzgHsa9CtNSSZFZSG9OahxsdkKqZ1lvc4bBbBGO/vWjBciTCe3J9Oa5OK7Q46A1pWt4OOcY6e5qbGvMdP5gxgnOenParcUgCnBJA/CueivMgfN+XWraSgsemDmk4lKZtCXPyD8vWq7FXIIGFBxg1UE/HA59akSRduC2Mc5z0qGjRSGklGEkLFXQcYPvS3s63UOHYRyoMJhc7vUU1iOGbggjt1FVpkJO9DgnJBHalaxrGXUqPGsYbzRknpnI4rR028kWMIGBGc4Hao2nWSExT5Zh0YjpVdwbUI+D8wyD7UtjdT51ZnYabdMZEBKtzn/9dbUbooIOcHjg85rjLK7ikBZC4Y8MAeRW5Z3BDDdyMZJ9BRuc84m7hgeVGMdPWoD8sShOe/Hp3qNbkOo/vDofSjccEkYzz15FSzFLuJIElkDE/KB1JyQanErBQu7O7jDYz+dV1UK3B29x71E3QbweOeD/AEoRRLvDStLEfukAg+nr9abf/PIsrHleFBOc/WmRNyViYDI49sVXuGDlVVT8pzjPAoAdMY1hG2HeM8Dp+HsKoTQq1tG6ggg4k960Jl/d4ZmUjAGPWqioXcgscL2PQ1XMWmZtwkfnz+SCsbNlVJyRVC9URzOXVd2AMdCD7VpXCbS0g4fI2Y9qzrs75HUkM7Kct3Jp3uaJmRtYMwxjqcHnIpLdQAZCcFW6DuMVcWJ5If3anKck9ceopskJwpUZj6jPHNBZUYZYnPDDPFU74jysnqO/tWmVWOP5hnJPzVj6lKqI+OmMfWmFuxnbGdyq/h3zUFzuhbgHrjHpVmIuXjIBDHnC/wB2p2iia8jZfmfduy/b2NPoQ1qattKqWUQhs1xj77ckmstYLfVpJrK/jV4pgRg9j7VpX12JypjRIsLghe9YkxAfcGKMuASOtaOVnp0Od0rrVHinibRJdI1CeHaWgRyEfsRWJzX0VcaZo1/bGK8ZvnH3sd68i8aeE5NElMts/n2jHgqPu/WtIt9Tza1Dl1RyS7TIoc4QsAx9Bnn9K9ev9SuNOfxFaadoungaUlvPZRm0Dma3JAZs9WznO4dK8hC73C8fMwXLdOfWu9vZtE8M62LaXVfEr6pp6CD7RA6IFBGSqBudvP0qrHMQeNtTurLxbIz4jEsEEywhQvkhowfLIHdeme9Fcrr11bXurT3NnNeTwy4YyXrBpWbHzFiOOvSijlKU5LqfXccfmZcyYK1NG0iHJb8aiKlI8sMccYqaGUiHbwwPWuQ+h6FvBEIbCkE1BMAAMAZ74pRnb8vPtSOrBhuXBNJheyJrRPYD0xV8bQCD+dVrcfu+vPtVhAAAG5rNGctWSCHkE9MdqV4USMlODQmcHn8zTGBYEZ6VS1IM65Pr+Nc1q6YJJX92Rwa6O4hd3cIxYL3rMkVLlHiOCu0gt6EU0h2OSsHEcskeAw6getbXnnyEZlHzEbWPbFc/LEYLoOGwASMVcNwI7cru9MgVotjCa1LlxPiWQS8OoxjNS/a8nIbgjAX2rmpNRDzx8kn+L3q+lwSMjGPSmtSL2LMsoYcLjjscU3djuoHaqLzBmAHepJZ0SM7iCAKqKvqDdhLiYK33sf1rJ1DUhEjYPTvVDVtZht0JeTao5ya858ReJpb0mG3JSLue5q0rmM6iRqeJPFeGMNodznq3pXEXMzzSFpWJc9SaYDls9TTkG4bm6VajY5JTchoG7ilKYfBNO4xkd6UgIh5yxqiBqRF2JXtSbGLH5enWpQGii3L1NIWYYHc0wIWFIB71K6jcFHXvTWUZwOtIBnOa19K1260/AVi0X90npWUy4IBPFJjnnpSauVFtbHpeleKbe5UKzlJPRjXRWuqqerBlPQ14kCeo/OrdtqF1b8xzMB6E1Lh2N413sz3y01EFQQ9acN9xy/bivCbHxXdQcSDePUV02m+MoHVVkfa3fdUNNGqqpnrK3i49TVuCUnDE/JnI/wDr157b69DKwKyA5HBBrbttXViAGAHbmpsjVTOxMpjRXQ7gvc9uahe5HLDgEHtwKwxqe7+Lr+RonuBtJUk5Bz7fSplE1jM2p5Q4ZgcHgdetRxD7TE4bhgccHt9KyLa+BUKT0wc1bgmDnKg5OelZNHRGdi9BeG2jVI1wAT1GM89607C/cKAzkk9qyARIvzjacY3dafDbuSZAQUHYGjU1Uk9zsLW6Lk7RwRz3FXhMCRyNvrXK2kshICjoO3AxWrv+dQkw6ZJPb2p2M3G5sLMGPr6HrTZHz1OScdaxWumGDtYEHqOv1ojv9xJbPzc/hSsLkNyPaFLq4LA4AHGKSNzuJxjOSCeeazobjzNy7jtznPpVpG6hie3NKxLVhzO0jhSpB53cdfcU1VRVZUPzdSOpqQOSmD0I4I6rVcqpff0we1AioFPnMdoKp2HqazJoQZXZV5bvjpituMhpcEY3dDUc9riJn44J/D/GgpOxkrGq7UG5GZcOenHvUQYrcZVePunHTOK0vJJYPnO7IBxUPlx4BxhmOfbj+tO5SkZlxFn+ABe3Nc5rNudrmI7gv3h6V1V2VjEhwS3HI4wK5rUZXiYHBYs23Hr7U21YuL1KGkWhlEk2ZcJwxVcgfWp/9ROxPJ5wcc1q6bEYUUiV4xkFoyOCev41HrKo3nXEaYw+HwMKc+lUloNy96xjzzFiBn5/cVEo+0P8wxjkmklZZEXYMsDj3qe0O0sAAR05qeo2tAkt8AheRntVG6hSWN45UDq3BUjORWyf4s5FVpoCMYOau9jKUU0eK+M9Fj03UA0Kn7LKR8q9R6gV1/iV9et9SEGneEbS602ONFtZptPaZ3j2jG5ic568HpXUSaJpmqSSx6rdfZkAG0iMuSfw6VyfiHR7HS7oh/HmpxxNyuYpT/Jq2hK+55GIpcsro8/8RvdvrErahp8enXO1d1tHB5KqMcHZ2yOfeimeIPJ/taX7NqcuqRbVxdyqys/HTDZPHSitLnMfWccv71UersjqXRBwMckVn+TJKuSCAO9SeS5XnntmuO59G0i/lFbhvenO3nOoXAx3qCxgViNxOa1FhSPkfeFQ3czeg63Q4AI6d6tCPdwRUcRLN26VYUY6nn2pJEtjTGBg8fSifAQ4HPU1OvI6c1BcPtU7uapAtTOU+e7xqdmeSelc0jmx1Fi2DEG5HtXRq8Xmv5g5PpWNeWqR3RTBbefu46Cq3NY21TMbxHZxGI3drnyXPI/u1yt3dSRoDgYC4KjvXo9pZR3lreaf5gicHcm/pXmnii3lsHkD8FTg4qrHNUVjKtrks5LADPOPQVqLfhYxggGuTkvUiHDYxWZe+Io4FyDluwFXFHK5o7v+0UiQs7ADvmuT8Q+MEjBjtzuauL1PW7u8cqzFU9BWXklueTWiiznlV7F2/wBSnvmLTueeg9Ko8beuTS8M+McCnKgaTAyBWiVjBtvcURkbQCOadJGVAAOabGcOSx+UVInLMy5IFAiLcSfLA6daewDSBemOtOBwu9gAelNJXBLn5m6U7AIATLjdle1OjBLs3XFNZAkWDndUmxo4QVIyaYDN7Z8zbQoVxuPB6Ukm5cLnIPWnMysoRQcikvMCFkKjB61Ky+XED1zTBiSUBuAKH/1hG4bRRYBhO3j1pM4OKVPvlscDpQ2NhYj5jQAKPMcKKVgVbaT0o27IwTwx6UjBfU7jQBNBczRPmORhjtmtmz8T3UBBI3Ae9YJGwDBHPWk+YtjGalxTKU5LZnodj4zhZV80lH7g9K0/+EstP4J1yPU+9eUHk8A0gOTUuBqq8j1uy8QW810CZUABIwDXaWF8kqghxgjPBr5z8xgeDj6V3Hg/xMsZW3vDtcfcbsfrWcoWOiliLuzPbbaZGYeg5qyCMZUkdSa5Ox1IPtKuOlbdtOJCOe4rNpHZGRqxPJHKg3bTgnI6cjpSyTuGyuQQMZJzmo4nEi4UcHkjH609vkXcDlD2JziosaxmhG1OU7VJ+UdOKsJd7hv4xkKOOc/Ss148/OBuz26YqDznikDRkxsOmOoqdUdMUpbHT2sjqVfaRkbhnkH3q/Hd7kzgknkkGuOh1N435DMuOAW6VoW2rQgnzU2fj96qumRKmzo1uSzkKxGO/rT0YOcE5XvXN/aEaRSkoUbgCD1q7JcxrGo3AuTjk4DDvRZESpmpE22Uhm4A+XnpViQIyfdOW4GeMVgRtJI7Nuwi85z1NaiTgRRu3SQZ69KErkOJLMjhDtbnJ6dqSSLDIuOU6ZHWq0l4sW3nPJ6nkn0qws4leNWyp259zSSZPLoZmpJ+7KhQWbAHtWKbFZLxjy4UDr1BreuOZMr83PCnrUMGxLpVVTtkHzYHeotqNOwJCih9o3BAOc4qpqtuZrB4QAy/fXjnj3rQc4QhRxzj1qhcvIIBkjcp6Z7HtXQnoCZw6AxqV65PpzWrbW21BkgsRn6UXcC+cskSHbu+Yeh9qdGJM5HT19ahKx0XTRLJGfKGKRrYSBjGx4XODVmDncjgU6JTE78ZB4/CncykzIs9MuNQeQWke8oMt8wGM/Ws7W/A+o6lGYpbVenDeanH61oTQkzFASBnAPvmtq503Q4BfCW1u5msSiyv52C27gsB2we1OJhVV9D5u8W+HLzw3qslnex7WADDBBGCMjkUV69450G0nvJreOAJAUV4TuLEqVBDEn19KK2U11PPlh3fQ9QG/wApsEbakjDKgO3FRq7hVUrk98VKJJAckcGuc9hjwSrqexq/G24dfzrKeRiQGGMVoWsoCgEZz6VBDNS3jUqCRUrjDcdhVaGVlYAHg1NMXLJhuPUHp70GXUnzx0xxiq11tEfTOBUgBdM7j/jVe5b5RzSuVEy5Y975HBBzUkU8D2s5nJSSMHZjqaWBt0wHY8c1S1G3dWlYgY6BRWkdDZpN6nPyySGRtm7cDncKg8bWf27Sknba4kXy96jvWmZFhGAnzEfMWqpBNskWCVd8Dtyvp7imnYVWHNsfMusNd219NbTMwMbEAEdqzQGZjk5r2T4v+FbU+fqFhIwnh+9EV5ZPXPtXjhO1eBya6INM8OtBxlqMySTmnRts+bGe2aYwwvXrQGIAUDNaGRKjEknA5pQnGN2GJpqly2w8YpXdWcEDhaBCuFEe1Rlu9K25EVVxnvTrdVeUsflX1NCriV2ZsqOlNIBhRmYBjn6U4gNJ0Py0sLMqtIFJA6UGRgpdlxmqAZkSSjd8oHWpHVC/D/L2pEVDE284YnimOihNoGXoAVIzhn5OKYCyKZMfepz71CovTHNIc7lVzkelICN1CxA/xNTiFEeDnd60+Qhn4XIWmxnzZMkYHpQIayMqBQRzRGhkkVcjFI21XYlvpQvyRFv4m4FAyUnfLjHCVCzF3JbgCjcQoCn5jSkMAI9vPU0WATOMsfwqaIlYy/HNRH5yE24NI2A+0E7RSYD2YxqeB81NK4UHJ3mmxYaTLHKipC53mQYwOAKAI2AA4OSetKCVx2PXNSxKrEyyHC1GRuJbdx2oauO51/hvxM0ZS2vG9g5r0rSdSRgmJMjGRXgoI+82QO1b2h+IZrBwjkvDn8RWModjqpV7aSPoO0vEbBVtpAx9far63GRldvQ8EfpXnGh69HdRq0Tgg459K6u0vldMAjGORWTR2Rka0jbAOM7eox29ainhadBIgDDOODg04SJL0JPTaD29jTfKAYFTjrkelRY3jUsM+yfKP38YLL+XtUckLxJ86/Q54q2sZGMHjocikIUYUg7ByR60NG8a3cpqQsW/+NuBk9KVGLOuGJA5FW7uxZmLpERGRuVVySB6moI7fD/LwQM9eKk2U01oaum3Js5kmjB3A/NnkH8KsT6xFcTMVXyMHcvcZ+lZO5lTPJx+tVW3Ek45p3sTyxkzWF0JblCWD4AycVpyXfk7tjMYiMlR2P1rBsmIdZQm7DDhhkcdqttcGRnYYROgGe30prQTgWLVfMLqu9pAN64H86fG4kReoY/xZ5BqC0njSQlWKswAznFRiYJMeRjP5mlJXM5R1NYpvUlsAlcgjuKozQlmyBlQe45PpVtJtxUY2tjB46D0p7Ou0LjgdKF5maVjLRBE77fmJ7svf1pJW+UARR5DZ4q7JHvGANtNSADqAWzRcTZnSBlBKj5sjnFTGHy4+uTjBq8lttYE8kDjjpRcKfLwfXoKCOa5zV4gGCRwePrWjPJdwalEt+9mXnhWK4DjK7eo8zH8XTkVFdwvOpeNTtiOSQMgema0Lu2tr6Q3FzbanFNJzIkUW5WPcg9s1USpWtqct4jW6/tSb7csaygAAR/c24+Xb7YxRV3X2e4vXeSJrcBVRImHKqBgZ/Cii4lZJHV27OmCV4z3q1IQyliMHsBVCGfcEViav7j5akHIxQabFWRy4O5cEd6t2pLDA4AqBfvfN9009HwcDgjrzUSQnqakILEbmx71bUDIwR6cfzrOtw7jAbg+lWXQptz068GlYktgjkDNVnUN978KspgbSe9OMaE9ce9ISdjImgZOQMZ5pyzqwYTIGyMA+lankgjkbh71DLaDBKLn+VWnYu6a1Mi7tojbN5cJkkxgn0rGutMuEZX8skLjkGulNs8YY7iAewrOuEdDksfvfjmnuUm0cv4ls4Z7shMlTGAwPPNeB+O/DraRqReFT9klJZTjhD6V9J6nbLPJlIysoGcnoa4zxHpMOo2UkM6BkkHzCqhOzOWvSVSNup86YOSOuKauQSw6itXXdLm0i/ltpQeDlHxwy+tZTAgYzXUmeS007MejruLvznrT12KC23O6oRgDbjrTwSzKmAAOaoklMYFufnwSaJABAoHJoKq8gO75QOakjVRJjnGMincAYsqqg4B61GSXfy2Pyj070473Dnpjpmmxp5SeYQW9aYCFkLjaTlaInDyliBgCnBgilwmQeKZsAjIzhm5FACK+ZGy3HaiMMqM55OOMimyRqqgBst3FPmDrtQd6SQEbmRUzjANSROiwYPLNQyysRGSDxULHaW44WgAYCSUIn4mpZUTeMn5VGKjhYRoZCvzN0ppcqhBXlqYBEm+QsCQB3p24qGfdlqVSBGI88k5NMdVaRUUnHegB8BYRNJjkng1E+4NsPBNPDHDDd+7WnRDcWlbkrzigAcJHGEBzIetNCbiBGck9qVnbcZyoG7oKLaQJucnBI44pAOxIw+zgDjmmMSXEZGCKVJAiFww39zSsmIhJIrbmPBoAYxJOwcgelK4OANuG9KkhVApJY7hzxSFhnzHz83SkkBNYX89jMrW7kH+72rvfDvi1JJEincRSHu3SvO4iMl26Uwkghx2PBFRKFzSFWUNj6F07VUkUEOOe+eorXiud3I6dya+e9I8QXdgQN5eP0Y132h+MLe4UK77X9GPNZuJ2wrKR6gku4kADr09TU7hWQkEYB6elctZatHIoww9jWrFfB8ZYDnrUcpqpGul9dFdpfcqKUXI6D0pYpYCDvhyT0wcEVnC7ByWyGxnI7ketTLcKQNxALAcj0qXE1UrbF2JomLBgQnTYOp/GpJo7SXlT5TdMY4+tUBKB8vpS7gwLZBI/WlY0U33JWby7dUGR/Fjsapu8jAnI/LkVaVsRMsgJQEEYPT1/CiJVljDoGKAhSc1JvGqiqjALkg7U5Ga1LG0aSOKebCAH92gHUepqG2t1mcFwRDGcsMcM1WJrhi4CMV28DatUlfccpX0JbrMUbfvgfVTxTIHZZdh6t0JPFUXJuZlR/lydu7HeteMRWsQiUZdQCT15pbkNWHLI2cEDIqxHH0bIGOKqPG025lOD1+uas2BLImcnH6UrGUloWRExDcdvWq5jJ3Db9TWqsW5B055AqERF5CgUZPJNNGN7GI0LxxSJGzKsn3lH8VaM6Jbz+VLrd8rgDd8pIX680+SEsGJOAvfvVqS1F5/pFxp7mRwDhZggl98Hn8qZMpf1oc1r+lcXE63j3MsIXzfMXDbT0YHPIoq7qE7vBeRyQeXczbUbJ+4i9EA/rRSavsaQbS1My0lKur8HmtQSsBkEYPasW1KEhX4Hc1q2rqFKnBU9Ko3Zac748nr2qG3LKwD9qBKUhcMpZh0I7022BM65GM9faokJG5CwUL82FPTjpU33pArZI9argqEVM/Nj8quRqRtxye9DJehZiXseQKkPHPH402F1C4GRmrLR/LwOagggDMX/ANn2qXgLjJxTljCqMg4qORCTjr9KYLUhkU7TxnvWbcAMU3jHrxWh5brkFgPSqV1k8EHA61SNEUr1Y/M2j/Vnk44OPauZ1mzihYtbNvtm4BPUGt3V8L5WCcEVm2kYUyCRcwMD74NPfQrksrnmPjXw9HqlmQoVZl+aN8ng+n0rxqWJoZnhuFIdDgjHSvpXUbQxl0wWQdD7V5t438OGcfa7VN10g6AffH+NaU5WdmefiaHN70Ty0uN+VUcUqEDczd6JVIPIwehHpRlDHtPUV0nnWHoipHnPWnxbjAWHXtULMHUKAc9KlIYFQp4xzTQhsiyLGG3deCKcszpiLbwfanRZ3sD82OcVKsvnBpNmNvSqArPIxPl7eM0hIMpbBwgxUyoGbzJOKafLUsBk55pAMEe6QOjcUYb5mduTxTSMQkg4JPApJFO1FJO6mAQmRUdzkkcCmSBmVR/e70+TfG4VT8uOlMiLFncHhRQIM7SqHBC80ITNKWbAVecU0k+WXOMk0+3dUUhlJLcZoGDnf84FRqdsZJHzN0qU5aQRn7i9cU1GRZASuQuaBDGThY05LdaeC4bykIwepohk2lpTx2A96Yuzy2L53tzQMJEZpQg5Ht2pWkB2oy/Kp7VOltIlgbgMOT0zzVYhoxz1PNAErRiWUCHgdTSmWSUFcgrGOKECxQ/MW856YXESbQDvPWkIRN08m3OM1IwZpvJyCq0IUjhZZFIcjg+9CReVD5u876BjZsZEcWfekJ3MoxgDg03cRlieTS5Kr83fmkA6TafudqYGYEEZHuKFLKOf4ulSsuyIA9W6UrAaOma/eWJG196Ds1dbpnjiNlC3Ksh7+hrzyRSmA2M0hweKTiaxquJ7jZeIradMpMrdeM1qw6pGy43AAgDrXz5HK8bZRmU+oNXrfWL+D7k7ke5qHE1WI7nvsd4oIKueSeM1LFfhWGDkY6V4rZeLLpSFmJIJ5bNd1omppOqsDuP1rJxsdNOspbHoVq7TLzwTV60ne0bmNGQn5gRWBZXJZQR0P6VtwSBgDwSfXvUuJvzXLYnjZD5TFZGfd5TdB9DVUuPPCOMFRnAOM1KqxO2Mc9SaWe3CZYHIPoeamxpGVhChjUBHBLHdgdvxqRWx8pYe4rOcGNw2457fSpVbeCFJL9fwoubKSNQzZTspUcE1b01toJIxhsfSufhmWM5kDE+lXPtamFRCzbwQSCOtO4ppvY6mKYMuQRlh09KnBQRccyHj/wCvXO2U5DqSQMdRnOK3I5MOMcjP44oOaSsLcoUiwVzjGcenfNF/ZLfzNcRXEQRsEB3wU46Y9qkuYnaA+UrOScvtycegqGWCT7M7Lby5ACrlDknvQR8zO1hkub5jEd6KqqZOm4gYzRVjWIttwSqhT5SADpztGaKBx2RxUUzNHnaCB3q/BOWChvTqKx7WUBQGOF71bjyHHzHHbFUdEXc10uQYhtBUirVs6uMkEtWYHCgbjlSa1oFRAoQ8EZrNob0Ro20YyNx5961rcbQD61lW5XOQenWtBJTtXBzUmbuXCwVwcVOj8glvwqrESysB+JqZcEDk0hFzcGXGKYo5IGADSJwDk59KPm3E9qBDLiJlxuIOKy74qoJLd61JGYgKcfWqctsjElqtGkXqc/eNHcRbjwsZ5xVCW4jjR1hRmQ84JropEjBZY4l2t8prCv7P7OTkH2BoVzZNPRlTf9rtWheFQ3Zvaua1Oxw0sLYZlPGOa62O2RojICEx1X1rLnsklYsWKkjrjvRcynFXPFPG3hlmka8tE+ccyRgYBAHJHvXAP5eQQtfRGp2YO4EfXivLPGvhz7M8l9aR4XrIg6D3Fb059GeZXoW96JxMO3zuuBSquC538ZpPLLLkHn0oYYVQevetzjFEnlpuHLmrGXWNc8BqjUAyKu3oM0m+RpNr/dHNUhDpCiqE5JPWoQC0m1OMdand4nw4UDaPzplsQzszYCnoKLANKqWGCNq9c0iY82R/amyKIw4Y5z0pW3CNE2jLck0XAAGWF3Y8npSgkRIijlutI6hpEQMSB1FL837x14A4FMCEqzT7O3pUytkn5eI+BxSx5jt2kxlycCoZVdY15w7claAFTdHGZCMhjik3KsO0L8x71IcqY425UfMfrUIO5nkA6HigQpVdwTBKrySKcf38gHCxr3pCxQbh1fr7Ck+7CTwGc4+lAEoT966GT90MZB70kCl52YIZFQdKHaIwCJQTJ7jnNPBubPEaFf3nBFADHuDK5lZMKvAUU62gF1M5BCgDPPc0S7ov3GB6D3NRyAoqxq/zZ5waQCM0shLFQVjODT5GMsixp07nNNc+SpRG3ZHP1pqKBEWVv3npTGOUeY5DD5U6mgsruF2kIvBNAVo42LZG8cc0EeVFtGDvGSaAEjG+XJPyL0odi5L4yO1ISI4MEfMaTcPKVFPJPJoAQZYb26UKOCT36U5zjCrkr3FBcZwOgpWAbggYPenHHQUFs8mm9Oe9IAJwea0NJ1OewnDxOdvcVnYJP1pfu0mhptO6PZPDHiKK8iGH+bup612dtd71+Xr2NfOVjeTWk6yQOVI5wD1r0fwz4rjuFWOZgkg7GspROylVvuerwXOeD1q4r/N8vUk9a5az1BJAOQRj161rxXCkhkboaysdKkX2xKACe3eoXicIMHoeOetEc4bGfQjFTxLvGYgeRgc9Klq5qpFMF3DDBZuoOP51LFbzN8sSFvU56VOttuw2SAT196uR2cxQhXcKe2cbqmxr7S2g3y1hkClsy4AIA6VuW05FuM4LsQowO1Z9vZLGA7Lk981YRSowvfqfSmjNu5aF1KoIjkkTJ5CnFJc6hdFkRbmVQB/ep1lbpczmPzvLJHy5XOT6U1rezDkPfYPQ5hOfp1p2ZHu3tYrzuZo/nlJdjhnY54oqG9lTzn8txLEoAUhcZ9eKKVxo4RZFI4JwavxchdvYdqx423qCMgjtVuGYrjbknoRVjpyNMPuKqRle1bFrKdigtWAkm4hGBxnNaUMoQZUHp+RqGb7o34JBvAPAxzWjC4xWFYysVJb5vX2rUilAYYOcjpUMlqxr2jZP1q4rgAcVlW5J5Jx6VbVztxnNBFi4hwD3xzUhkxz271Xt1Zhk5xUqoW4/nSYDwpPLEc9qbtDbsEcdqk27DgZOfWlUK2cj8qYrmZcRLGA5yTmkmt47qLc8iYx909RV+ZUHJAOOlZ88bMCAoJAz0pqVi73Me9gRG2qQ2B2qk2Y4+I97Z4B71qvbOuSQM4qpJHv2lmwAaLjtc53U7dJ0aaJgj/xR+lctqFixBEke0N2bo1egTSJGrh4kjjYHcw5J/Csq5hjvgEj3rEPmIHLfUD0qkZyTPnrxd4ebT7g3Fqp+zOfmH9w/4Vy6gb2z26V79r+mIUlgkXfGwPb7wrxjxHpT6VfPGigRnlOc8V0U530PMr0uX3lsZStIwbHaljc/6xunSmkOi5HelLYCxjoepNbHOPLKFwF4NPjjjC4J+f0qENyFGMCrEnlhgyNxjmmIgaLzJVC8knkU+SMpO7MVKgYHNLbnajuOM9M1E4Cx/OTuPIoAjjBjV5OD2FNKuAiHOT2qYxsUjQYweWpqkeY7ZJC9D6UwJB/r1CL+7Qc1GAWkaY5OOabnbA24nLGniKRUijXILckUAMl81U3OMb6kXHlxRKhUt95m701Vaa6AL7tvr0FDM21vM+90U5pACoZ7oISDjsO9IWXDNsGVOAD61PH59taieJSGZsFjz9AKilLoAygEHjJHJJpiFhZWuQ8uFjWlhjQyMZJAikfKTzikkEJVYY1dpWIye/vTJmEmxUBH8OCOQPegBgB8wvHueNTjcaF2Fmd1YK3T2qZhIZFt4TlMfTPqTTGLGQwoNuWwM9qAEt0y28IWRfXvSqFnn3qCijGfrTnP2f5YHLeYNp702RjHCYwu3vj1PrSGRud0pDElVp8SlyWUDaOgNMyUQoVyXwcnqKlz5CKUwWPBB7UwGN8zF/4R/OkhAbc7cYpGIKqsZ5PUUSFgojwA3ekIQMcE96QfKpJHWlUB5VX7uOtOuDucgDgUMBinpStgvg9qahwpPFLjJHvSGSKcnPpTTyc0r/LhR+NKEJfA5FMQ3BHJFKsjRuGUkMOhp8hJ4UYAqMDc1JoZ12g+KpICkd0xwOjV6LpGtJcRqUkBUivDTkHFXtP1O5sXDQyHA7E1m4nRCs1oz6GtbkPwODWrbzJuBQ+Wcdu9eOaD4zViFuCVfpzXdWGsxSgbHDDHY1m0dUZp7HoNjKpXJUYK8kc8elakYjKgxEAjqB1rhrHUtpxvrbTU1k25OPXbSLN8leDyADz7mqkkxEjBOmelUP7QLk4b5fX0pBclgeRjvUstGlbrNMx8iN2ZecoMkU2ezv3csbW4ZyclihzUGn3UkFxG8WSx42/3x6GrjR3gZ28u6SPOVBLHA9M0rAm0yn5UsUoR42STqQw5/GirMTliXcsXPG49aKOUu7PK7aclRjle9XYpcSDsB+lcvpl4GUENnPBrdgcOuOQfWqepzwlY1xK2/nnnNalpMpVlPXOVzXPxTMTgnkdKvQTHepxUs7YSujpUlCuB0z1xWjDHgB0OQfSsCGTON3GBWxp8gEfUsP5VBTWhs27DywW6+mav2m5pVPG0etY0Fz16+xrSikONvepM32NlHycZ+tTqFDY3Vkx3GcZUkVahxuzu+maCGi5LgkeophLAtjHNKzqseQcvnvTEJYEHjPNIFsNXDbgQMmopCQv0qYhVG31/OoZT8gBIx9KBooXAUrjnNZ065yMcDsK0ZBt38VVID46g+gqkaIwNWVEKnBbcMfSsgu6OCjlWHCsK6TU4TJHhE+52xzXPSKVJ3LkDqDS6mkbNFHWI5vs0ccqHIJbcO5rz7xlpAvdPlIUGaMF1x2x1r1e2hlunEWAwxxu7Cuc1XTWjyVXMTE9OefSrTs7nLUgmnFnzp85OCc96ZvJbJHSu18XaAbeaW/sl3KTukjAxs+grjXY9RjLV1xkpI8mcHB2YKynLkcdMDuacgRV2tksaiPAC56nJxT/My44yFq0yCSQ/ugnGRTU+eU7hnApAfmeRug6CmKSInY8FjwKLiHZOJJM/KeBim+UTCEBGWOaTBV4o8c9TTzjzJJAfkHApoBAoe4GOQv6VJOX8yaUsNp4VgetQpHiGRslQ3Y96AjSMkSnO3nimAxUkEQCA5kPHqRUir5s6xkDCDnJp5yXM+7Cx/KPr6AVEWYglB88xxtx2oETsHLS5ICIOBngGooA77nJzsBIz0omUoixsTuB+b608rJLKqxLhFUE5PA9c0ICKOWRR5wGWb+LpgCpoPLBE10QBLkYHYVEC00xV2ADcnHTHpSyyLOyRlBGI85IHJoAa8aqjF5BuP3V64HvSxMEPnSxMQ2VHHWk2m5wIkPGNx9PrUt0Z3l+zybf3fB29PrQBHbKgG7cUbBOD6e1PgCyP58x/drnAHb0pkkjsI4vLG/G3p2om3Rq0AUHoc0AJbZMhZvmA6Z+tOxvMsvVRnB9abMQscarkEjBHrTDhlVI2I45zSAWEBUMxJDA/L6U0sGEjtnf2qecoypChGQeeOKiCGWcRjAA4oAeiiO3Yvw/b3qD5sHPU1LckmbYcYTjIpqkM5yOnSmAyTGQB6Ui54bsKMEk+p4qU4Cqp6jrSsA0EFSTyamhbyV56kVGMM/yjgU7cepwQKYCuRj5ep600sVGB1pYwDlycCm5DHJoAcQQBmkZNuPelX1bpUqDcpY846UrAQjjHY1estUurNh5UjYHbNUuSeaULgbjScUxptbHaab41ePC3Kn6iuu0nxjbSkBpgvsa8f2AjPSmZK9Mj6VDpm8cRJbn0Paa1DN9yUYPvWjFqCM/yncfevnbTNTntZlPmsUHUZr1Dw1q0dzGrBsn61i4tHXSqqSPYPD1zv+0qkqR3boBE7HHfkA9jitSOHV0ZTvdD/fMwx/OuS0B7dre6ubxWlhgRf3aHG4k4GT2FbBSC6s3utODqYRmS3ZtxUf3l9RSSLvqaWoSq9/I0boQAoZh0LY5I/Gis/VXjtr3y41whjRuueSoopm0bWR85aHqQKKc5B/Su0065VkBPpXj2n3ZtZQcnyyea73Rb/cqjdweetVJWPPpzud1bOSNwwTVyKQlj/KsXT7gYByOa1VwxBVuvpWbR2U52NiMyGFWrTsrkR8MD83U+lYFpI/IJPBxir1tPhwfvKDUHWndHTJMqsoXnIzWnDNjBJFY8VxDLt2HBxVyMrxk5H8qkhm9E42g8dOalDEHPAHbmsmGUgDB4qx5mF5PFJk2NVZMpk4z/ADpWdeq9azVlJwKcZdp6n1pMLF4S7sU2XOeDn8aqm5VQDx16Zpj3oXd92kUkSy7s4UYPcmomQoyt2zkn1qBtQ3dVwMVAZ5pF2gE9xVRZSixbt1juCZCAr/d9vrWPeRJ5zTSfKp6gDrV+SzmkH7xsqT+VNNvuQxk7lX9KqzHsY6XMKROYlfe3HLYwKj/s5J4UntpjsLZePupq1fWaxAMi4jbrnpSwRx2yljIQJMEgDBI9KE2iZpNXRx/iHSFjikZQPNByWLcFT2xXj3i3QPs0xubVD5JOXjUH5PU/SvoDxRGm+QW6hk2BlJ5I9q4O/sw3mJIAVccHHBqozszlqUudaniQIDFgMgdKEbaCWH3q3vFWivpdwZIhutpeh/un0rnm52jPA611xdzy5RcXZkrsNghzknkmnSIGKDOFXmolbLZ7CnKdkTMctu4FUhDlIk8yYsBtHy+5qNgUhVM/MxzipDEZNsYKqD82PSms3mzM6/KEHaqEKcb40kIBjBJ96RHCRySHA3HA9qjbsWwS5AqWRUE2w4KRD5sd6AI/LQGNM57kjrTwymUyGXCJ9zPXPpTIMbDJkgs20cU6ZFhk8hcyN6juTQIeoUebIpX0BPQnviojG6W+4vgSc7QetK4ZisDMP3Wc8dKdBGssudpEac56ADtTACJbaMPsABOPfOKSXzY13BR83LN3zUkZea4ed2ZjyBx1Y8cUyPBci5YtHFk5X+I0gHmLZaNIZcS5Bxn72e1IuVthIXUuHycnr7f1oUQS3TyElYUAbGM5PpUccfnXDYVpIlJYqOM0AEJi2s0kpWU/NkjI+lEBCfvZPmfptJ5pbuZLmVCsewIuGxRcLGbnbCD5ZAzx+dADVRvIaZMHB2nuRTYshC7cDBHPepGZHnj8vKxDGQR0ocF2ERI6kj6UAMGPLZyp8xuR7U0h1BckZP606MeZJtI+Uc5FTShbi4WMOgA/i6CgCKN1WGRJIyZn+62elMm+UInRh1p0alpCWyQvftTXkBySAWPQ0ANU5ctx8ooDfeZup6UjoVULn5jyaTHzbW7UASYKIcdWpgPQdeeacSMZHQUDhSSMHtQBIxDkKnGKaxBIUDpTd2EOPvUKNoJ5zQBI+OAOnenQEltoPFRgZwH4JqdFWIcHJNMSHsoc49Kix+8xnKjpQ7jBHO6lbCRgAjJ60hg7bmAXpTWO4gAUuB5Xy/eojG1eeSaAIyOlX9K1Kawn3RsdvpVFwQeRg0YO3PrUSVyoycdUexeD/GTQvuiaNi67JI5BuVx6EV1ema48dws1tII5AcgA/pj0rxXwVaCW5mu5IjcLC8cMVsH2CeeRsIrEdFGCx9hXf+HfFcl3qt3pk7aTcrbhvLjit/LWfbywicDIOAcE9cVi4tHZTrp7nolzqLahc/aZNiuVAIXgcDHSiuYku47a9CW8jSW8iJNC7dSjDIz79vwoqLM7ItW0Pnr6VraNftbyrG5OOxJ6VjnpT+4rokeQnZnq2l3gcDHBxXT2VwFZC3IPavOtBJ2R8npXaWXSsDuizojICQ6jANXYDuUYwABWVbfcWr9tWcjqg2adsWDBlIAFbVvOSM44rFTp+NakX3ahmjdzVhlG3qKk+0nbgnPPFZq9Pwpjk569qTegLc0zcMDn0pDd54PX2NYwdtw+Y9fWrll99vpWbbNVHqX43eToDip0t5HA4yB1NPsa2eh49qajclztoipbWagKWGT3Bq48CJ9wc47CgUo6H61a0IbbM24T5dwzjuPWq8GFuWViMMMmrc/U/WqzgfLx2q4loq33lhZIZF+QjK+xrMuFeQbODgdfStUAGbnnnvVSXh7jFJ6iMyO2zvD/ADjaRk+vpWDe6au0hlPlYLA56V1cX/HvHWd4gUBY8ADn0oexEjzrXNOt7y2kgdQ0brjPce4rx3U7J9PvJYJhhkPB/vD1r3mYAxPn1ry74jqBPbEAZwRmt6TOHEwXLc4of6s44JNSkgCOJecck+lRH7y0q/61q3Rwk6hQZJN3OMD3qNOLcRg4Mh6DrTT/AKtfrTv+WqfSncQ0BTJwTtQZNICsdq6kfvJCMewqWD/UXP8Au0+MAzpkD/V/0poBoQRTAMwIjG4gcjdT0VQhnGS0aksW/vE4AFQD/lt/vLQhP2G4/wA96YhFkVImLfNJKMk+gz/WpZA3lJbBQHwCxB69+anugP8AROB1/oKpQcyXGefkegCaUJ5Ssr4KARrtH3j3Y0XMrwqluiKpIGTjBfPeoLb/AFw/3f6VqWgDxSFgGIg4J5xQBQkZQGijhLDOQc/eNSiSW0ji8mRNxBOdvcjn61Hfki6ABIAXgDtUMJPnjk8Dj2oAmUi3WRShZsYbdwM9qR45LWHfyC/QjryOlS3pJgs8k/NDk+5zVcc3qDtnpTALdC0bv5gXZhiG7+lIXAVmZP3khJBqaYDE3H8VRXv/AB9p9FpdAFdTbplmyWHIB6GoXUxrtByxG5gB0qxdj54/94/zpll/r5PoaGgBj5cYRWLBgD+JprAO3yj5UHUUkfLnNOT/AI95vrQAi4YPIT93getRupwpPVqV/wDUJUk3+tT6UARuuMAdeppWbzCOmBUsn3j9Kqj7poAl2BskkcU5CCcnoKa/+rFOP/HvQAM2TkgECliJHzE59qjH3KkT7yUCHx/eLOvamOfmJxxU11wVxUc33FoYx8KhgT2pQNuWPQetRr/qj9aJu30pgKPmJY09ACpY9KjH3BT3/wBWKQG14V1GG1e5t7qdrWGdo5Y7pU3fZ5423RuR3Xkg+xrodlvbTT3yx6DprzKwe/t74z7Qwwxhg6hiCQM9M9q4Rv8AVGkkUBkIAz/9apaC51i+Kkm1ZnRXhsUVIYEY/MsaAKuffAyfc0VydsAZQCAR70VhNWZ1U6skrH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Linear erythematous plaques with prominent keratotic rims are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Linear porokeratosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Slightly atrophic erythematous plaques with peripheral keratotic rims are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41560=[""].join("\n");
var outline_f40_37_41560=null;
var title_f40_37_41561="Female perirectal perivesical sp1";
var content_f40_37_41561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56539%7EOBGYN%2F66156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56539%7EOBGYN%2F66156&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Female perivesical and perirectal spaces",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A transverse diagram showing the relationships between the bladder and rectum.",
"    <div class=\"footnotes\">",
"     BL: bladder; VVS: vesico-vaginal space; VA: vagina; RVS: rectovaginal space; RE: rectum; RRS: retrorectal space.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 486px\">",
"   <div class=\"ttl\">",
"    Palpating for tumor extension in the female perirectal and perivesical spaces during radical hysterectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 466px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Placing an index finger in the perivesical space and the middle finger in the perirectal space allows the tissue in between (parametrium) to be palpated to assess for tumor extension.",
"    <div class=\"footnotes\">",
"     BL: bladder; VVS: vesicovaginal space; VA: vagina; RVS: rectovaginal space; RE: rectum; RRS: retrorectal space.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William J Mann, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41561=[""].join("\n");
var outline_f40_37_41561=null;
var title_f40_37_41562="Antithrombotic therapy for intracoronary stent implantation: Clinical trials";
var content_f40_37_41562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"7\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antithrombotic therapy for intracoronary stent implantation: Clinical trials",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/37/41562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/37/41562/contributors\">",
"     Thomas Levin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/37/41562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/37/41562/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?40/37/41562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?40/37/41562/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?40/37/41562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Percutaneous transluminal coronary angioplasty (PTCA) has been associated with two major limitations: acute or threatened vessel closure, and restenosis. The availability of intracoronary stents and the ongoing improvements in stent design, technique, and antithrombotic therapy have resulted in significant reductions in both of these complications without an increase in subacute thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because they are generally made of stainless steel or cobalt chrome alloys, stents are inherently thrombogenic until they are fully covered by endothelial tissue. The earliest studies utilizing older stent deployment techniques without routine anticoagulation showed that acute (usually less than 24 hours) or subacute (up to five to six days) thrombosis occurred in approximately 18 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aggressive anticoagulation regimens, such as that used in BENESTENT, reduced the stent thrombosis rate to 3 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/3\">",
"     3",
"    </a>",
"    ]. However, this approach also resulted in higher rates of vascular complications, in particular, bleeding [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Aggressive anticoagulation was also associated with increased hospital stay and procedural costs.",
"   </p>",
"   <p>",
"    Subsequently, alternative regimens were evaluated, including the use of more potent antiplatelet agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) and elimination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    therapy unless otherwise indicated. These strategies lowered both the vascular complication rate and the incidence of stent thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current standard antithrombotic regimen after stent implantation includes",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    given indefinitely and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    given for a variable time depending in part upon stent type. The CREDO and PCI-CURE trials have suggested that continuing combination therapy with aspirin and clopidogrel for at least 9 to 12 months reduces late cardiac events including death, myocardial infarction (MI), and stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical trials evaluating the different aspects of antithrombotic therapy around the time of stent implantation will be reviewed here. Other issues regarding antithrombotic therapy and recommendations for its use are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The discussion of and the recommendations for long-term dual antiplatelet therapy is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link\">",
"     \"Coronary artery stent thrombosis: Incidence and risk factors\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    General issues, including the importance of optimal stenting, methodologic considerations, complications associated with stents, and the use of newer stents are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=see_link\">",
"     \"General principles of the use of intracoronary stents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link\">",
"     \"Periprocedural complications of percutaneous coronary intervention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=see_link\">",
"     \"Drug-eluting intracoronary stents: General principles\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTIPLATELET THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;If tolerated,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    is given indefinitely to all patients undergoing percutaneous coronary intervention (PCI) with stenting. In addition, an adenosine diphosphate P2Y12 receptor blocker and, in some patients, a glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor have become part of the antithrombotic regimen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Aspirin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    is recommended for all patients undergoing coronary stenting, based primarily upon data from randomized trials of aspirin or aspirin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     dipyridamole",
"    </a>",
"    versus placebo in patients undergoing PTCA prior to the development of stents:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one trial, 376 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (990",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      (225",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo beginning 24 hours before PTCA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/10\">",
"       10",
"      </a>",
"      ]. There was a significant reduction in periprocedural Q wave MI with aspirin and dipyridamole (1.6 versus 6.9 percent).",
"     </li>",
"     <li>",
"      In another study, 333 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (650",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"       dipyridamole",
"      </a>",
"      (225",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"       ticlopidine",
"      </a>",
"      (750",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      or placebo prior to PTCA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/11\">",
"       11",
"      </a>",
"      ]. Immediate procedure-related complications (abrupt occlusion, thrombosis, or major dissection) were significantly less frequent with aspirin plus dipyridamole or with ticlopidine than with placebo (5 and 2 versus 14 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/25/41366?source=see_link\">",
"     Dipyridamole",
"    </a>",
"    was added to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    in both of the trials described above. However, the elimination of dipyridamole from this regimen does not increase the risk of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    used in initial studies was high (650 to 990",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    A comparative trial found that lower doses are equally effective. In this study, 495 patients were randomly assigned to one of two aspirin doses (80 mg or 1500",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    prior to PTCA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/12\">",
"     12",
"    </a>",
"    ]. There was no difference between the two groups in the incidence of MI (3.6 versus 3.9 percent) or in the need for coronary artery bypass graft surgery (CABG) (3.6 versus 3.7 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     P2Y12 receptor blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The thienopyridines",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    , and the non-thienopyridines",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/0/38919?source=see_link\">",
"     ticagrelor",
"    </a>",
"    and cangrelor achieve their antiplatelet effect by blocking the binding of ADP to a specific platelet receptor P2Y12 that activates Gi, thereby inhibiting adenylyl cyclase and platelet aggregation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/13\">",
"     13",
"    </a>",
"    ]. Clopidogrel and ticlopidine have been extensively evaluated in patients undergoing stent implantation, both during and after the procedure and then when also given as pretreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Ticlopidine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early randomized trials evaluated the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    in patients receiving stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/6,7,14-18\">",
"     6,7,14-18",
"    </a>",
"    ]. In those with simple lesions and successfully deployed bare metal stents (BMS), short-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus therapy with dual antiplatelet therapy (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    indefinitely plus ticlopidine administered for three to four weeks after BMS) reduced subacute stent thrombosis compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    as shown in the STARS, MATTIS, and ISAR trials, as well as in the FANTASTIC study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/6,14-17\">",
"     6,14-17",
"    </a>",
"    ]. As an example in the STARS trial, the incidence of a primary end point (death, emergency CABG, Q wave MI, or angiographically evident thrombosis) was significantly lower with aspirin and ticlodipine (3.6, 2.7, and 0.5 percent, respectively) at 30 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1136003648\">",
"    <span class=\"h3\">",
"     Clopidogrel",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h4\">",
"     Efficacy and safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     Clopidogrel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with or without a 300 mg loading dose) plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    after stenting has shown seemingly equal efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    plus aspirin in terms of major cardiac events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    has fewer side effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/19,20,24,25\">",
"     19,20,24,25",
"    </a>",
"    ]. In the CLASSICS trial the adverse event rate (major peripheral or bleeding complications, thrombocytopenia, neutropenia, or early discontinuation of drug for a noncardiac adverse event) was significantly lower in the patients treated with clopidogrel (4.6 versus 9.1 percent with ticlopidine) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/19\">",
"     19",
"    </a>",
"    ]. A similar difference was noted in another trial (5.3 versus 10.6 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H13#H13\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'TTP-HUS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis from randomized trials and registries comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    in 13,955 patients found that clopidogrel was associated with a lower incidence of major adverse cardiac events (2 versus 4 percent for ticlopidine, adjusted odds ratio 0.72) and a lower 30-day mortality (0.5 versus 1.1 percent, adjusted odds ratio 0.55) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, these findings were based largely on the results from noncurrent registries. Two of the three randomized trials in the analysis showed a nonsignificant trend toward benefit with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    . In CLASSICS, for example, the incidence of major adverse cardiac events was 1.2 to 1.5 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    compared to 0.9 percent with ticlopidine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/19\">",
"     19",
"    </a>",
"    ]. Another trial noted a significant reduction in mortality and nonfatal MI with ticlopidine compared to clopidogrel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It should be noted that the applicability of the findings in this trial and in CLASSICS to current practice is uncertain since",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    were only given for 28 days and the use of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor was restricted, neither of which is now standard practice. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Overall data suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is better tolerated and has fewer side effects, particularly hematologic side effects, than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    and is a safe and preferable alternative in patients receiving a stent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/27\">",
"     27",
"    </a>",
"    ], including those who receive a smaller stent with a diameter &le;3 mm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h4\">",
"     Timing and dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    before PCI with stenting is of benefit in patients with a non-ST elevation acute coronary syndrome (ACS) undergoing pretreatment, as was demonstrated in the PCI-CURE trial. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the CURE trial of non-ST elevation acute coronary syndromes, 2658 patients underwent PCI (PCI-CURE) and (bare metal) stenting was performed in 82 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H16#H16\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Clopidogrel'",
"    </a>",
"    .) The patients were pretreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    or placebo for a median of six days prior to intervention; all received aspirin and clopidogrel for four weeks after intervention. The primary endpoint (cardiovascular death, myocardial infarction, or urgent target vessel revascularization at 30 days after PCI) was significantly reduced with clopidogrel (4.5 versus 6.4 percent for placebo). After four weeks study the drug was restarted. There was a significant decrease in the rate of the primary outcome at an average of eight months follow-up (",
"    <a class=\"graphic graphic_figure graphicRef70192 \" href=\"mobipreview.htm?37/31/38397\">",
"     figure 1",
"    </a>",
"    ) and this benefit was seen in both stented and nonstented patients. There was no significant difference in major bleeding episodes between the two groups.",
"   </p>",
"   <p>",
"    The CREDO trial confirmed the benefit of pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in more than 2100 patients undergoing elective PCI (almost all with stenting) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/8\">",
"     8",
"    </a>",
"    ]. The patients were randomly assigned to pretreatment with placebo or clopidogrel at a loading dose of 300 mg 3 to 24 hours before the procedure; after the procedure, all patients received clopidogrel (75",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 28 days; clopidogrel or placebo, according to original randomization, was then given for the remainder of one year. All received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for the duration of the study, and more than 40 percent of patients also received concomitant therapy with an intravenous GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      At 28 days,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      therapy was associated with a nonsignificant reduction in the combined end point of death, MI, or urgent target vessel revascularization (6.8 versus 8.3 percent, relative risk reduction 18.5 percent, 95% CI 14.2 to 41.8 percent). In a prespecified subset analysis, a strong trend for reduction in these events was seen when clopidogrel was begun &ge;6 hours before the procedure (relative risk reduction 38.6 percent, 95% CI -1.6 to +62.9 percent), with no benefit with shorter pretreatment intervals (",
"      <a class=\"graphic graphic_figure graphicRef67652 \" href=\"mobipreview.htm?4/9/4254\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A subsequent subgroup analysis showed that the benefit of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      loading dose was first significant when given at least 15 hours before PCI and was greatest when given at least 24 hours before PCI (",
"      <a class=\"graphic graphic_figure graphicRef79395 \" href=\"mobipreview.htm?32/47/33533\">",
"       figure 3",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/29\">",
"       29",
"      </a>",
"      ]. The absolute risk reduction in patients with &ge;15 hours of clopidogrel pretreatment was 6.2 percent compared to placebo pretreatment in the same time interval (3.5 versus 9.7 percent). The risk reduction with prolonged clopidogrel pretreatment was greatest in patients who did not receive a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor.",
"     </li>",
"     <li>",
"      At one year, the combined end point of MI, stroke, and death was significantly reduced by loading and long-term",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      (8.5 versus 11.5 percent with placebo, relative risk reduction 26.9 percent, 95% CI 3.9-44.4) (",
"      <a class=\"graphic graphic_figure graphicRef80138 \" href=\"mobipreview.htm?35/49/36637\">",
"       figure 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      There was no significant increase in bleeding, including the subset patients also treated with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The need to give a 300 mg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    loading dose at least 15 hours before the procedure may be problematic for many ACS patients who undergo PCI less than six hours from presentation and for stable patients who undergo planned PCI within 15 hours after a decision to do so or ad hoc PCI at the time of diagnostic coronary angiography. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=see_link\">",
"     \"Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=see_link&amp;anchor=H4#H4\">",
"     \"Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome\", section on 'Time from hospital arrival (door-to-balloon time) on outcomes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This time limitation may be at least in part overcome by giving a",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    loading dose of 600 mg, 900 mg, or two 600 mg doses, rather than 300 mg as used in CREDO. Evidence for efficacy within two to three hours of administration of 600 mg comes from the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The time dependence of platelet inhibition after 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      was evaluated in an unselected cohort of 1001 patients scheduled for possible PCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/30\">",
"       30",
"      </a>",
"      ]. The maximum antiplatelet effect using several in vitro measures was seen by two hours.",
"     </li>",
"     <li>",
"      The ISAR-REACT trial evaluated the efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      in 2159 patients undergoing elective percutaneous coronary intervention (PCI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/31\">",
"       31",
"      </a>",
"      ]. All patients were pretreated with 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      at least two hours before PCI. When the study subjects were grouped into four subsets based upon duration of clopidogrel pretreatment (two to three hours, three to six hours, 6 to 12 hours, and &gt;12 hours), there was no significant difference among the four groups in the incidence of death, MI, or urgent revascularization at 30 days or in the rate of major bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The higher loading dose also may improve outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. This was suggested in the ARMYDA-2 trial in which 255 patients (75 percent stable angina, 25 percent non-ST elevation ACS) scheduled to undergo PCI were randomly assigned to a 300 or 600 mg loading dose four to eight hours before the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/32\">",
"     32",
"    </a>",
"    ]. All but two patients received a stent (20 percent drug-eluting), most patients had only single vessel intervention, but only 13 percent were treated with a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor.",
"   </p>",
"   <p>",
"    The primary end point (death, MI, or target vessel revascularization) occurred significantly less often with the 600 mg loading dose (4 versus 12 percent), a difference that was entirely due to a lower rate of periprocedural MI (4.0 versus 11.6 percent, adjusted odds ratio 0.48). Major bleeding did not occur in either group, but the authors could not comment on bleeding risk if emergency CABG were required.",
"   </p>",
"   <p>",
"    Similar findings were noted in a single center trial in which 292 patients with non-ST elevation ACS were randomly assigned to either 300 or 600 mg at least 12 hours before scheduled stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/33\">",
"     33",
"    </a>",
"    ]. The rate of recurrent cardiovascular events at 30 days was significantly lower with the 600 mg dose (5 versus 12 percent).",
"   </p>",
"   <p>",
"    The following mechanisms may contribute to the apparently better outcome with the 600 mg loading dose:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 300 mg loading dose would not be fully active when given four to eight hours before PCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A 600 mg loading dose produces a greater maximal antiplatelet effect [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/33-37\">",
"       33-37",
"      </a>",
"      ], an earlier antiplatelet effect (the degree of platelet inhibition at two hours is greater than the maximal effect with 300 mg, which is also seen later) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/36\">",
"       36",
"      </a>",
"      ], and may diminish the likelihood of both",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/38\">",
"       38",
"      </a>",
"      ] and of a reduced antiplatelet effect in patients taking drugs that are metabolized by CYP3A4 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/30,39\">",
"       30,39",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=see_link&amp;anchor=H2#H2\">",
"       \"Nonresponse and resistance to clopidogrel\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The possible additional antiplatelet effect of a 900 mg loading dose was evaluated in the ISAR-CHOICE and ALBION trials, which had similar findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]. The results can be illustrated by the larger ALBION trial, which randomly assigned 103 patients with an non-ST elevation MI, most of whom underwent PCI with stenting, to 300 mg, 600 mg or 900 mg loading doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and evaluated measures of platelet activity at eight time points over six hours [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/36\">",
"     36",
"    </a>",
"    ]. Clinical end points such as death, MI, recurrent ischemia, and troponin level were also evaluated.",
"   </p>",
"   <p>",
"    A 900 mg loading dose, compared to a 600 mg loading dose, was associated with small, nonsignificant trend toward a more rapid onset and greater degree of platelet inhibition, a lower serum troponin, and less recurrent ischemia, without an apparent adverse effect on safety.",
"   </p>",
"   <p>",
"    The potential benefit of 1200 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    given in two divided doses was evaluated in the PREPAIR trial of 148 patients undergoing elective PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/40\">",
"     40",
"    </a>",
"    ]. Those patients randomly assigned to 600 mg the day before and the morning of the procedure had a higher percent platelet inhibition at the time of angiography than either those given 300 mg the day before and 75 mg the day of the procedure or those given 600 mg the only on the day of the procedure.",
"   </p>",
"   <p>",
"    Clinical trials looking at outcomes are necessary before one should consider a 900 mg or two 600 mg loading doses. At this point in time, data are insufficient to justify routine clinical use of loading doses greater than 600 mg.",
"   </p>",
"   <p>",
"    The above trials evaluated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    dosing before PCI. However, the need to give clopidogrel hours before PCI is potentially problematic even for stable patients referred for diagnostic coronary arteriography, since many of these patients do not have coronary artery disease (CAD) requiring intervention and some will have a critical lesion requiring early CABG. Both of these groups would therefore be unnecessarily exposed to any bleeding risk associated with clopidogrel therapy. These issues were addressed in the PRAGUE-8 and ARMYDA-5 PRELOAD trials:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In PRAGUE-8, 1028 stable patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      600 mg given either more than six hours before or immediately after elective coronary arteriography in patients undergoing PCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/41\">",
"       41",
"      </a>",
"      ]. PCI was performed in 29 percent of patients and CABG in 12 percent. There was no significant difference between the two regimens in a combined primary clinical endpoint",
"      <span class=\"nowrap\">",
"       (death/MI,",
"      </span>",
"      stroke, TIA, repeat PCI, 0.8 versus 1.0 percent), but there was a statistically significant increase in the rate of bleeding (mostly minor) in those who received the earlier clopidogrel dose (3.5 versus 1.4 percent). However, there were several important limitations of this trial, including the small number of patients undergoing PCI and a higher than expected rate of bleeding complications [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In ARMYDA-5 PRELOAD, 409 patients (61 percent with stable angina, 39 percent with non-ST elevation MI) were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      600 mg either four to eight hours before or immediately after coronary angiography (but before PCI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/43\">",
"       43",
"      </a>",
"      ]. There was no significant difference in the 30-day incidence of major adverse cardiac events of cardiac death, myocardial infarction, or unplanned target vessel revascularization (10.3 versus 8.8 percent) nor was there a difference in the rates of either risk of",
"      <span class=\"nowrap\">",
"       bleeding/vascular",
"      </span>",
"      complications (7.8 versus 5.4 percent). A post-hoc subgroup analysis of the patients with stable angina showed no significant difference in these events.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The issue of whether patients already taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    75 daily need to be reloaded at the time of PCI is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H5#H5\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Clopidogrel'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The duration of dual anti-platelet therapy is an important issue that is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H9#H9\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Duration'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Prasugrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials (JUMBO-TIMI 26 and PRINCIPLE-TIMI 44) have compared the effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    on platelet function in patients with planned PCI:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In JUMBO-TIMI 26, a dose-ranging, double-blind safety trial,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      had a more rapid onset of action and was able to achieve higher degrees of platelet inhibition than",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      with a comparable rate of significant bleeding [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In PRINCIPLE-TIMI 44, 201 patients undergoing elective PCI were randomly assigned to either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      60 mg or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      600 mg one half-hour before PCI and then to either prasugrel 10 mg or clopidogrel 150 mg daily with crossover of therapy at 15 days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/45\">",
"       45",
"      </a>",
"      ]. Prasugrel was associated with a significantly higher rate of achieving the primary end point of inhibition of platelet aggregation during both the loading dose and maintenance dose phases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"     prasugrel",
"    </a>",
"    was compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in the TRITON-TIMI 38 trial of 13,608 moderate- to high-risk ACS patients (including those with both ST and non ST-elevation MI) undergoing PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/46\">",
"     46",
"    </a>",
"    ]. Prasugrel was given with a loading dose of 60 mg and maintenance dose of 10",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    while clopidogrel was given with a 300 mg loading dose and a 75",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    maintenance dose; the median duration of therapy was 14.5 months. Long-term",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    therapy was recommended in all patients in addition to thienopyridine therapy.",
"   </p>",
"   <p>",
"    At 15 month follow-up, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The primary efficacy end point of cardiovascular death, nonfatal MI, or nonfatal stroke occurred significantly less often in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (9.9 versus 12.1 percent; hazard ratio [HR] 0.81; 95% CI 0.73-0.90). This was driven primarily by a significant reduction in nonfatal MI (7.4 versus 9.7 percent), including in the subset of patients with periprocedural MI. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=see_link&amp;anchor=H12#H12\">",
"       \"Periprocedural myocardial infarction following percutaneous coronary intervention\", section on 'Prevention'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The safety end point of major bleeding occurred significantly more often in patients treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      (2.4 versus 1.8 percent; HR 1.32; 95% CI 1.03-1.68). The rate of life-threatening bleeding was also significantly increased with prasugrel.",
"     </li>",
"     <li>",
"      The rate of definite or probable stent thrombosis (ARC definition) was significantly reduced in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?26/63/27639?source=see_link\">",
"       prasugrel",
"      </a>",
"      group (1.1 versus 2.4 percent). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=see_link&amp;anchor=H2#H2\">",
"       \"Coronary artery stent thrombosis: Incidence and risk factors\", section on 'Definitions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Cangrelor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cangrelor is an intravenous (non-thienopyridine) adenosine triphosphate analogue that blocks the adenosine diphosphate P2Y12 receptor. Advantages of cangrelor, which might improve clinical outcomes, over other antiplatelet agents, are its rapid onset of action and rapid return of platelet function after cessation. Our recommendations for the use of cangrelor in patients undergoing PCI, based on the studies below, are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H3#H3\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'P2Y12 receptor blockers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H17#H17\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'With primary PCI'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H15#H15\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Platelet P2Y12 receptor blockers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two early trials evaluated cangrelor in patients undergoing PCI and both failed to show clinical superiority to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. In both trials, which enrolled patients with ACS or stable angina requiring PCI, cangrelor infusion was given for two hours or for the duration of the procedure, which ever was longer:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the CHAMPION PLATFORM trial over 5000 patients were randomly assigned to either cangrelor infusion or placebo 30 minutes before PCI, followed by 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      after the procedure in both groups [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/47\">",
"       47",
"      </a>",
"      ]. There was no significant difference in the primary composite end point (death, MI, or ischemia-driven revascularization) at 48 hours (7.0 versus 8.0 percent, respectively).",
"     </li>",
"     <li>",
"      In the CHAMPION PCI trial almost 8000 patients were randomly assigned to either cangrelor infusion or 600 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      given 30 minutes before PCI [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/48\">",
"       48",
"      </a>",
"      ]. Using an identical primary end point as CHAMPION PLATFORM, there was no significant difference between cangrelor and clopidogrel (7.5 versus 7.1 percent respectively) at 48 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A third trial, CHAMPION PHOENIX, randomly assigned 11,145 patients undergoing urgent or elective PCI to receive a bolus and infusion of cangrelor or a loading dose of either 600 or 300 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/49\">",
"     49",
"    </a>",
"    ]. At 48 hours, the rate of the composite primary efficacy end point (death, MI, ischemia-driven revascularization, or stent thrombosis) occurred less often in the cangrelor group (4.7 versus 5.9 percent; adjusted odds ratio 0.78, 95% CI 0.66-.093). There was no significant difference in the rate of the primary safety end point of severe or life-threatening bleeding at 48 hours (0.16 versus 0.11 percent; odds ratio 1.50, 95% CI 0.53-4.22).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1221867311\">",
"    <span class=\"h3\">",
"     Ticagrelor and prasugrel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two platelet P2Y12 receptor blockers have been evaluated in patients with ACS. The relevant trials and our recommendations for their use are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H22#H22\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H26#H26\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Ticagrelor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link&amp;anchor=H43#H43\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\", section on 'Summary and recommendations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H547672759#H547672759\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Prasugrel'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H547672766#H547672766\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Ticagrelor'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cilostazol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     Cilostazol",
"    </a>",
"    is approved for the treatment of intermittent claudication. In addition its use has been associated with a reduction in the rate of restenosis after coronary stent placement. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29081?source=see_link&amp;anchor=H6#H6\">",
"     \"Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention\", section on 'Long-term medical therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=see_link&amp;anchor=H451547835#H451547835\">",
"     \"Medical management of claudication\", section on 'Cilostazol'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an inhibitor of type III phosphodiesterase in platelets,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    is an effective antiplatelet agent. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link\">",
"     \"Platelet biology\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Triple antiplatelet therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    compared to dual antiplatelet therapy with aspirin and clopidogrel has been associated with a lower rate of adverse cardiovascular outcomes after stent placement in patients with either stable or unstable coronary disease in a few studies. This is true for both short- and long-term outcomes. In each of the studies below, cilostazol was given with a loading dose of 200 mg and then maintained at 100 mg twice daily, unless otherwise stated.",
"   </p>",
"   <p>",
"    Short-term outcomes were evaluated in a retrospective study of over 3000 patients with stable or unstable coronary disease who received either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    (n = 1597) or aspirin, clopidogrel, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    (n = 1415) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/50\">",
"     50",
"    </a>",
"    ]. While there was no significant difference in the rate of the primary outcome of major adverse cardiovascular outcomes (death, MI, target lesion revascularization, or stent thrombosis) at 30 days, the rate of stent thrombosis was significantly lower in patients receiving cilostazol compared to aspirin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/27/35255?source=see_link\">",
"     ticlopidine",
"    </a>",
"    alone (0.1 versus 0.5 percent).",
"   </p>",
"   <p>",
"    Longer-term outcomes come from one randomized trial and two observational studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an open-label, randomized trial of 1212 patients with acute coronary syndromes undergoing stent placement with either BMS or DES, patients were treated with either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      (for six months; no loading dose given) in addition to aspirin and clopidogrel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/51\">",
"       51",
"      </a>",
"      ]. At one year the primary end point (composite of cardiac death, nonfatal MI, stroke, or target vessel revascularization) occurred significantly less often in the group that received cilostazol (10.3 versus 15.1 percent; hazard ratio 0.65, 95% CI 0.41-0.91).",
"     </li>",
"     <li>",
"      In the KAMIR registry of patients with ST-elevation MI treated with primary percutaneous coronary intervention using drug eluting stents (DES), there were 2569 individuals who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and 1634 who received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      (for at least one month) in addition to aspirin and clopidogrel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/52\">",
"       52",
"      </a>",
"      ]. At eight months patients who received cilostazol had significantly lower rates of cardiac death (2.0 versus 3.2 percent; adjusted odds ratio [OR] 0.52, 95% CI 0.32-0.84), and total major adverse cardiac events (all cause mortality, nonfatal MI, and repeat PCI or revascularization procedure) (7.6 versus 9.3 percent; adjusted OR 0.74, 95% CI 0.58-0.95).",
"     </li>",
"     <li>",
"      In the DECREASE registry of patients with stable or unstable coronary disease who underwent stenting with DES, 1443 received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      and 1656 received",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"       cilostazol",
"      </a>",
"      for at least four weeks in addition to aspirin and clopidogrel [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/53\">",
"       53",
"      </a>",
"      ]. At 12 months there was no significant difference between the two groups in combined rate of death, MI, or stent thrombosis. However, the hazard ratios for MI or stent thrombosis were significantly lower in those who received all three antiplatelet agents (0.23, 95% CI 0.08-0.70 and 0.14, 95% CI 0.04-0.52 respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In all studies, there was no significant difference in the rate of major bleeding between groups.",
"   </p>",
"   <p>",
"    We believe the data are insufficient to recommend addition of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/38/38502?source=see_link\">",
"     cilostazol",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus thienopyridine as standard therapy. Further blinded randomized, placebo controlled trials should be performed to confirm clinical outcome results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors do not reduce the incidence of angiographic complications (major dissection, distal embolization, residual thrombus, abrupt closure, or side branch occlusion) of stent implantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/54\">",
"     54",
"    </a>",
"    ], but do improve subsequent outcomes. A meta-analysis of 19 randomized trials of PCI (some with and some without stenting) found that GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy was associated with the following findings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/55\">",
"     55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant reduction in mortality at 30 days (relative risk 0.69, 95% CI 0.53-0.90) and at six months (relative risk 0.79, 95% CI 0.64-0.97) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/55\">",
"       55",
"      </a>",
"      ]. The mortality benefit was similar in trials evaluating stenting (relative risk 0.69 and 0.70, respectively) and with or without acute MI as the indication for intervention.",
"     </li>",
"     <li>",
"      The number needed to treat (NNT) to prevent one death at 30 days and six months was 320 and 220. The NNT was lower in high-risk patients with an acute MI and higher in low risk patients undergoing elective PCI in whom the mortality risk is very low. The concept that the benefit is primarily seen in high risk patients was supported by a meta-analysis of non-ST elevation ACS trials described below in which a benefit from GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor therapy was seen only in patients in whom PCI or CABG was performed within 30 days and in those who had elevated serum troponins (ie, a non-ST elevation MI) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Myocardial infarction also was significantly reduced at 30 days and six months (relative risk 0.63 and 0.67, respectively), while major bleeding was increased only if",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was continued after the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Elective stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in elective stenting was addressed in the EPISTENT trial which randomly assigned 2399 patients undergoing PCI to stenting alone, stenting plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    , or PTCA plus abciximab; all patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , and standard pharmacologic therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/57\">",
"     57",
"    </a>",
"    ]. The following results were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The 30 day incidence of the primary end point (death, MI, and urgent revascularization) was significantly lower with the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      (5.3 and 6.9 percent with stenting or PTCA plus abciximab versus 10.8 percent with stenting alone, respectively), primarily because of a reduced incidence of NSTEMI. The benefit was similar in those with stable angina or an ACS.",
"     </li>",
"     <li>",
"      The beneficial effects of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      on the combined end point of death or MI were maintained at six months and with stenting plus abciximab on death or large MI at one year (5.3 versus 11 percent with stenting alone) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/58,59\">",
"       58,59",
"      </a>",
"      ]. There was also a significant survival benefit at one and three years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/59,60\">",
"       59,60",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar benefits were noted with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    in the ESPRIT trial of patients undergoing elective stenting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/61\">",
"     61",
"    </a>",
"    ]. The trial was prematurely terminated because eptifibatide reduced the primary end point (48 hour rate of death, MI, urgent revascularization, or need for \"bail-out\" GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) by 37 percent (6.6 versus 10.5 percent for placebo). There was also a reduction in the secondary end point of 30 day rate of death, MI or target vessel revascularization (6.8 versus 10.5 percent). As with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in EPISTENT, the improved outcomes with eptifibatide were maintained at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the reasons described above,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    is given to all patients who receive a stent. For low-risk elective stenting, a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor may not provide any additional benefit if the patient is pretreated with clopidogrel. This was demonstrated in the ISAR-REACT trial, in which 2159 patients with stable native vessel coronary disease and no major comorbidities underwent elective PCI (90 percent with stenting) at least two hours after pretreatment with 600 mg of clopidogrel (median duration of pretreatment 7.4 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The study subjects were randomly assigned to either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (70",
"    <span class=\"nowrap\">",
"     U/kg)",
"    </span>",
"    or placebo plus heparin (100 to 140",
"    <span class=\"nowrap\">",
"     U/kg).",
"    </span>",
"    At 30 days, there was no difference in the incidence of death, MI, or urgent target vessel revascularization between abciximab and placebo (4 percent in each group). Major bleeding complications occurred in 1 percent of each group. A later follow-up at one year continued to show no effect of abciximab on death or MI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The study population in ISAR-REACT was clearly at lower risk than those in EPISTENT and ESPRIT, since the adverse event rate in the placebo group was much lower in ISAR-REACT (4 versus 10.8 and 10.5 percent in the other two trials) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/63\">",
"     63",
"    </a>",
"    ]. This suggestion that lower risk patients may not benefit from a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor if they are treated with a thienopyridine is consistent with a later analysis from ESPRIT in which",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    significantly reduced the risk of death of MI at one year in high risk patients (8.0 versus 15.9 percent with placebo) but not in low risk patients (8.1 versus 9.0 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/65\">",
"     65",
"    </a>",
"    ]. Low risk was defined as age &le;75 years, no diabetes, serum troponin or CK-MB below the upper limit of normal, and no acute coronary syndrome as the reason for admission.",
"   </p>",
"   <p>",
"    The use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in patients with diabetes who undergo elective PCI was specifically addressed in the ISAR-SWEET trial. This study is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=see_link&amp;anchor=H19#H19\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Glycoprotein IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &nbsp;Non-ST elevation ACS &mdash; The efficacy of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors given with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients with a non-ST elevation acute coronary syndrome (ACS) was evaluated in a meta-analysis that examined individual data from six randomized trials of 31,400 patients who did not undergo early (&lt;48 hours) revascularization during study drug infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/56\">",
"     56",
"    </a>",
"    ]. From the point of view of stent implantation, the major finding was that the benefit of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors was limited to the 38 percent of patients in whom PCI or CABG was performed within 30 days (OR for death or MI 0.89, 95% CI 0.80-0.98) and to those who had elevated serum troponins (ie, a non-ST elevation MI). However, current practice is to perform diagnostic angiography and PCI soon after ACS presentation.",
"   </p>",
"   <p>",
"    In addition, the meta-analysis was published before the current use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    in patients with a non-ST elevation ACS, raising the possibility that GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors might not be of benefit in patients already treated with clopidogrel. This issue was addressed in the ISAR-REACT 2 trial in which 2022 patients with a non-ST elevation ACS undergoing PCI with stenting (recommended within six hours from diagnosis) were treated with clopidogrel (600 mg loading dose at least two hours before PCI) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and were randomly assigned, in the catheterization laboratory, to placebo or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus followed by a 12 hour infusion of 0.125",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min [maximum 10",
"    <span class=\"nowrap\">",
"     &micro;g/min])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/66\">",
"     66",
"    </a>",
"    ]. The primary end point was death, MI, or urgent target vessel revascularization within 30 days after randomization.",
"   </p>",
"   <p>",
"    The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       Abciximab",
"      </a>",
"      therapy was associated a significant reduction in the primary end point (8.9 versus 11.9 percent with placebo, relative risk [RR] 0.75, 95% CI 0.58-0.97). The benefit was seen in each of the components of the primary end point.",
"     </li>",
"     <li>",
"      On subgroup analysis, the benefit with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      was only seen in the 52 percent of patients with an elevation troponin concentration (13.1 versus 18.3 percent, RR 0.71, 95% CI 0.54-0.95). There was no benefit in patients without an elevated troponin who were at lower risk (4.6 percent in both groups, relative risk 0.99).",
"     </li>",
"     <li>",
"      The risk of major and minor bleeding and the need for transfusion were similar in the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These benefits were maintained at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/67\">",
"     67",
"    </a>",
"    ]. In patients with a positive troponin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    therapy was associated a significant reduction in the primary end point compared with placebo (28.6 versus 33.3 percent). For patients without an elevated troponin, there was a trend towards fewer events (17.8 versus 22.0 percent).",
"   </p>",
"   <p>",
"    The optimal time of initiation of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy in patients with an NSTEMI who are treated with early PCI with stenting was addressed in the EVEREST trial in which 93 high-risk patients were randomly assigned to one of three regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/68\">",
"     68",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Upstream (in the coronary care unit)",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      &mdash; 0.4",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min bolus for 30 minutes followed by 0.1",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min for up to 12 hours after PCI",
"     </li>",
"     <li>",
"      Downstream (in catheterization laboratory just prior to PCI) high dose bolus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"       tirofiban",
"      </a>",
"      &mdash; 25",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min bolus per three minutes, 10 minutes before PCI followed by 0.15",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min for up for 12 hours after PCI",
"     </li>",
"     <li>",
"      Downstream",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      &mdash; 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      bolus ten minutes before PCI, followed by 0.125",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min (maximum 10",
"      <span class=\"nowrap\">",
"       &micro;g/min)",
"      </span>",
"      for up to 12 hours after PCI",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following significant benefits were noted in upstream",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    : a lower rate of TIMI myocardial perfusion grade",
"    <span class=\"nowrap\">",
"     0/1",
"    </span>",
"    before PCI (28 versus 67 and 71 percent in the other two groups); improved perfusion on intracoronary myocardial contrast echocardiography before and after PCI; a lower rate of postprocedural cardiac troponin I elevation (9 versus 30 and 39 percent); and a lower serum cardiac troponin I after PCI. Thus, upstream tirofiban was associated with improved tissue level perfusion and a lesser degree of myocardial necrosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=see_link&amp;anchor=H6#H6\">",
"     \"Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy\", section on 'TIMI myocardial perfusion grade'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms of benefit from upstream therapy are not well understood, but probably represent additional antiplatelet activity in patients with NSTEMI who are treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/69\">",
"     69",
"    </a>",
"    ]. Most of the benefit occurred in patients undergoing PCI and the event rate in the period between presentation and PCI was low even in patients treated with aspirin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . As a result, the upstream benefit may be related to a lower thrombus load at the time of PCI and therefore a lower rate of distal embolization during the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=see_link\">",
"     \"Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, no clinical benefit from upstream GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor was seen in the ACUITY trial. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Direct thrombin inhibitors and fondaparinux'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Primary stenting for acute ST elevation MI",
"    </span>",
"    &nbsp;&mdash;&nbsp;GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors also appear to be effective compared to unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    without GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in patients undergoing primary stenting, particularly when there is an imperfect mechanical result, persistent slow flow, or filling defects compatible with thrombus. The discussion of the individual trials that evaluated the efficacy of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors in this setting and recommendations for their role in STEMI are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=see_link\">",
"     \"Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H24#H24\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Glycoprotein IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Timing of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal timing of GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy in patients undergoing primary PCI for ST elevation MI has been evaluated in a number of trials. A meta-analysis of nine trials concluded that the administration of a GP",
"    <span class=\"nowrap\">",
"     IIb/IIa",
"    </span>",
"    inhibitor in the ambulance or emergency department rather than in the catheterization laboratory was associated with a significant increase in initial TIMI 3 (normal) flow (26 versus 15 percent) but NO difference in either final TIMI 3 flow after PCI (90 versus 85 percent) or in major clinical outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/72\">",
"     72",
"    </a>",
"    ]. Similar early improvements in angiographic parameters of perfusion and a significant improvement in left ventricular function recovery at one month were noted in the RELAx-AMI trial published after the meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link&amp;anchor=H28#H28\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Timing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Complex lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The adjunctive use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    with stenting in patients with complex lesions (long, tandem, severely calcified, restenotic, thrombotic, or ostial total occlusions; bifurcations; saphenous vein grafts; and multivessel interventions) was examined in a report of 823 patients enrolled in the EPISTENT and EPILOG trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/74\">",
"     74",
"    </a>",
"    ]. Compared to placebo, abciximab reduced the one year rate of death or MI (16 versus 8 percent) but not target vessel revascularization (18 versus 20 percent). There was no trend for benefit from abciximab in saphenous vein graft intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention, presentation, and management of saphenous vein graft stenosis\", section on 'Possible role of GP IIb/IIIa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Comparison of different agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative clinical efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    at currently recommended doses has been uncertain for patients undergoing percutaneous coronary intervention (PCI). The efficacy of any of the agents appears to be closely related to the degree of platelet inhibition achieved during and in the initial period after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/75-77\">",
"     75-77",
"    </a>",
"    ]. This effect is clearly related to the potency of the initial bolus dose. The degree of platelet inhibition is similar at two hours after initiation of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/75\">",
"     75",
"    </a>",
"    ], but the current dosing regimen of tirofiban (10",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    bolus followed by 0.15",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min infusion) often produces a lesser degree of platelet inhibition compared to the other two agents in the clinically important period of 15 to 60 minutes after intervention [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/76,78\">",
"     76,78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The only trial that has directly compared the relative efficacy of two GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors was the TARGET trial, in which 4809 patients who underwent nonemergent stent-based PCI were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    (0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    bolus followed by 0.125",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    [maximum 10",
"    <span class=\"nowrap\">",
"     &micro;g/min]",
"    </span>",
"    for 12 hours) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    bolus followed by 0.15",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    for 18 to 24 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/79\">",
"     79",
"    </a>",
"    ]. Abciximab was significantly superior to tirofiban in the composite end point of death, infarction, or the need for urgent revascularization at 30 days (6 versus 7.6 percent, hazard ratio 0.79) (",
"    <a class=\"graphic graphic_figure graphicRef70472 \" href=\"mobipreview.htm?22/20/22861\">",
"     figure 5",
"    </a>",
"    ). The magnitude and direction of the effect were similar for each component of the composite end point, but the benefit was due primarily to fewer MIs (5.4 versus 6.9 percent). The superiority of abciximab was independent of age, gender, or the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    pretreatment.",
"   </p>",
"   <p>",
"    Subgroup analysis revealed the benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    was limited to patients undergoing stenting for an ACS, in whom platelet activation is more marked, and to nondiabetics, since the outcomes at 30 days were similar with the two drugs in diabetics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/80\">",
"     80",
"    </a>",
"    ]. However, these subgroup results should be interpreted with caution, given the increased probability of a chance occurrence with multiple looks at the data.",
"   </p>",
"   <p>",
"    By six months of follow-up, there was no significant difference in the combined end point or the individual end points between the two drugs (",
"    <a class=\"graphic graphic_figure graphicRef75026 \" href=\"mobipreview.htm?30/63/31741\">",
"     figure 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/81\">",
"     81",
"    </a>",
"    ]. The 1.6 percent absolute benefit and 21 percent relative reduction in the combined end point at 30 days with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    had fallen to nonsignificant levels (0.5 percent and 4 percent, respectively). Although there remained a significant benefit with abciximab in the subgroup of patients with an acute coronary syndrome at six months, this effect was no longer present at one year [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the only benefit from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in TARGET appeared to be a reduction in procedure-related MI, primarily in patients with an ACS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/81\">",
"     81",
"    </a>",
"    ]. This difference was evident in the early periprocedural period and may have been due to less effective platelet inhibition with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    with the dosage regimen used (10",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    bolus followed by 0.15",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min for 18 to 24 hours) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two other studies also demonstrated reduced response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    using the 10",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    bolus. In one, the proportion of patients in whom there was &ge;80 percent inhibition of platelet activation at 15 minutes was significantly higher with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    than tirofiban (93 versus 60 percent);",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"     eptifibatide",
"    </a>",
"    was as effective as abciximab [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/76\">",
"     76",
"    </a>",
"    ]. In the second, abciximab achieved &gt;90 percent inhibition of maximal platelet aggregation during the first 15 to 60 minutes, a critical interval after intervention-induced vascular injury, compared to only 61 to 66 percent inhibition with tirofiban [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A newer high-dose bolus regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    before high-risk PCI (25",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    bolus over three minutes, followed by 0.15",
"    <span class=\"nowrap\">",
"     &micro;g/kg",
"    </span>",
"    per min for 18 hours) was evaluated in the ADVANCE trial, in which 202 patients were randomly assigned to tirofiban or placebo in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/83\">",
"     83",
"    </a>",
"    ]. The primary end point of death, MI, urgent target vessel revascularization, or bailout GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy was significantly lower with tirofiban (20 versus 35 percent). This high-dose bolus with a 12-hour infusion was also used in the EVEREST trial cited above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/68\">",
"     68",
"    </a>",
"    ], and is being compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"     abciximab",
"    </a>",
"    in the TENACITY trial.",
"   </p>",
"   <p>",
"    The importance of appropriate dosing to attain maximal platelet inhibition can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The GOLD study evaluated 500 patients undergoing PCI who were treated with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor (mostly",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/15/6392?source=see_link\">",
"       abciximab",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/77\">",
"       77",
"      </a>",
"      ]. Major adverse cardiac events within seven days were significantly more common in the one-quarter of patients who did not achieve at least 95 percent platelet inhibition 10 minutes after the bolus (14.4 versus 6.4 percent).",
"     </li>",
"     <li>",
"      With",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      therapy after PCI, there was unclear benefit with a regimen of a 135",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      bolus followed by a 0.5 to 0.75",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min infusion in IMPACT-II [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/84\">",
"       84",
"      </a>",
"      ]. By comparison, a regimen of two boluses of 180",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      10 minutes apart followed by a continuous infusion of 2.0",
"      <span class=\"nowrap\">",
"       &micro;g/kg",
"      </span>",
"      per min for 18 to 24 hours in ESPRIT demonstrated a clear benefit [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     PAR-1 antagonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thrombin is a potent activator of platelets and the primary receptor for thrombin on platelets is known as the protease-activated receptor-1 (PAR-1). The role of PAR-1 in platelet biology is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=see_link&amp;anchor=H6#H6\">",
"     \"Platelet biology\", section on 'PAR-1 antagonists'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The safety of SCH 530348, an oral platelet PAR-1 antagonist, was compared at multiple doses to placebo in a randomized, phase II trial of over 1000 patients with stable CAD undergoing PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/85\">",
"     85",
"    </a>",
"    ]. Most patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    , approximately two-thirds received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    , approximately one-third received an anticoagulant, and less than 10 percent received a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor. Aspirin and clopidogrel were continued after discharge according to local protocol, and the study drug was continued for 60 days.",
"   </p>",
"   <p>",
"    The primary end point of the incidence of clinically significant major or minor bleeding was not statistically different between any of the doses used and placebo. While the secondary end points of death, MI or stroke occurred significantly less often in the active treatment group, studies with larger number of patients are necessary to demonstrate superior efficacy of SCH 530348.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    with or without GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors, low molecular weight heparin, direct thrombin inhibitors, and oral anticoagulants have all been studied in patients undergoing PCI with or without stenting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intravenous unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is typically given during the procedure to prevent acute vessel closure due to thrombosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/86\">",
"     86",
"    </a>",
"    ]. This practice was initiated when PTCA was the procedure of choice and has been continued with the routine use of intracoronary stents. However, as heparin use is associated with an increased of access site bleeding and heparin induced thrombocytopenia, an acceptable benefit to risk ratio must be present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=see_link&amp;anchor=H2#H2\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Incidence and risk factors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=see_link&amp;anchor=H23#H23\">",
"     \"Periprocedural complications of percutaneous coronary intervention\", section on 'Vascular complications'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dosing of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and the role of ACT monitoring during heparin therapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H24#H24\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Heparin with GP IIb/IIIa inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    regimen should probably be less aggressive when GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors are used, based upon the following observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/87-89\">",
"     87-89",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the ESPRIT trial, 2064 patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/24/32135?source=see_link\">",
"       eptifibatide",
"      </a>",
"      or placebo prior to PCI; all patients received stents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/87\">",
"       87",
"      </a>",
"      ]. The incidence of death or MI at 48 hours was 5.5, 6.1, and 6.1 percent for patients treated with eptifibatide with an ACT of &lt;244, 244 to 292, or &gt;292 seconds, respectively. The risk of major bleeding was lowest in the low-ACT group, though the differences were not statistically significant.",
"     </li>",
"     <li>",
"      A meta-analysis of four trials (CREDO, TARGET, REPLACE-1, and REPLACE-2) included 8369 patients with ACT data; 93 percent received a stent and 89 percent received a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/89\">",
"       89",
"      </a>",
"      ]. The incidence of death, MI, or target vessel revascularization was similar for patients with ACT &lt;256, 257 to 296, 297 to 347, and &gt;348 (6.2, 6.8, 6.0, and 5.7 percent, respectively). The incidence of major or minor bleeding at 48 hours increased with increasing quartile of ACT. In a multivariate analysis, the risk of bleeding increased with increasing ACT up to 356 seconds, with a nonsignificant decline in risk at higher ACT values.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In summary, an ACT of 200 to 250 seconds appears to be safe and effective when used with GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Low-risk patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bleeding complications resulting from the combined use of potent antiplatelet and anticoagulant agents are a major risk of PCI. Strategies to minimize that risk, such as withholding GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    therapy in low risk patients, have been evaluated. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Elective stenting'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The issue of whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is necessary in patients at very low risk of ischemic complications after PCI was addressed in the CIAO trial of 700 patients already taking",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    and undergoing elective PCI for an uncomplicated lesion; the patients were randomly assigned to either unfractionated heparin (70-100",
"    <span class=\"nowrap\">",
"     IU/kg)",
"    </span>",
"    or no heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. Patients with calcified, bifurcation, or long lesions, as well as those with thrombus, small vessels, and bypass graft lesions, were excluded. No patients in either group received GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy.",
"   </p>",
"   <p>",
"    The primary end point of death, MI, or urgent target vessel revascularization at thirty days occurred more frequently in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    group (3.7 versus 2.0 percent), but this difference was not statistically significant. Although there were fewer bleeding events in the no-heparin group, too few events occurred to permit important conclusions.",
"   </p>",
"   <p>",
"    Despite the results of this small study, we believe that anticoagulant therapy should be used in all low-risk patients. While bleeding risk is recognized as a major safety issue and safer strategies require investigation, the omission of any anticoagulant is not prudent with the current level of evidence. Any clinical investigation should be of sufficient size to evaluate safety in a low risk population and should include an attempt to establish angiographic criteria for labeling patients as low risk.",
"   </p>",
"   <p>",
"    The dose of unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    is discussed below. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Bivalirudin'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Low molecular weight heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy and safety of low molecular weight",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMWH) compared to UFH has been evaluated in trials of stable and non-ST elevation acute coronary syndrome patients (ACS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/92-94\">",
"     92-94",
"    </a>",
"    ]. The relative therapeutic efficacy and safety of LMWH in patients with a non-ST elevation ACS who undergo a planned early invasive strategy was evaluated in over 10,000 patients in the SYNERGY trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/92\">",
"     92",
"    </a>",
"    ]. Patients were randomly assigned to receive open label",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (1",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously every 12 hours) or UFH (60",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    initial bolus followed by an infusion of 12",
"    <span class=\"nowrap\">",
"     U/kg",
"    </span>",
"    per hour). The primary end point was all-cause mortality or nonfatal MI at 30 days.",
"   </p>",
"   <p>",
"    At 30 days, there was no significant difference between the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    and UFH groups with respect to efficacy end points (14.0 versus 14.5 percent with UFH) or to overall procedural complications in those patients undergoing PCI. The lack of difference in outcomes between the enoxaparin and UFH groups persisted at longer-term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/95\">",
"     95",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In terms of specific early end point of bleeding,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    therapy was associated with a statistically significant increase in in-hospital bleeding defined according to TIMI criteria as \"major\" and a nonsignificant increase in GUSTO criteria for severe bleeding.",
"   </p>",
"   <p>",
"    The STEEPLE safety trial randomly assigned 2528 patients presenting for elective PCI to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (a single intravenous bolus of either 0.50 or 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    before PCI) or UFH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/93\">",
"     93",
"    </a>",
"    ]. There was a higher mortality rate among patients receiving the 0.50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    dose of enoxaparin than in either of the other two groups, causing the data monitoring committee to recommend termination of this dose late in the trial. There was an observed reduction in the primary end point of major and minor bleeding in the 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    group compared with UFH (6.5 versus 8.5 percent), but the difference was not statistically significant. The incidence of major bleeding, which was a secondary end point, was significantly reduced with enoxaparin.",
"   </p>",
"   <p>",
"    Dosing of LMWH, as described in the SYNERGY and STEEPLE trials above, has been based upon patient weight, without laboratory monitoring.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    does not reliably prolong the ACT at the doses used in PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. However, the ACT may be a useful assay in monitoring",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The discussion of the studies that have compared UFH to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    in patients with ST-elevation MI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link&amp;anchor=H21647888#H21647888\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\", section on 'UFH versus enoxaparin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Pretreatment with oral anticoagulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized trial of 530 patients, one-third of whom received a stent, suggested a benefit from oral anticoagulation prior to PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. However, adding oral anticoagulation to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    has not been widely adopted in clinical practice. It is our opinion that the increased risk of bleeding and vascular complications outweighs any potential benefit of this strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Direct thrombin inhibitors and fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The limitations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy noted above, including dosing difficulties and bleeding complications, have led to the search for better anticoagulants in patients undergoing stent implantation.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    , a direct thrombin inhibitor, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    have been studied in patients undergoing PCI with stenting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=see_link\">",
"     \"Anticoagulants other than heparin and warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    , with or without a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, was an acceptable alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    therapy in two randomized trials of predominantly stable or low risk ACS patients (REPLACE-2 and ISAR-REACT 3) and one trial of higher risk ACS patients (ACUITY).",
"   </p>",
"   <p>",
"    In the REPLACE-2 trial 6010 patients (85 percent of whom received a stent) were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    with provisional GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    with planned GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy; almost all patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    pretreatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/101\">",
"     101",
"    </a>",
"    ]. In the heparin arm, 97 percent received the \"planned\" GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor while, in the bivalirudin arm, only 7 percent received a \"provisional\" GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, primarily for procedural or angiographic complications (eg, side branch closure, obstructive dissection, thrombus).",
"   </p>",
"   <p>",
"    REPLACE-2 satisfied prespecified criteria for noninferiority for the primary end point of death, MI, urgent revascularization, or in-hospital major bleeding and for the secondary end point of death, MI, or urgent revascularization. In addition, the event rate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    proved superior to a calculated historical event rate for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    alone.",
"   </p>",
"   <p>",
"    Interpretation and clinical application of the results of REPLACE-2 has centered on the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       Bivalirudin",
"      </a>",
"      was associated with a significant reduction in protocol-defined major bleeding (2.4 versus 4.1 percent) compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      plus a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor. However, major bleeding by TIMI criteria was similar for the two groups (0.6 versus 0.9 percent), and it has been argued that heparin dosing and higher than usual procedural ACT values may have accounted in part for the increase in TIMI minor bleeding seen with heparin.",
"     </li>",
"     <li>",
"      The",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      plus GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor group had a nonsignificant reduction in postprocedure non-ST elevation MI (5.8 versus 6.6 percent), driven mostly by a reduction in intermediate (CK-MB greater than five times normal) and large (CK-MB greater than 10 times normal) MIs. The clinical significance of this trend is uncertain.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subsequent analysis of longer-term outcomes, the incidence of death, MI, or any revascularization at six months was comparable for patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    versus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor (18.8 versus 17.5 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/102\">",
"     102",
"    </a>",
"    ]. Mortality at one year was also not significantly different (1.9 versus 2.5 percent).",
"   </p>",
"   <p>",
"    Similar findings were noted in the 37 percent of patients who were diabetic, including no significant difference in mortality for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    with provisional GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors compared with unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and routine GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors (2.3 versus 3.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/103\">",
"     103",
"    </a>",
"    ]. Bivalirudin was associated with less minor bleeding and no difference in major bleeding.",
"   </p>",
"   <p>",
"    This issue of how",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    compares to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    without GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor therapy in stable or low risk ACS patients (biomarker negative) was addressed in the ISAR-REACT 3 trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/104\">",
"     104",
"    </a>",
"    ]. In this study, 4570 patients pretreated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    600 mg at least two hours before the procedure were randomly assigned to anticoagulation with either bivalirudin (0.75 mg per kilogram bolus, followed by 1.75",
"    <span class=\"nowrap\">",
"     mg/kg/hr",
"    </span>",
"    infusion for the duration of the procedure) or a high dose of unfractionated heparin (140",
"    <span class=\"nowrap\">",
"     units/kg).",
"    </span>",
"    After 30 days, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no significant difference in the incidence of the composite primary end point of death, myocardial infarction, urgent target-vessel revascularization due to myocardial ischemia, or major bleeding during the index hospitalization between the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      groups (8.3 versus 8.7 percent, respectively).",
"     </li>",
"     <li>",
"      The composite secondary endpoint of death, myocardial infarction, or urgent target vessel revascularization due to myocardial ischemia was similar in the two groups (5.9 versus 5.0 percent, respectively).",
"     </li>",
"     <li>",
"      The incidence of protocol-defined major bleeding (using the same definition as in REPLACE-2) was significantly lower in the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      group (3.1 versus 4.6 percent). Most of this difference was attributable to a decrease in hemoglobin",
"      <span class=\"nowrap\">",
"       &ge;3g/dL",
"      </span>",
"      without an overt source. There was no significant difference in the rate of transfusion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At one year, there was no significant difference in the incidence of the primary composite endpoint (17.1 versus 17.5 percent respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/105\">",
"     105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the applicability of ISAR-REACT 3 to current practice is somewhat uncertain, as the dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    was higher than that recommended in United States and European guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H24#H24\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ISAR-REACT 3A study addressed this issue by treating 2505 similar patients with a lower dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    bolus (100 International units",
"    <span class=\"nowrap\">",
"     (IU)/kg)",
"    </span>",
"    and comparing their outcomes to the historical groups in ISAR-REACT 3 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/108\">",
"     108",
"    </a>",
"    ]. At 30 days the rate of the primary composite endpoint was not statistically different between the two heparin doses. The rate of major bleeding was lower (3.6 versus 4.6 percent) with the 100",
"    <span class=\"nowrap\">",
"     IU/kg",
"    </span>",
"    dose, but did not achieve statistical significance. In addition the lower dose was noninferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    with regard to the primary composite outcome.",
"   </p>",
"   <p>",
"    Since the majority of patients in the REPLACE-2 and ISAR-REACT 3 trials had either stable coronary artery disease or low risk ACS, the role of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    therapy in moderate to high risk ACS patients with planned PCI was not answered. This issue was addressed in the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial.",
"   </p>",
"   <p>",
"    The ACUITY trial randomly assigned almost 14,000 moderate to high risk ACS patients to one of three treatment arms:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    alone, bivalirudin plus a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor, or a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/109\">",
"     109",
"    </a>",
"    ]. Patients assigned to either GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    group were randomly assigned a second time in a 2 x 2 factorial design to either routine upstream administration immediately after randomization or selective deferred (after angiography) administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/110\">",
"     110",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The primary end points were a composite ischemia end point (death, MI, or unplanned revascularization for ischemia), as well as major bleeding or a net clinical outcome (the combination of the ischemia and bleeding outcomes). PCI was performed in 56 percent, CABG in 11 percent, and medical therapy alone in 33 percent.",
"   </p>",
"   <p>",
"    The goal of the trial was to prove that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    alone was not inferior to a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    or to a GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor plus bivalirudin. This hypothesis was confirmed as illustrated by the following findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The composite ischemia end point was not statistically different among the patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      alone, bivalirudin plus GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor, or GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor plus",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"        heparin",
"       </a>",
"       /",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?35/24/36233?source=see_link\">",
"        enoxaparin",
"       </a>",
"      </span>",
"      at 30 days (7.8, 7.7, and 7.3 percent, respectively) or one year (16.2, 15.4, and 16.0 percent, respectively). Among patients treated with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor, there was no significant difference in the composite end point between patients receiving routine upstream or selective deferred therapy.",
"     </li>",
"     <li>",
"      The similar outcomes in patients assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      alone compared to combined therapy with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor were only seen in those pretreated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/9/34969?source=see_link\">",
"       clopidogrel",
"      </a>",
"      . Among the 37 percent of patients who were not given clopidogrel before angiography, bivalirudin alone was associated with a significant 29 percent increase in events at 30 days compared to the other two groups treated with a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor.",
"     </li>",
"     <li>",
"      The rate of major bleeding at 30 days with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      alone was significantly lower than in the other two groups (3.0, 5.3, and 5.7 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a prespecified subgroup analysis of the 7789 patients (56 percent) who underwent PCI, the 30-day and one year composite rates of ischemia was not statistically different among patients who received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    alone versus those who received GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/111,112\">",
"     111,112",
"    </a>",
"    ]. However, major bleeding was significantly less frequent in the former group (4 versus 7 percent). Again, the importance of thienopyridine pretreatment was noted in this study as the subgroup not pretreated tended to have more ischemic events with bivalirudin (10 versus 7 percent).",
"   </p>",
"   <p>",
"    Early (upstream) GP",
"    <span class=\"nowrap\">",
"     IIB/IIIa",
"    </span>",
"    inhibitor use in ACUITY was not associated with any incremental benefit. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Timing of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The possible benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    compared to unfractionated",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    appears to be more apparent in patients with renal insufficiency, which is associated with an increased risk of ischemic and bleeding complications after PCI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/113\">",
"     113",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    pentasaccharide analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    is a selective inhibitor of factor Xa that appears to be more effective than low molecular weight heparin for the prevention of deep vein thrombosis in patients undergoing hip or knee surgery. In the ASPIRE pilot trial of 350 patients undergoing urgent or elective PCI, almost all with stents, there was no difference in efficacy or safety between intravenous fondaparinux and unfractionated heparin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?40/37/41562/abstract/114\">",
"     114",
"    </a>",
"    ]. More data are needed to better assess the role of either intravenous or subcutaneous fondaparinux. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=see_link\">",
"     \"Therapeutic use of fondaparinux\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antithrombotic therapy, using both antiplatelet and anticoagulant drugs, is essential for the performance of percutaneous coronary intervention with stenting. However, even with proper administration, thrombotic events and major bleeding can occur. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H29#H29\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Bleeding'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic presents the evidence that has led to the use of multiple antithrombotic drugs in the periprocedural period. Many of the studies included patients with stable angina, although some studies of patients with acute coronary syndromes have been included if relevant. Recommendations for the periprocedural use of antithrombotic therapy in patients with stable coronary disease are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=see_link&amp;anchor=H35#H35\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of antithrombotic therapy in patients with acute coronary syndromes undergoing PCI is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=see_link\">",
"     \"Antiplatelet agents in acute non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=see_link\">",
"     \"Anticoagulant therapy in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term use of antiplatelet therapy to prevent stent thrombosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=see_link\">",
"     \"Antiplatelet therapy after coronary artery stenting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7666302\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The authors and editors would like to thank Dr. David O. Williams for his contributions as a Section Editor to previous versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/1\">",
"      Sutton JM, Ellis SG, Roubin GS, et al. Major clinical events after coronary stenting. The multicenter registry of acute and elective Gianturco-Roubin stent placement. The Gianturco-Roubin Intracoronary Stent Investigator Group. Circulation 1994; 89:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/2\">",
"      George BS, Voorhees WD 3rd, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol 1993; 22:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/3\">",
"      Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/4\">",
"      Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/5\">",
"      Tan K, Sulke N, Taub N, Sowton E. Clinical and lesion morphologic determinants of coronary angioplasty success and complications: current experience. J Am Coll Cardiol 1995; 25:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/6\">",
"      Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/7\">",
"      Sch&ouml;mig A, Neumann FJ, Walter H, et al. Coronary stent placement in patients with acute myocardial infarction: comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy. J Am Coll Cardiol 1997; 29:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/8\">",
"      Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288:2411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/9\">",
"      Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/10\">",
"      Schwartz L, Bourassa MG, Lesp&eacute;rance J, et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988; 318:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/11\">",
"      Lembo NJ, Black AJ, Roubin GS, et al. Effect of pretreatment with aspirin versus aspirin plus dipyridamole on frequency and type of acute complications of percutaneous transluminal coronary angioplasty. Am J Cardiol 1990; 65:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/12\">",
"      Mufson, L, Black, A, Roubin, G, et al. A randomized trial of aspirin in PTCA: effect of high dose versus low dose aspirin on major complications and restenosis (abstract). J Am Coll Cardiol 1988; 11:236A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/13\">",
"      Foster CJ, Prosser DM, Agans JM, et al. Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest 2001; 107:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/14\">",
"      Sch&ouml;mig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/15\">",
"      Sch&uuml;hlen H, Hadamitzky M, Walter H, et al. Major benefit from antiplatelet therapy for patients at high risk for adverse cardiac events after coronary Palmaz-Schatz stent placement: analysis of a prospective risk stratification protocol in the Intracoronary Stenting and Antithrombotic Regimen (ISAR) trial. Circulation 1997; 95:2015.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/16\">",
"      Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/17\">",
"      Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/18\">",
"      Steinhubl SR, Ellis SG, Wolski K, et al. Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse cardiac events: data from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial. Circulation 2001; 103:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/19\">",
"      Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/20\">",
"      Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 99:2364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/21\">",
"      Mishkel GJ, Aguirre FV, Ligon RW, et al. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am Coll Cardiol 1999; 34:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/22\">",
"      Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol 1999; 34:1891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/23\">",
"      Dangas G, Mehran R, Abizaid AS, et al. Combination therapy with aspirin plus clopidogrel versus aspirin plus ticlopidine for prevention of subacute thrombosis after successful native coronary stenting. Am J Cardiol 2001; 87:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/24\">",
"      Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med 2000; 342:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/25\">",
"      Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/26\">",
"      Mueller C, Roskamm H, Neumann FJ, et al. A randomized comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol 2003; 41:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/27\">",
"      Klein LW, Calvin JE. Use of clopidrogel in coronary stenting: what was the question? J Am Coll Cardiol 1999; 34:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/28\">",
"      Calver AL, Blows LJ, Harmer S, et al. Clopidogrel for prevention of major cardiac events after coronary stent implantation: 30-day and 6-month results in patients with smaller stents. Am Heart J 2000; 140:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/29\">",
"      Steinhubl SR, Berger PB, Brennan DM, et al. Optimal timing for the initiation of pre-treatment with 300 mg clopidogrel before percutaneous coronary intervention. J Am Coll Cardiol 2006; 47:939.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/30\">",
"      Hochholzer W, Trenk D, Frundi D, et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005; 111:2560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/31\">",
"      Kandzari DE, Berger PB, Kastrati A, et al. Influence of treatment duration with a 600-mg dose of clopidogrel before percutaneous coronary revascularization. J Am Coll Cardiol 2004; 44:2133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/32\">",
"      Patti G, Colonna G, Pasceri V, et al. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) study. Circulation 2005; 111:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/33\">",
"      Cuisset T, Frere C, Quilici J, et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006; 48:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/34\">",
"      von Beckerath N, Taubert D, Pogatsa-Murray G, et al. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 2005; 112:2946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/35\">",
"      Angiolillo DJ, Fern&aacute;ndez-Ortiz A, Bernardo E, et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004; 25:1903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/36\">",
"      Montalescot G, Sideris G, Meuleman C, et al. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 2006; 48:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/37\">",
"      Bates ER, Lau WC, Bleske BE. Loading, pretreatment, and interindividual variability issues with clopidogrel dosing. Circulation 2005; 111:2557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/38\">",
"      Gurbel PA, Bliden KP, Hayes KM, et al. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J Am Coll Cardiol 2005; 45:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/39\">",
"      M&uuml;ller I, Besta F, Schulz C, et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 2003; 108:2195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/40\">",
"      L'Allier PL, Ducrocq G, Pranno N, et al. Clopidogrel 600-mg double loading dose achieves stronger platelet inhibition than conventional regimens: results from the PREPAIR randomized study. J Am Coll Cardiol 2008; 51:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/41\">",
"      Widimsky P, Motovsk&aacute; Z, Simek S, et al. Clopidogrel pre-treatment in stable angina: for all patients &gt; 6 h before elective coronary angiography or only for angiographically selected patients a few minutes before PCI? A randomized multicentre trial PRAGUE-8. Eur Heart J 2008; 29:1495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/42\">",
"      Schiele F, Meneveau N, Bassand JP. Routine pre-treatment with clopidogrel before diagnostic coronary angiography: the question is right, but what about the answer? Eur Heart J 2008; 29:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/43\">",
"      Di Sciascio G, Patti G, Pasceri V, et al. Effectiveness of in-laboratory high-dose clopidogrel loading versus routine pre-load in patients undergoing percutaneous coronary intervention: results of the ARMYDA-5 PRELOAD (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) randomized trial. J Am Coll Cardiol 2010; 56:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/44\">",
"      Wiviott SD, Antman EM, Winters KJ, et al. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 2005; 111:3366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/45\">",
"      Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007; 116:2923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/46\">",
"      Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/47\">",
"      Bhatt DL, Lincoff AM, Gibson CM, et al. Intravenous platelet blockade with cangrelor during PCI. N Engl J Med 2009; 361:2330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/48\">",
"      Harrington RA, Stone GW, McNulty S, et al. Platelet inhibition with cangrelor in patients undergoing PCI. N Engl J Med 2009; 361:2318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/49\">",
"      Bhatt DL, Stone GW, Mahaffey KW, et al. Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events. N Engl J Med 2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/50\">",
"      Lee SW, Park SW, Hong MK, et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005; 46:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/51\">",
"      Han Y, Li Y, Wang S, et al. Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: a randomized, controlled study. Am Heart J 2009; 157:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/52\">",
"      Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009; 119:3207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/53\">",
"      Lee SW, Park SW, Yun SC, et al. Triple antiplatelet therapy reduces ischemic events after drug-eluting stent implantation: Drug-Eluting stenting followed by Cilostazol treatment REduces Adverse Serious cardiac Events (DECREASE registry). Am Heart J 2010; 159:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/54\">",
"      Blankenship JC, Tasissa G, O'Shea JC, et al. Effect of glycoprotein IIb/IIIa receptor inhibition on angiographic complications during percutaneous coronary intervention in the ESPRIT trial. J Am Coll Cardiol 2001; 38:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/55\">",
"      Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 2003; 41:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/56\">",
"      Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/57\">",
"      EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet 1998; 352:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/58\">",
"      Lincoff AM, Califf RM, Moliterno DJ, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. N Engl J Med 1999; 341:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/59\">",
"      Topol EJ, Mark DB, Lincoff AM, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1999; 354:2019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/60\">",
"      Topol EJ, Lincoff AM, Kereiakes DJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002; 113:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/61\">",
"      ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356:2037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/62\">",
"      O'Shea JC, Buller CE, Cantor WJ, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002; 287:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/63\">",
"      Kastrati A, Mehilli J, Sch&uuml;hlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/64\">",
"      Sch&ouml;mig A, Schmitt C, Dibra A, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel. Eur Heart J 2005; 26:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/65\">",
"      Puma JA, Banko LT, Pieper KS, et al. Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. J Am Coll Cardiol 2006; 47:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/66\">",
"      Kastrati A, Mehilli J, Neumann FJ, et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/67\">",
"      Ndrepepa G, Kastrati A, Mehilli J, et al. One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial. Eur Heart J 2008; 29:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/68\">",
"      Bolognese L, Falsini G, Liistro F, et al. Randomized comparison of upstream tirofiban versus downstream high bolus dose tirofiban or abciximab on tissue-level perfusion and troponin release in high-risk acute coronary syndromes treated with percutaneous coronary interventions: the EVEREST trial. J Am Coll Cardiol 2006; 47:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/69\">",
"      Dalby M, Montalescot G, Bal dit Sollier C, et al. Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel. Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study. J Am Coll Cardiol 2004; 43:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/70\">",
"      Ben-Yehuda O. Upstream/downstream glycoprotein IIb/IIIa in non-ST-segment elevation myocardial infarction. J Am Coll Cardiol 2006; 47:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/71\">",
"      Simon DI, Sakuma M. Platelet disaggregation: putting time on your side in acute myocardial infarction. J Am Coll Cardiol 2004; 44:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/72\">",
"      Keeley EC, Boura JA, Grines CL. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006; 367:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/73\">",
"      Maioli M, Bellandi F, Leoncini M, et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 2007; 49:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/74\">",
"      Cura FA, Bhatt DL, Lincoff AM, et al. Pronounced benefit of coronary stenting and adjunctive platelet glycoprotein IIb/IIIa inhibition in complex atherosclerotic lesions. Circulation 2000; 102:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/75\">",
"      Neumann FJ, Hochholzer W, Pogatsa-Murray G, et al. Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. J Am Coll Cardiol 2001; 37:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/76\">",
"      Batchelor WB, Tolleson TR, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide. Circulation 2002; 106:1470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/77\">",
"      Steinhubl SR, Talley JD, Braden GA, et al. Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/78\">",
"      Kabbani SS, Aggarwal A, Terrien EF, et al. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002; 89:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/79\">",
"      Topol EJ, Moliterno DJ, Herrmann HC, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/80\">",
"      Roffi M, Moliterno DJ, Meier B, et al. Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-up. Circulation 2002; 105:2730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/81\">",
"      Moliterno DJ, Yakubov SJ, DiBattiste PM, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002; 360:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/82\">",
"      Mukherjee D, Topol EJ, Bertrand ME, et al. Mortality at 1 year for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularization: do tirofiban and ReoPro give similar efficacy outcomes at trial 1-year follow-up. Eur Heart J 2005; 26:2524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/83\">",
"      Valgimigli M, Percoco G, Barbieri D, et al. The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. J Am Coll Cardiol 2004; 44:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/84\">",
"      Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/85\">",
"      Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet 2009; 373:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/86\">",
"      Popma JJ, Weitz J, Bittl JA, et al. Antithrombotic therapy in patients undergoing coronary angioplasty. Chest 1998; 114:728S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/87\">",
"      Tolleson TR, O'Shea JC, Bittl JA, et al. Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention: observations from the ESPRIT trial. J Am Coll Cardiol 2003; 41:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/88\">",
"      Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/89\">",
"      Brener SJ, Moliterno DJ, Lincoff AM, et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004; 110:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/90\">",
"      Stabile E, Nammas W, Salemme L, et al. The CIAO (Coronary Interventions Antiplatelet-based Only) Study: a randomized study comparing standard anticoagulation regimen to absence of anticoagulation for elective percutaneous coronary intervention. J Am Coll Cardiol 2008; 52:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/91\">",
"      Dauerman HL. Coronary intervention without a safety net. J Am Coll Cardiol 2008; 52:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/92\">",
"      Ferguson JJ, Califf RM, Antman EM, et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004; 292:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/93\">",
"      Montalescot G, White HD, Gallo R, et al. Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006; 355:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/94\">",
"      Bhatt DL, Lee BI, Casterella PJ, et al. Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. J Am Coll Cardiol 2003; 41:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/95\">",
"      Mahaffey KW, Cohen M, Garg J, et al. High-risk patients with acute coronary syndromes treated with low-molecular-weight or unfractionated heparin: outcomes at 6 months and 1 year in the SYNERGY trial. JAMA 2005; 294:2594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/96\">",
"      Linkins LA, Julian JA, Rischke J, et al. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002; 107:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/97\">",
"      Henry TD, Satran D, Knox LL, et al. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin? Am Heart J 2001; 142:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/98\">",
"      Marmur JD, Anand SX, Bagga RS, et al. The activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration. J Am Coll Cardiol 2003; 41:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/99\">",
"      ten Berg JM, Kelder JC, Suttorp MJ, et al. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. Circulation 2000; 102:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/100\">",
"      ten Berg JM, Hutten BA, Kelder JC, et al. Oral anticoagulant therapy during and after coronary angioplasty the intensity and duration of anticoagulation are essential to reduce thrombotic complications. Circulation 2001; 103:2042.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/101\">",
"      Lincoff AM, Bittl JA, Harrington RA, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/102\">",
"      Lincoff AM, Kleiman NS, Kereiakes DJ, et al. Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004; 292:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/103\">",
"      Gurm HS, Sarembock IJ, Kereiakes DJ, et al. Use of bivalirudin during percutaneous coronary intervention in patients with diabetes mellitus: an analysis from the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (REPLACE)-2 trial. J Am Coll Cardiol 2005; 45:1932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/104\">",
"      Kastrati A, Neumann FJ, Mehilli J, et al. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 2008; 359:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/105\">",
"      Schulz S, Mehilli J, Ndrepepa G, et al. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J 2010; 31:582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/106\">",
"      Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 2006; 47:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/107\">",
"      Silber S, Albertsson P, Avil&eacute;s FF, et al. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005; 26:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/108\">",
"      Schulz S, Mehilli J, Neumann FJ, et al. ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention. Eur Heart J 2010; 31:2482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/109\">",
"      Stone GW, McLaurin BT, Cox DA, et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006; 355:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/110\">",
"      Stone GW, Ware JH, Bertrand ME, et al. Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 2007; 298:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/111\">",
"      Stone GW, White HD, Ohman EM, et al. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Lancet 2007; 369:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/112\">",
"      White HD, Ohman EM, Lincoff AM, et al. Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. J Am Coll Cardiol 2008; 52:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/113\">",
"      Chew DP, Bhatt DL, Kimball W, et al. Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials. Am J Cardiol 2003; 92:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?40/37/41562/abstract/114\">",
"      Mehta SR, Steg PG, Granger CB, et al. Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. Circulation 2005; 111:1390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1577 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-A3F5C7E4D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41562=[""].join("\n");
var outline_f40_37_41562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTIPLATELET THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Aspirin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      P2Y12 receptor blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Ticlopidine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1136003648\">",
"      - Clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Efficacy and safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Timing and dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Prasugrel",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Cangrelor",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1221867311\">",
"      - Ticagrelor and prasugrel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cilostazol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Elective stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Primary stenting for acute ST elevation MI",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Timing of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Complex lesions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Comparison of different agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PAR-1 antagonists",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Heparin with GP IIb/IIIa inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Low-risk patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Pretreatment with oral anticoagulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Direct thrombin inhibitors and fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7666302\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1577|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?37/31/38397\" title=\"figure 1\">",
"      Clopidogrel outcome stenting",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?4/9/4254\" title=\"figure 2\">",
"      Clopidogrel in CREDO 28 days",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/47/33533\" title=\"figure 3\">",
"      Clopidogrel timing before PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/49/36637\" title=\"figure 4\">",
"      Clopidogrel in CREDO one year",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?22/20/22861\" title=\"figure 5\">",
"      Abciximab is more effective than tirofiban at 30 days after PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/63/31741\" title=\"figure 6\">",
"      Abciximab and tirofiban produce similar outcomes at six months",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/57/5018?source=related_link\">",
"      Anticoagulant therapy in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/20/39242?source=related_link\">",
"      Antiplatelet agents in acute non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/24/10634?source=related_link\">",
"      Antiplatelet therapy after coronary artery stenting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/1/29722?source=related_link\">",
"      Coronary arteriography and revascularization for unstable angina or non-ST elevation acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/59/9146?source=related_link\">",
"      Coronary artery stent thrombosis: Incidence and risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/43/43702?source=related_link\">",
"      Drug-eluting intracoronary stents: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/31/19961?source=related_link\">",
"      Early trials of platelet glycoprotein IIb/IIIa receptor inhibitors in coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/38/7786?source=related_link\">",
"      Fibrinolytic (thrombolytic) agents in acute ST elevation myocardial infarction: Markers of efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/19/24889?source=related_link\">",
"      General principles of the use of intracoronary stents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/21/32090?source=related_link\">",
"      Medical management of claudication",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/34/37418?source=related_link\">",
"      Nonresponse and resistance to clopidogrel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/48/38666?source=related_link\">",
"      Periprocedural complications of percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/51/39737?source=related_link\">",
"      Periprocedural myocardial infarction following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/7/1146?source=related_link\">",
"      Platelet biology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/25/29081?source=related_link\">",
"      Possible role of long-term medical therapies to prevent restenosis following percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/58/26538?source=related_link\">",
"      Prevention, presentation, and management of saphenous vein graft stenosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/46/16106?source=related_link\">",
"      Primary percutaneous coronary intervention in acute ST elevation myocardial infarction: Determinants of outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/48/9994?source=related_link\">",
"      Suboptimal reperfusion after primary percutaneous coronary intervention in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f40_37_41563="Possible triggers of mast cell activation";
var content_f40_37_41563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F70309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=20\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F70309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=20\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential non allergic triggers for mast cell activation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Insect stings, envenomations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hymenoptera",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jellyfish",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Snakes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Narcotic analgesics (eg, codeine, morphine)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiocontrast materials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aspirin and non-steroidal antiinflammatory drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle relaxants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some antibiotics (eg, vancomycin, cephalosporins)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Changes in temperature",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heat, cold",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Mechanical irritation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massage, friction, pressure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Invasive procedures (eg, surgery, biopsies, endoscopy)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alcohol",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Emotional stress",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very spicy foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Infections (viral, bacterial, parasitic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fever&nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41563=[""].join("\n");
var outline_f40_37_41563=null;
var title_f40_37_41564="Drug and toxin related electrolyte change";
var content_f40_37_41564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Drug- and toxin-induced electrolyte abnormalities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <colgroup span=\"2\" width=\"50%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hyperkalemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Cardiac glycosides",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoride",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypokalemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Beta-adrenergic agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Albuterol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Epinephrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Methylphenidate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Diuretics",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Toluene",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Barium",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypocalcemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethylene glycol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oxalate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fluoride",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hyperglycemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1_start\">",
"            Beta-adrenergic agonists",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Albuterol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Theophylline",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Epinephrine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"sublist1\">",
"            Caffeine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Calcium channel blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Iron",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Vacor (rodenticide)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Hypoglycemia",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ackee fruit (unripe)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Beta blockers",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Insulin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Oral hypoglycemic agents",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Ethanol",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Quinine",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Salicylate",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41564=[""].join("\n");
var outline_f40_37_41564=null;
var title_f40_37_41565="PVSG thrombosis-free survival";
var content_f40_37_41565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F59865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F59865&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 493px\">",
"   <div class=\"ttl\">",
"    Thrombosis-free cumulative survival in the PVSG 01 protocol",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 473px; height: 273px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Cumulative survival during the first ten years of the PVSG 01 protocol. During the first three to four years of the study, there were significantly more thrombotic events in patients randomized to the phlebotomy-only arm. This difference disappeared as the study continued.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Wasserman, LR, Berk, PD, Berlin, NI (Eds), Polycythemia Vera and the Myeloproliferative Disorders, WB Saunders, Philadelphia, 1995.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41565=[""].join("\n");
var outline_f40_37_41565=null;
var title_f40_37_41566="Bronchioalveolar carcinoma CT";
var content_f40_37_41566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F57134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F57134&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchioloalveolar cell carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    CT scan of bronchoalveolar cell carcinoma demonstrates a right lower lobe mass, measuring 3.5 cm in diameter with a so-called rabbit ear sign and with central lucencies that probably represent air bronchograms rather than cavitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41566=[""].join("\n");
var outline_f40_37_41566=null;
var title_f40_37_41567="Treatment algorithm for hepatocellular carcinoma";
var content_f40_37_41567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F57014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F57014&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 551px\">",
"   <div class=\"ttl\">",
"    Treatment algorithm for hepatocellular carcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 531px; height: 640px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ETOH: ethanol; PEI: percutaneous ethanol injection; PVE: portal vein embolization; RFA: radiofrequency ablation; TACE: transcatheter arterial chemoembolization.",
"     <br/>",
"     * Suitability of patients with Child-Pugh B cirrhosis for surgical resection is highly controversial.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     If not a liver transplantation candidate because disease is outside transplant (Milan) criteria, downstaging therapy (RFA, TACE) could be considered, followed by reassessment for liver transplantation.",
"     <br/>",
"     &Delta; Systemic therapy options include participation in a clinical trial (preferred) or sorafenib.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f40_37_41567=[""].join("\n");
var outline_f40_37_41567=null;
